drug	genes	question	answer	incorrect_recommendations	concurring_recommendation	llm_answer	bert_score_precision_llm_vs_ref	bert_score_recall_llm_vs_ref	bert_score_f1_llm_vs_ref	bert_score_precision_llm_vs_concurring	bert_score_recall_llm_vs_concurring	bert_score_f1_llm_vs_concurring	oai_embedding_llm_vs_ref	oai_embedding_llm_vs_concurring	oai_embedding_llm_vs_counterfactual	negation_mpnet_llm_vs_ref	negation_mpnet_llm_vs_concurring	negation_mpnet_llm_vs_counterfactual	base_mpnet_llm_vs_ref	base_mpnet_llm_vs_concurring	base_mpnet_llm_vs_counterfactual	roberta_llm_vs_ref	roberta_llm_vs_concurring	roberta_llm_vs_counterfactual	gte_llm_vs_ref	gte_llm_vs_concurring	gte_llm_vs_counterfactual	gpt4_llm_vs_ref
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Abacavir is not recommended	['Proceed taking abacavir as normal. There is no recommendation.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Avoid abacavir. Take an alternate therapy.	According to clinical guidelines, individuals who are HLA-B*57:01 positive should not be prescribed abacavir due to the increased risk of hypersensitivity reaction (HSR), a potentially life-threatening adverse effect. The American Academy of HIV Medicine and the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend avoiding abacavir in HLA-B*57:01-positive individuals, as the presence of this allele is a strong predictor of HSR. Alternative antiretroviral therapy options should be considered for these individuals to minimize the risk of HSR.	-0.19140175	0.32400525	0.014320754	tensor(-0.1502)	tensor(0.2778)	tensor(0.0192)	0.7018361395257449	0.6578988040887144	0.7600543178364253	0.7637198	0.6457613	0.81565624	0.66455036	0.6200985	0.8705849	0.59122556	0.5833575	0.81285465	0.642473	0.66074246	0.7781236	1
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Use abacavir per standard dosing guidelines	['Avoid abacavir. Take an alternate therapy.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Proceed taking abacavir as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are HLA-B*57:01 negative can safely initiate abacavir therapy, as the risk of hypersensitivity reaction is significantly lower in this population. However, it is still important to monitor patients for signs and symptoms of hypersensitivity reaction, as it can still occur in HLA-B*57:01 negative individuals. Routine HLA-B*57:01 screening is not recommended for patients who will not be treated with abacavir.	-0.14156441	0.25106344	0.025461497	tensor(-0.1294)	tensor(0.3453)	tensor(0.0657)	0.6444266694622739	0.6070956473455326	0.7523120277915231	0.62039596	0.57728857	0.66466814	0.62507063	0.6285106	0.7724148	0.49393576	0.4639474	0.74568725	0.5941933	0.56642425	0.68976	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Allopurinol is contraindicated	['Proceed taking allopurinol as normal. There is no recommendation.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Avoid allopurinol. Take an alternate therapy.	According to clinical guidelines, individuals who are HLA-B*58:01 positive should avoid taking allopurinol due to the significantly increased risk of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The FDA recommends screening for HLA-B*58:01 in patients of Asian ancestry, as they are more likely to carry this allele, and alternative treatments should be considered for HLA-B*58:01-positive individuals. This guidance is supported by multiple studies and professional organizations, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the American College of Rheumatology.	-0.21900856	0.2133136	-0.040739086	tensor(-0.1951)	tensor(0.2973)	tensor(-0.0105)	0.5792205884952705	0.5565111990896908	0.7334331181180042	0.7597368	0.5949902	0.7339339	0.626773	0.5642545	0.78995836	0.40569198	0.4718789	0.6430116	0.6481131	0.61579347	0.6872222	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Use allopurinol per standard dosing guidelines	['Avoid allopurinol. Take an alternate therapy.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Proceed taking allopurinol as normal. There is no recommendation.	For individuals who are HLA-B*58:01 negative, the clinical guidance is that they can be prescribed allopurinol without an increased risk of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, it is still important to monitor patients for any signs of hypersensitivity reactions, as HLA-B*58:01 is not the only risk factor for SCARs. In general, the FDA recommends that HLA-B*58:01 testing should not be used to rule out the use of allopurinol in patients who are negative for this allele.	-0.17435187	0.2347166	-0.0025030037	tensor(-0.1550)	tensor(0.3186)	tensor(0.0283)	0.6157302267130559	0.603455746410295	0.7373529677825363	0.601711	0.6207691	0.71061313	0.5809354	0.5276444	0.818009	0.46280286	0.4401683	0.70139337	0.6407059	0.6027321	0.6518097	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking amikacin as normal. There is no recommendation.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Avoid amikacin. Take an alternate therapy.	Based on pharmacogenomics guidelines, individuals with the mitochondrial MT-RNR1 variant (m.1555A>G or m.1494C>T) are at increased risk of aminoglycoside-induced hearing loss. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends avoiding amikacin and other aminoglycosides in these individuals, or using alternative antibiotics when possible, due to the high risk of ototoxicity. If amikacin must be used, close monitoring of hearing and renal function is advised, along with consideration of alternative dosing regimens or additional therapeutic monitoring.	0.04536366	0.24400136	0.13956116	tensor(-0.1073)	tensor(0.2982)	tensor(0.0504)	0.6933009009658974	0.5128152157883389	0.47300988554893864	0.67972314	0.5449272	0.55981016	0.69338596	0.5258415	0.507757	0.66800743	0.49691665	0.51828355	0.6238985	0.64811903	0.5752193	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss, as determined by their MT-RNR1 genotype, clinical guidance suggests that amikacin can be used at the standard dosage and monitoring schedule, as the risk of ototoxicity is not significantly increased. However, it is still important to closely monitor for signs of hearing loss or vestibular toxicity, particularly in patients with other risk factors or those receiving prolonged or high-dose therapy. Regular audiological assessments and monitoring of renal function are also recommended to minimize the risk of adverse effects.	0.034299616	0.25484002	0.13767119	tensor(-0.0785)	tensor(0.3673)	tensor(0.1042)	0.7068501389782349	0.5847064178870073	0.4983220689341493	0.6638739	0.60251915	0.5545074	0.7127613	0.63738936	0.5777282	0.7521633	0.49363813	0.530801	0.69909346	0.57795405	0.60883355	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (particularly the m.1555A>G or m.1494C>T variants) are at increased risk of aminoglycoside-induced hearing loss, including with amikacin. The CPIC recommends that these individuals avoid or use alternative antibiotics whenever possible, and if amikacin is necessary, to closely monitor for ototoxicity and consider audiometric testing. Additionally, the CPIC suggests that the benefits of amikacin therapy should be carefully weighed against the potential risk of hearing loss in these individuals.	-0.0824712	0.17971592	0.037044786	tensor(-0.1386)	tensor(0.3833)	tensor(0.0713)	0.5772088078217154	0.5056129732377064	0.4983220689341493	0.48221764	0.43824282	0.5545074	0.6590626	0.5734997	0.5777282	0.6788798	0.53355616	0.530801	0.55434847	0.552472	0.60883355	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid using aminosalicylic acid, as it can increase the risk of hemolytic anemia. This is because aminosalicylic acid is known to precipitate hemolysis in G6PD-deficient individuals. Alternative therapies should be considered, and if aminosalicylic acid is deemed necessary, close monitoring for signs of hemolysis is recommended.	-0.093377225	0.15662944	0.02121405	tensor(-0.0099)	tensor(0.4397)	tensor(0.1801)	0.61237531449484	0.5657688522564266	0.3628768605253921	0.620685	0.6657098	0.45775127	0.6092254	0.64116156	0.3852969	0.55484957	0.54541045	0.36039174	0.5335133	0.54521954	0.42451632	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and therefore, aminosalicylic acid (PAS) should be used with caution or avoided due to the risk of hemolytic anemia. This is because PAS can trigger hemolysis in individuals with G6PD deficiency, and the indeterminate result may indicate a reduced enzyme activity. As a result, alternative treatments should be considered, and the patient should be closely monitored for signs of hemolysis if PAS is used.	0.053483672	0.3100085	0.1717731	tensor(-0.1148)	tensor(0.4394)	tensor(0.1061)	0.6614145105864919	0.5462667782407543	0.301519857334226	0.5518173	0.6571308	0.32068476	0.6799908	0.6648158	0.33260477	0.62635696	0.551718	0.25907266	0.5381938	0.5453029	0.4185267	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class I or II deficiency (such as those with a CNSHA variant) should avoid using aminosalicylic acid due to the increased risk of hemolytic anemia. This is because aminosalicylic acid can exacerbate G6PD deficiency, leading to severe hemolysis. As such, alternative medications should be considered for these individuals.	-0.10071315	0.11060589	-0.0018215363	tensor(-0.0620)	tensor(0.4187)	tensor(0.1372)	0.44083503517272643	0.5648833046145352	0.4288612522394752	0.46178627	0.64564514	0.54422027	0.45496398	0.6318584	0.49296308	0.47515652	0.55410033	0.39857784	0.5074432	0.5552607	0.4836932	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	Based on current evidence, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take aminosalicylic acid without concern for hemolytic anemia, as they are not at increased risk for this adverse effect. Aminosalicylic acid is not contraindicated in individuals with normal G6PD activity, and no dose adjustments are recommended. Therefore, normal G6PD individuals can receive standard dosing of aminosalicylic acid without increased monitoring or precautions.	-0.09260349	0.17123902	0.027470985	tensor(-0.0169)	tensor(0.4015)	tensor(0.1585)	0.6452672489807254	0.6143447347482315	0.32600336670886454	0.5458489	0.7199068	0.2866903	0.46575522	0.71724224	0.21298236	0.42268538	0.610539	0.13092467	0.55951715	0.6044942	0.3716985	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	Based on the pharmacogenomic profile, for an individual who is an Ultrarapid Metabolizer (UM) for CYP2D6 (activity score ≥3.0) and an Intermediate Metabolizer (IM) for CYP2C19, clinical guidance suggests that they may require closer monitoring and potential dose adjustments when taking amitriptyline. The UM CYP2D6 genotype may lead to increased metabolism and reduced efficacy of amitriptyline, while the IM CYP2C19 genotype may affect the drug's active metabolite formation. As a result, healthcare providers should consider initiating therapy at a lower dose and titrating slowly to achieve optimal therapeutic response while minimizing adverse effects.	-0.068493925	0.28789693	0.08705542	tensor(-0.1397)	tensor(0.4474)	tensor(0.0901)	0.703865219870709	0.5822540873635716	0.6761597814167967	0.6169349	0.5066103	0.65662014	0.6124108	0.6247948	0.72874606	0.49708802	0.47811	0.567458	0.50673586	0.52267206	0.5949565	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	Based on the pharmacogenomic profile, a person who is a Poor Metabolizer (PM) for CYP2D6 (activity score = 0.0) and an Intermediate Metabolizer (IM) for CYP2C19 may require caution when taking amitriptyline. The CYP2D6 PM status may lead to increased amitriptyline levels and potentially increased risk of adverse effects, such as drowsiness, dizziness, and anticholinergic effects. Dose reduction and close monitoring for adverse effects may be necessary, and alternative medications or therapeutic strategies may be considered, especially in patients with a history of sensitivity to tricyclic antidepressants.	-0.016146993	0.262098	0.11031502	tensor(-0.1175)	tensor(0.3491)	tensor(0.0668)	0.702786058509278	0.6084274682882269	0.7531740305806397	0.6374275	0.5715501	0.6956771	0.65348816	0.66028386	0.7862296	0.5457393	0.5769624	0.63873184	0.6020267	0.5989763	0.58493006	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥4.0, clinical guidance suggests using caution when initiating amitriptyline therapy due to the potential for reduced efficacy or increased risk of adverse effects. The UM phenotype may result in rapid metabolism of amitriptyline, leading to lower plasma concentrations and potentially reduced therapeutic response. Close monitoring of response and potential dose adjustments may be necessary to achieve optimal treatment outcomes.	0.1537291	0.18489335	0.17157242	tensor(-0.0750)	tensor(0.3722)	tensor(0.1126)	0.6342709320510659	0.5763418559863281	0.5419076213519441	0.69134337	0.5881816	0.50975627	0.6473762	0.6478072	0.4765109	0.6370569	0.5473759	0.42915663	0.55608296	0.56383586	0.459536	0
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	Based on the pharmacogenomic profile, the clinical guidance for someone who is an Ultrarapid Metabolizer (UM) with an activity score of 2.5 for CYP2D6 and a Rapid Metabolizer (RM) for CYP2C19, considering amitriptyline therapy, would be to exercise caution and closely monitor for adverse effects or therapeutic failure. Dosing adjustments may be necessary, as UM CYP2D6 individuals may metabolize amitriptyline too quickly, leading to reduced efficacy, while RM CYP2C19 individuals may metabolize it too rapidly, increasing the risk of toxicity. Therefore, a lower initial dose and gradual titration, accompanied by regular therapeutic drug monitoring, is recommended to optimize treatment outcomes.	-0.055142336	0.37973863	0.12866113	tensor(-0.1690)	tensor(0.3845)	tensor(0.0493)	0.6975989011651086	0.5637503790552275	0.6761597814167967	0.6471362	0.5488107	0.65662014	0.6304822	0.6266956	0.72874606	0.52155244	0.50606567	0.567458	0.5587952	0.5730174	0.5949565	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid using high doses of aspirin (>130 mg/day) due to the increased risk of hemolytic anemia. Low doses of aspirin (≤130 mg/day) may be used with caution, but close monitoring of hemoglobin levels and signs of hemolysis is recommended. It is essential to weigh the benefits of aspirin therapy against the potential risks in G6PD-deficient individuals.	-0.06761673	0.18788761	0.049377844	tensor(-0.1399)	tensor(0.2812)	tensor(0.0362)	0.6390710700621144	0.5250934317747125	0.3495356277549228	0.6363567	0.55904716	0.3433225	0.6348945	0.5444058	0.2283978	0.601984	0.53084695	0.22196458	0.58399343	0.534918	0.3789261	0
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and aspirin therapy should be used with caution. Aspirin is not contraindicated in G6PD-deficient individuals, but they may be at increased risk of hemolytic anemia. Therefore, close monitoring of hematological parameters is recommended, especially in high-risk individuals or those taking high doses of aspirin.	0.102086574	0.32269534	0.20575805	tensor(-0.0991)	tensor(0.3052)	tensor(0.0606)	0.6737460891625465	0.49909541820946757	0.29399567449795266	0.5198708	0.60947186	0.1665624	0.6222891	0.49865	0.091090694	0.5874379	0.4916374	0.089750946	0.54207253	0.58695567	0.40198952	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, specifically those with Class I (severe) or Class II (moderate) deficiency, should avoid using aspirin or use it with caution due to the increased risk of hemolytic anemia. This is because aspirin can exacerbate the enzyme deficiency, leading to hemolysis. However, for those with Class III (mild) deficiency, aspirin can be used with normal dosing and monitoring.	-0.036550097	0.17773262	0.06389547	tensor(-0.1544)	tensor(0.2835)	tensor(0.0205)	0.46842858919602004	0.48960850707793807	0.4508183629622349	0.52696145	0.58122855	0.54445606	0.49532038	0.52406186	0.4783494	0.4542454	0.5096896	0.37036338	0.5308287	0.5338041	0.50539386	0
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For an individual who is normal for G6PD (glucose-6-phosphate dehydrogenase), there are no specific clinical precautions or restrictions for taking aspirin. Aspirin is not a trigger for hemolytic anemia in individuals with normal G6PD activity, and it can be used at usual therapeutic doses without concern for G6PD-related adverse effects. Therefore, the usual clinical guidelines for aspirin therapy, including dosing and monitoring, should be followed in individuals with normal G6PD activity.	-0.031878524	0.18437165	0.06940455	tensor(-0.1157)	tensor(0.2811)	tensor(0.0534)	0.6343627758568487	0.5924570557372817	0.291013348601024	0.5266674	0.62414086	0.21995851	0.48238397	0.5899864	0.1263408	0.38588434	0.50235766	0.043413773	0.5419856	0.55284935	0.33837625	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal metabolizers for UGT1A1 (i.e., *1/*1 or *1/*28 genotype) can be prescribed atazanavir at the standard dose without adjustment, as they are not at increased risk of hyperbilirubinemia. Monitoring of bilirubin levels is still recommended, but no dose reduction or alternative therapy is necessary. This is because normal metabolizers have sufficient UGT1A1 enzyme activity to metabolize atazanavir and are less likely to experience elevated bilirubin levels.	0.096023045	0.21115659	0.15353149	tensor(-0.1145)	tensor(0.4371)	tensor(0.0996)	0.7676743224454694	0.6376211429216786	0.6132105652246198	0.6782786	0.56899995	0.61266357	0.7603685	0.59435517	0.6482699	0.6895135	0.50931656	0.48351327	0.7204665	0.58743954	0.5765461	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	['Proceed taking atazanavir as normal. There is no recommendation.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Avoid atazanavir. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are poor metabolizers (PMs) for UGT1A1, which is responsible for glucuronidation of atazanavir, may be at increased risk of hyperbilirubinemia and jaundice due to reduced clearance of atazanavir. Therefore, CPIC recommends that UGT1A1 PMs should be closely monitored for bilirubin elevations and alternative antiretroviral therapy should be considered. Additionally, the FDA label for atazanavir also recommends caution in patients with UGT1A1 polymorphisms.	0.061776213	0.1548744	0.109222226	tensor(-0.0920)	tensor(0.2991)	tensor(0.0536)	0.7189101145250035	0.5774642163618472	0.6241943652007613	0.63831586	0.47374532	0.52034414	0.6278822	0.55098116	0.6405023	0.60373133	0.4964775	0.5209363	0.6262001	0.5738417	0.6180625	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	No recommendation	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for UGT1A1 (i.e., unable to be classified as normal metabolizer, intermediate metabolizer, or poor metabolizer) should be treated similarly to intermediate metabolizers. For atazanavir, this means that no specific dosage adjustment is recommended, but close monitoring for hyperbilirubinemia is advised. Additionally, alternative antiretroviral therapy may be considered, especially in patients with pre-existing hyperbilirubinemia or those at increased risk for bilirubin-related adverse effects.	-0.30344155	0.03273511	-0.159957	tensor(-0.1229)	tensor(0.4204)	tensor(0.0943)	0.2844970789349051	0.6442415331367293	0.27681807077981246	0.12883207	0.52326584	0.27900407	0.11472588	0.5152572	0.14376321	-0.00576702	0.47947663	0.14414586	0.27222818	0.53383166	0.4572534	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are intermediate metabolizers for UGT1A1 (UGT1A1*28 or UGT1A1*36) may require reduced dosing of atazanavir, as they may have increased exposure to the drug due to reduced glucuronidation activity. This is because UGT1A1 is the primary enzyme responsible for atazanavir glucuronidation, and reduced activity may lead to increased risk of hyperbilirubinemia and bilirubin-related adverse effects. Therefore, close monitoring of bilirubin levels and potential dose reduction may be necessary in these individuals.	0.118964046	0.18129624	0.15188237	tensor(-0.1374)	tensor(0.3632)	tensor(0.0546)	0.7667860114677146	0.537041381298789	0.6132105652246198	0.6653625	0.47829565	0.61266357	0.74881417	0.575464	0.6482699	0.6303272	0.41575393	0.48351327	0.7046527	0.46483248	0.5765461	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	Based on the pharmacogenomics data, a Normal Metabolizer with a CYP2D6 activity score of 1.25 is expected to have normal enzyme function. For atomoxetine, a substrate of CYP2D6, this means that the individual can metabolize the drug normally, and no adjustments to the recommended dose are necessary. Therefore, atomoxetine can be prescribed at the standard dose, and the individual can be monitored for response and adverse effects as per usual clinical practice.	-8.357842e-05	-0.027647767	-0.011045047	tensor(-0.0608)	tensor(0.2613)	tensor(0.0821)	0.5029080375208065	0.6061936535402168	0.4182017632778383	0.3291891	0.3803602	0.40674835	0.34664348	0.5196564	0.39670482	0.45587507	0.5422529	0.47296175	0.31381252	0.64052856	0.2939223	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥3.75) may require a lower dose of atomoxetine, as they may experience increased metabolism and reduced efficacy. Alternatively, consideration can be given to using an alternative medication that is not a CYP2D6 substrate. Close monitoring of response and adjustment of dosage as needed is recommended.	-0.021138186	-0.03741884	-0.026304794	tensor(-0.0864)	tensor(0.4653)	tensor(0.1349)	0.5401777521030434	0.6400173139654024	0.4182017632778383	0.35651955	0.5878888	0.40674835	0.33686122	0.5910473	0.39670482	0.49577695	0.5553941	0.47296175	0.42530403	0.6983799	0.2939223	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥4.0) may require lower doses of atomoxetine due to increased metabolism and potential lower efficacy. The CPIC recommends considering a 25-50% reduction in the usual starting dose of atomoxetine and close monitoring for efficacy and adverse effects. Additionally, clinicians should be prepared to adjust the dose further based on the individual's response to treatment.	-0.010845004	0.0030373242	-0.0009894529	tensor(-0.1085)	tensor(0.3016)	tensor(0.0654)	0.5514741981270708	0.6479207512239682	0.4182017632778383	0.34280694	0.555864	0.40674835	0.358284	0.5779968	0.39670482	0.5146812	0.5567316	0.47296175	0.41827798	0.6942574	0.2939223	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	Based on the pharmacogenomics data, a patient who is a Normal Metabolizer with a CYP2D6 activity score of 1.5 is expected to metabolize atomoxetine normally. No dosage adjustment is recommended, and the standard dosing regimen for atomoxetine can be followed. However, it's essential to monitor the patient's response to treatment and adjust the dosage as needed based on clinical response and tolerability.	-0.010730882	-0.060184263	-0.032954197	tensor(-0.0492)	tensor(0.3136)	tensor(0.1090)	0.5039506122212661	0.6336144561200115	0.4182017632778383	0.41851032	0.4959191	0.40674835	0.4410671	0.51827437	0.39670482	0.54993933	0.5994944	0.47296175	0.31687742	0.5961246	0.2939223	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	According to clinical guidelines, individuals with increased function of SLCO1B1 (encoding OATP1B1) are at higher risk of myotoxicity when taking atorvastatin due to increased uptake of the statin into muscle cells. As a result, the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends considering an alternative statin or initiating atorvastatin at a lower dose with close monitoring for muscle toxicity in these individuals. Additionally, more frequent monitoring of creatine kinase (CK) levels and patient education on muscle toxicity symptoms are also advised.	-0.11652193	0.15692097	0.0070631523	tensor(-0.0721)	tensor(0.4817)	tensor(0.1454)	0.2985632065577118	0.502342797698161	0.38486914070619466	0.3289506	0.43533108	0.44341806	0.31860605	0.5273662	0.3772863	0.29743236	0.49390987	0.38324484	0.38935888	0.54730093	0.6314302	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	According to clinical guidelines, individuals with normal function of the SLCO1B1 gene (c.521CC or c.521CT genotype) can be prescribed atorvastatin at standard doses without adjustment, as they are expected to have normal transport of atorvastatin into the liver and typical response to the medication. No specific dosage adjustment or monitoring is recommended for these individuals. They can be treated according to standard clinical practice for atorvastatin therapy.	-0.08220967	0.18136717	0.037857246	tensor(-0.0420)	tensor(0.3475)	tensor(0.1157)	0.404164484724512	0.5759709138712709	0.38486914070619466	0.5230133	0.61412084	0.44341806	0.51323205	0.6602904	0.3772863	0.42046452	0.53036416	0.38324484	0.51134765	0.6161026	0.6314302	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate SLCO1B1 genotype (i.e., unable to determine functional allele) can still be considered for atorvastatin therapy, but may require closer monitoring for potential myotoxicity. The indeterminate genotype is not considered a strong predictor of atorvastatin-induced myotoxicity, and the benefits of statin therapy may outweigh the risks. However, it is recommended to initiate therapy at a lower dose and titrate up as needed, while monitoring for muscle-related adverse effects.	-0.2926897	-0.0073873503	-0.16708057	tensor(-0.0918)	tensor(0.4374)	tensor(0.1033)	0.2453141373501085	0.5031206703585808	0.2874412334636927	0.13603829	0.47747374	0.19976714	0.047082752	0.5643454	0.08437013	-0.009698075	0.49506634	0.09674076	0.28363788	0.5638189	0.48837376	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking atorvastatin as normal. There is no recommendation.', 'Avoid atorvastatin. Take an alternate therapy.']	Take atorvastatin with an altered dose.	For individuals with possible decreased function of SLCO1B1, the clinical guidance is to consider an alternative statin, such as rosuvastatin or pravastatin, as atorvastatin is a substrate of OATP1B1 (encoded by SLCO1B1) and may be associated with increased risk of myopathy. If atorvastatin is still chosen, close monitoring for muscle toxicity and consideration of a lower starting dose may be warranted. Additionally, the FDA recommends reducing the dose of atorvastatin by 50% in patients who are SLCO1B1 poor metabolizers.	0.13543372	0.16077931	0.15049088	tensor(-0.0416)	tensor(0.4308)	tensor(0.1554)	0.6726328727039632	0.5955733478737307	0.6248005278375613	0.6127414	0.5830882	0.61793417	0.6070718	0.5475011	0.71948	0.551252	0.53290075	0.5779946	0.6334255	0.62862897	0.58950794	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Take azathioprine with a reduced dose.', 'Take azathioprine with an increased dose.']	Avoid azathioprine. Take an alternate therapy.	Based on the pharmacogenomic profile, a Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15, the clinical guidance for azathioprine therapy would be to initiate therapy with a reduced dose (e.g., 25-50% of the standard dose) and closely monitor for myelosuppression, as the NUDT15 poor metabolizer status increases the risk of azathioprine-induced myelotoxicity. Additionally, frequent complete blood counts (CBCs) should be performed to detect early signs of bone marrow suppression. This approach can help mitigate the risk of adverse effects while still allowing the patient to potentially benefit from azathioprine therapy.	0.09955123	0.060927972	0.08264741	tensor(-0.1001)	tensor(0.4843)	tensor(0.1308)	0.7170063173611895	0.5837933378202856	0.6336741091520266	0.6906521	0.55569446	0.6728961	0.67203724	0.57718027	0.6272959	0.6334775	0.57249403	0.6039137	0.6171908	0.6465144	0.59734607	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	Based on the pharmacogenomic profile, a Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 may be at increased risk for azathioprine toxicity due to reduced TPMT activity. Clinical guidance suggests initiating azathioprine at a reduced dose (e.g., 25-50% of the standard dose) and closely monitoring for signs of toxicity, such as myelosuppression, hepatotoxicity, and gastrointestinal symptoms. Additionally, regular complete blood counts and liver function tests should be performed to ensure safe and effective treatment.	0.17655545	0.15599474	0.16865158	tensor(-0.0646)	tensor(0.3913)	tensor(0.1262)	0.6689127456579408	0.6064431004737103	0.6123440158921024	0.51963425	0.5126501	0.5043845	0.5593937	0.44742662	0.6522019	0.51840585	0.5261611	0.5775165	0.55335027	0.6541884	0.5391916	1
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For an individual who is a Normal Metabolizer for TPMT and an Intermediate Metabolizer for NUDT15, the clinical guidance for taking azathioprine is to start with a standard dose and monitor closely for signs of myelosuppression, as they may be at increased risk of thiopurine-induced neutropenia. However, they are not at high risk of severe myelosuppression, and dose reduction may not be necessary initially. Close monitoring of complete blood counts and liver function tests is recommended to adjust the dose as needed.	0.10592147	-0.029098371	0.037408967	tensor(-0.0504)	tensor(0.4156)	tensor(0.1442)	0.7308109838804652	0.6199772800788479	0.6123440158921024	0.63866675	0.56794786	0.5043845	0.7547667	0.57474	0.6522019	0.663697	0.5773417	0.5775165	0.71333224	0.61668646	0.5391916	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	Based on the pharmacogenomics data, for an individual who is an Intermediate Metabolizer for TPMT and a Possible Intermediate Metabolizer for NUDT15, the clinical guidance would be to exercise caution when initiating azathioprine therapy. A reduced starting dose and close monitoring of thiopurine metabolite levels, complete blood counts, and liver function tests are recommended to minimize the risk of adverse reactions, such as myelosuppression and hepatotoxicity. Additionally, consideration of alternative therapies or more frequent monitoring may be necessary to ensure safe and effective treatment.	0.06893827	-0.048099894	0.010383713	tensor(-0.0357)	tensor(0.4658)	tensor(0.1712)	0.6560553802845877	0.5966446058739364	0.6123440158921024	0.517839	0.5224026	0.5043845	0.56881034	0.46602568	0.6522019	0.47050488	0.50911856	0.5775165	0.5737235	0.659175	0.5391916	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	Based on the pharmacogenomics data, for an individual who is an Intermediate Metabolizer (IM) with a Dihydropyrimidine Dehydrogenase (DPYD) activity score of 1.5, the clinical guidance suggests that they may be at increased risk of capecitabine toxicity, particularly hand-foot syndrome and diarrhea. It is recommended to consider reducing the initial dose of capecitabine by 25-50% and monitoring the patient closely for adverse reactions. Additionally, more frequent monitoring of complete blood counts and liver function tests may be necessary to mitigate the risk of toxicity.	-0.009379697	0.2721224	0.11843006	tensor(-0.1178)	tensor(0.2782)	tensor(0.0510)	0.48159971681147606	0.6505645268091896	0.41737586281915223	0.38785014	0.45286885	0.37031543	0.4360817	0.47502846	0.40144223	0.4152277	0.48132825	0.41396168	0.55314523	0.6573265	0.45501631	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Avoid capecitabine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are poor metabolizers (PM) of dihydropyrimidine dehydrogenase (DPYD) with an activity score of 0.0 should not receive capecitabine due to the high risk of severe and potentially life-threatening toxicity. Alternative therapies should be considered, and if capecitabine is unavoidable, close monitoring for toxicity and dose reduction or interruption should be implemented. Genetic testing for DPYD variants can help identify individuals at risk and guide personalized treatment decisions.	-0.112938605	0.038190916	-0.03947121	tensor(-0.1383)	tensor(0.3034)	tensor(0.0395)	0.47997680125594355	0.6214976572943013	0.503202223318939	0.5485849	0.5049837	0.6443426	0.38546637	0.39174	0.6201424	0.37551308	0.53162843	0.5533361	0.5522298	0.6618837	0.6299651	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a dihydropyrimidine dehydrogenase (DPYD) activity score of 1.0, indicating intermediate metabolizer status, may be at increased risk of capecitabine toxicity. The CPIC recommends that these patients be closely monitored for early signs of toxicity, such as diarrhea, hand-foot syndrome, and neutropenia, and that the dosage of capecitabine be reduced or altered as needed. Additionally, alternative therapies may be considered in certain situations, particularly in patients with a history of severe toxicity.	0.020447066	0.011947746	0.019080449	tensor(-0.1234)	tensor(0.3509)	tensor(0.0718)	0.5483911705727493	0.6227915164280132	0.45475867125318326	0.5325897	0.443976	0.4142069	0.49070308	0.49379942	0.46721348	0.4266815	0.5129176	0.3910352	0.46625084	0.6644043	0.3446653	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid capecitabine. Take an alternate therapy.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Proceed taking capecitabine as normal. There is no recommendation.	Based on the pharmacogenomic data, a patient with a Normal Metabolizer phenotype and a DPYD activity score of 2.0 is expected to have normal dihydropyrimidine dehydrogenase (DPD) enzyme activity. This suggests that they are at average risk for capecitabine-related toxicity, and no specific dose adjustments or alternative therapies are recommended. Standard dosing of capecitabine can be initiated, with routine monitoring for adverse effects.	-0.010454204	0.2724892	0.11791399	tensor(-0.0522)	tensor(0.3829)	tensor(0.1318)	0.4594588343101048	0.5671181563539907	0.4533250209630239	0.44296086	0.4638048	0.49402237	0.4411413	0.5669564	0.43519598	0.46358833	0.5811307	0.5211694	0.562136	0.61912125	0.4872182	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For an individual who is HLA-A*31:01 negative and HLA-B*15:02 negative, the clinical guidance is that they are not at increased risk of developing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) associated with these specific genetic markers. However, it is still important to monitor for signs of hypersensitivity reactions, as carbamazepine can cause SJS/TEN in individuals without these genetic markers. Therefore, the usual precautions and monitoring should still be taken when prescribing carbamazepine to this individual.	-0.12142667	0.3033812	0.05721306	tensor(-0.0977)	tensor(0.3251)	tensor(0.0809)	0.5345425225356485	0.5321017990292111	0.7301588816934647	0.35166016	0.5544152	0.76823014	0.48416263	0.51574165	0.8774866	0.3742163	0.43269217	0.79614604	0.50926805	0.5031686	0.7973516	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	Based on the pharmacogenomics literature, for an individual who is HLA-A*31:01 negative and HLA-B*15:02 negative, the clinical guidance for taking carbamazepine is as follows: This individual is not at increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) associated with HLA-A*31:01 or HLA-B*15:02 alleles, and carbamazepine can be prescribed without concern for these specific genetic risk factors. However, it is essential to still monitor the patient for signs and symptoms of SJS/TEN, as other genetic and non-genetic factors can contribute to the risk of this adverse reaction. Regular clinical monitoring and attention to patient-specific factors are still necessary to ensure safe and effective therapy.	-0.19629148	0.30562896	0.0050443625	tensor(-0.1707)	tensor(0.3665)	tensor(0.0426)	0.5716674065263493	0.5838583101786301	0.7301588816934647	0.53988296	0.5900246	0.76823014	0.5282393	0.5703761	0.8774866	0.38570905	0.43466318	0.79614604	0.5662279	0.5476644	0.7973516	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	Based on the pharmacogenomics guidelines, for an individual who is HLA-A*31:01 negative and has no HLA-B result, there is no increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) associated with HLA-A*31:01 or HLA-B*15:02. Therefore, carbamazepine can be prescribed and monitored as per the usual clinical guidelines, with no specific genotype-based precautions or contraindications. However, it is essential to still monitor the patient for signs of hypersensitivity reactions, as they can occur regardless of genotype.	-0.13602158	0.40532142	0.08004961	tensor(-0.1399)	tensor(0.3209)	tensor(0.0470)	0.5874576688399318	0.5881266606114834	0.7301588816934647	0.394008	0.5842469	0.76823014	0.5352735	0.57003284	0.8774866	0.37395483	0.41306323	0.79614604	0.58360696	0.5538054	0.7973516	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For an individual with no HLA-A result and HLA-B*15:02 negative, the clinical guidance recommends proceeding with caution when considering carbamazepine therapy. While the absence of HLA-B*15:02 reduces the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the unknown HLA-A status does not completely eliminate the risk of severe cutaneous adverse reactions (SCARs). As such, close monitoring for signs of hypersensitivity reactions is advised, and alternative medications should be considered if possible.	-0.15002729	0.33018878	0.04616228	tensor(-0.1114)	tensor(0.4284)	tensor(0.1052)	0.4990077789248316	0.5401489298280139	0.7301588816934647	0.5400255	0.66957986	0.76823014	0.54491323	0.57622546	0.8774866	0.39629734	0.46759668	0.79614604	0.5068984	0.53786737	0.7973516	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with a CYP2C9 activity score of 2.0, the clinical guidance suggests that they can likely metabolize celecoxib (a CYP2C9 substrate) normally. No dose adjustment is recommended, and the usual celecoxib dosing can be initiated. However, it's essential to monitor the patient for efficacy and adverse effects, as individual variability in response to celecoxib may still occur.	-0.07319348	0.12533829	0.020534493	tensor(-0.0468)	tensor(0.3123)	tensor(0.1076)	0.4385518090779034	0.652396380651176	0.46166114717639106	0.39399385	0.6214154	0.4888667	0.4223888	0.67480516	0.38466525	0.40354264	0.6022896	0.4365867	0.42982844	0.6491919	0.49844813	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 1.5 for CYP2C9 may require a moderate dose reduction of celecoxib, as they may experience higher celecoxib concentrations and increased risk of adverse effects. A recommended dose reduction of 25-50% may be necessary to achieve optimal therapeutic response while minimizing toxicity. Close monitoring of therapeutic response and adverse effects is also recommended.	-0.050876003	0.17255376	0.05326672	tensor(-0.0753)	tensor(0.3434)	tensor(0.0924)	0.46394984880120904	0.5885536236762042	0.46166114717639106	0.4208771	0.54171056	0.4888667	0.40105066	0.65097994	0.38466525	0.38092855	0.57886785	0.4365867	0.44663313	0.5860167	0.49844813	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	No recommendation	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	Based on the available evidence, individuals who are indeterminate for CYP2C9, meaning they have an unclear or unknown CYP2C9 genotype, should be treated as intermediate metabolizers. As such, they may require a moderate dose reduction of celecoxib, a CYP2C9 substrate, to minimize the risk of adverse effects, such as gastrointestinal toxicity. Close monitoring of therapeutic response and adverse effects is recommended to ensure optimal therapy.	-0.2793614	-0.011469494	-0.15997154	tensor(-0.0869)	tensor(0.3997)	tensor(0.1104)	0.2447777219280254	0.5538308969554928	0.2463854589858451	0.119569026	0.50370026	0.1827038	0.055956546	0.5839279	0.09324267	-0.019491814	0.5761056	0.10247386	0.34158564	0.6165612	0.5117869	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer (IM) with an activity score of 1.0 for CYP2C9, clinical guidance suggests that they may require a moderate dose reduction of celecoxib, a CYP2C9 substrate, to avoid potential adverse effects. This is because IMs may have reduced enzyme activity, leading to increased exposure to celecoxib and increased risk of gastrointestinal toxicity. Close monitoring of therapeutic response and adverse effects is recommended to ensure optimal treatment outcomes.	-0.043714073	0.06919093	0.012893598	tensor(-0.0692)	tensor(0.3797)	tensor(0.1049)	0.48504711620555196	0.5595164901855378	0.45955762479830464	0.5325654	0.535118	0.53302896	0.39453906	0.5886731	0.37706223	0.4180189	0.57273823	0.40605032	0.4664305	0.58979684	0.43486226	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and alternative antibiotics should be considered instead of chloramphenicol to minimize the risk of hemolytic anemia. If chloramphenicol must be used, close monitoring of hemoglobin levels and signs of hemolysis is recommended. However, it is essential to consult a healthcare professional for personalized guidance, as the management of G6PD deficiency can vary depending on the specific clinical situation.	0.1095731	0.30520028	0.20265436	tensor(-0.0461)	tensor(0.3911)	tensor(0.1387)	0.6588313506322129	0.5477923662344635	0.3298851050531941	0.5598999	0.5381156	0.21961899	0.64855886	0.49617124	0.16729653	0.61782336	0.5066059	0.19322641	0.5777855	0.55828595	0.4187926	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	According to pharmacogenomics guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with Class I or II deficiency (CNSHA, Class I being the most severe), should avoid chloramphenicol due to increased risk of hemolytic anemia. Chloramphenicol is known to exacerbate G6PD deficiency, leading to severe hemolysis, and alternative antibiotics should be considered. If chloramphenicol is deemed necessary, close monitoring of hemoglobin levels and signs of hemolysis is crucial.	-0.019051153	0.22968242	0.09559568	tensor(-0.0452)	tensor(0.3974)	tensor(0.1415)	0.47180440419205927	0.5212876737995076	0.47442339774490255	0.529267	0.5556818	0.5332437	0.55749243	0.5220099	0.44248256	0.4994261	0.5181921	0.37597755	0.5426758	0.60599756	0.49908352	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with normal G6PD activity can take chloramphenicol without concerns of hemolytic anemia, as they are not at increased risk of this adverse effect. However, it is still important to monitor for signs and symptoms of hemolysis, as chloramphenicol can cause hemolytic anemia in rare cases, even in individuals with normal G6PD activity. No dosage adjustments or special precautions are required for individuals with normal G6PD activity taking chloramphenicol.	-0.1096085	0.19895822	0.027508194	tensor(-0.0665)	tensor(0.3234)	tensor(0.0996)	0.5953138064511753	0.5988740289514948	0.31986378594455944	0.4739752	0.570252	0.2486875	0.40239298	0.5188856	0.14397222	0.39429894	0.5973107	0.11009276	0.5063587	0.5991177	0.3739946	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are G6PD variable (intermediate activity) should be cautioned when using chloramphenicol, as they may be at increased risk of hemolytic anemia. However, the risk is generally considered lower compared to individuals with G6PD deficiency (severe deficiency). Close monitoring for signs of hemolysis is recommended, and alternative antibiotics should be considered if possible.	-0.06901674	0.12572171	0.02314173	tensor(-0.0625)	tensor(0.4422)	tensor(0.1446)	0.6217668569665263	0.5510488770807177	0.376033049264508	0.65590316	0.47503927	0.3577101	0.63574904	0.5557082	0.23417139	0.6536338	0.5764466	0.3118298	0.5563765	0.59568244	0.44113037	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with Class I or II deficiency (including those with the CNSHA variant), should avoid using chloroquine due to the increased risk of hemolytic anemia. Alternative antimalarial agents should be considered, and if chloroquine is necessary, close monitoring for hemolysis is recommended. In addition, a careful risk-benefit assessment should be performed, taking into account the severity of the G6PD deficiency and the medical necessity of chloroquine treatment.	-0.043019887	0.3046759	0.10973588	tensor(-0.0858)	tensor(0.3805)	tensor(0.1079)	0.4543518670251822	0.5318035934846153	0.46427836923307836	0.45674887	0.5994281	0.5336378	0.42414507	0.5061892	0.4401186	0.48963985	0.54469955	0.2909989	0.5385455	0.51347536	0.52135956	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can take chloroquine without dose adjustment or special precautions, as they are not at increased risk for hemolytic anemia. This is because G6PD normal individuals have sufficient enzyme activity to protect against chloroquine-induced oxidative stress. Therefore, chloroquine can be used at standard doses in G6PD normal individuals.	-0.09761449	0.13792366	0.0111503	tensor(-0.0795)	tensor(0.3750)	tensor(0.1059)	0.6383830929581792	0.6061153728956912	0.3247903941760712	0.49047264	0.6640622	0.24304886	0.3724254	0.6364512	0.14943185	0.33493823	0.6053916	0.06893115	0.59717536	0.5705433	0.40493053	1
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a variant G6PD genotype (i.e., intermediate or reduced enzyme activity) may be at increased risk of hemolytic anemia when taking chloroquine. As a result, CPIC recommends caution and close monitoring for hemolysis when prescribing chloroquine to these individuals, especially at higher doses or for prolonged periods. In some cases, alternative antimalarial agents may be considered to minimize the risk of hemolytic adverse events.	-0.10601738	0.19187953	0.027099542	tensor(-0.0681)	tensor(0.4035)	tensor(0.1205)	0.5893454921586767	0.5346146137776403	0.3756918567212018	0.5233974	0.51653844	0.3692729	0.41701132	0.53377527	0.2781609	0.5197992	0.5433831	0.23147692	0.5272521	0.49781206	0.42640126	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid using chloroquine due to the increased risk of hemolytic anemia. This is because chloroquine can exacerbate the underlying G6PD deficiency, leading to severe hemolysis and potentially life-threatening complications. Instead, alternative antimalarial agents should be considered, and G6PD deficiency testing should be performed before initiating chloroquine therapy.	-0.06023704	0.14686859	0.037118692	tensor(-0.0546)	tensor(0.3792)	tensor(0.1288)	0.6183332231247867	0.513257523730962	0.3756918567212018	0.5874465	0.60657287	0.3692729	0.47020456	0.5139202	0.2781609	0.5771801	0.5407034	0.23147692	0.5636846	0.52962136	0.42640126	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking ciprofloxacin, as it can increase the risk of hemolytic anemia. The CPIC recommends alternative antibiotics, such as beta-lactams or macrolides, for G6PD-deficient patients. If ciprofloxacin is deemed necessary, close monitoring of hematologic parameters and clinical signs of hemolysis is recommended.	-0.0686161	0.13934205	0.029053727	tensor(-0.1518)	tensor(0.3293)	tensor(0.0446)	0.5488048495995805	0.5162535897967522	0.33948416727735087	0.59344625	0.5946488	0.3667072	0.5781954	0.55528677	0.22102182	0.59689444	0.5718956	0.29518616	0.546767	0.6007481	0.40462434	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and ciprofloxacin should be used with caution or alternative antibiotics considered. This is because ciprofloxacin has been reported to cause hemolytic anemia in G6PD-deficient individuals, and the indeterminate status may indicate a reduced enzyme activity. The patient's medical history and other factors should be taken into account when making a treatment decision.	0.09973832	0.34862578	0.2151718	tensor(-0.1321)	tensor(0.2629)	tensor(0.0354)	0.6407109044364133	0.49435802437897514	0.2808194196339871	0.54587126	0.59069365	0.21914718	0.6465112	0.53000325	0.14474614	0.65378934	0.5541343	0.19241762	0.553325	0.5796445	0.42260578	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II deficiency (including those with the CNSHA variant) should avoid taking ciprofloxacin due to the increased risk of hemolytic anemia. Alternative antibiotics should be considered, and if ciprofloxacin is deemed necessary, close monitoring for hemolysis is recommended.	0.0056005213	0.30895203	0.14211883	tensor(-0.1553)	tensor(0.3179)	tensor(0.0384)	0.4491925800485603	0.5083813446034471	0.4496948000741452	0.4631516	0.5472564	0.5394332	0.47001183	0.5498629	0.4210224	0.5048154	0.5409769	0.36975563	0.5290459	0.6039515	0.48262286	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For an individual who is normal for glucose-6-phosphate dehydrogenase (G6PD), there are no specific clinical guidelines or restrictions for taking ciprofloxacin. Ciprofloxacin is not typically associated with hemolysis or other adverse effects related to G6PD deficiency, and it can be used as indicated for bacterial infections in individuals with normal G6PD activity. Standard dosing and monitoring recommendations for ciprofloxacin should be followed, with no special considerations necessary due to G6PD status.	-0.008452922	0.27765158	0.12117836	tensor(-0.1343)	tensor(0.2455)	tensor(0.0284)	0.5852861565599722	0.5872624277237728	0.2902071009743858	0.53888965	0.61689705	0.2598927	0.48548073	0.6295406	0.13660517	0.37981942	0.5732246	0.09594931	0.55395776	0.5705725	0.38566232	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are rapid metabolizers of CYP2C19 may require higher doses of citalopram to achieve therapeutic efficacy, as they may metabolize the drug more quickly. However, the optimal dosing strategy for these individuals has not been established, and close therapeutic drug monitoring is recommended to ensure adequate response and minimize adverse effects. Additionally, clinicians should be aware of the potential for increased risk of QTc prolongation in rapid metabolizers, particularly at higher doses.	0.023422662	0.14073183	0.081977546	tensor(-0.1091)	tensor(0.4150)	tensor(0.1024)	0.647974044263728	0.5624517452213827	0.6105633635269513	0.6323355	0.5020624	0.5781292	0.6377141	0.5814268	0.4897257	0.62018126	0.53086674	0.5635615	0.6323844	0.5878723	0.61340344	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are likely poor metabolizers (PMs) for CYP2C19 may require a lower dose of citalopram due to increased exposure to the drug. The guideline suggests considering a 25-50% reduction in the usual starting dose of citalopram, with close monitoring for adverse effects and therapeutic response. This is because CYP2C19 PMs may be at increased risk for citalopram-related adverse effects, such as QTc prolongation and serotonin syndrome.	0.14684895	0.30099186	0.22187051	tensor(-0.0752)	tensor(0.4174)	tensor(0.1273)	0.7906336958655771	0.6229171509435283	0.6666624865154738	0.7458428	0.527862	0.60298085	0.78236085	0.6293389	0.67367387	0.8097546	0.630158	0.62969136	0.77493054	0.63920057	0.6552726	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2C19 may require higher doses of citalopram to achieve therapeutic response, as they may metabolize the drug too quickly. However, the optimal dosing strategy for UMs is unclear, and close monitoring of response and adverse effects is recommended. Additionally, consideration should be given to alternative selective serotonin reuptake inhibitors (SSRIs) that are not metabolized by CYP2C19, such as fluoxetine or sertraline.	0.11318359	0.30338007	0.2039379	tensor(-0.1009)	tensor(0.3948)	tensor(0.0888)	0.7407599497798191	0.6234001501455246	0.6376998478430596	0.6206192	0.5287499	0.59380543	0.7549653	0.579271	0.646408	0.7917481	0.6165395	0.6439027	0.75451726	0.6243366	0.6570368	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for CYP2C19, meaning they have a genotype that does not clearly predict normal or impaired function, should be treated as having normal CYP2C19 function. Therefore, no adjustments to citalopram dosing are recommended, and standard dosing can be used. However, clinicians should still monitor the patient's response to therapy and adjust as needed based on clinical presentation.	-0.26451364	0.060265932	-0.1241313	tensor(-0.0923)	tensor(0.3933)	tensor(0.1075)	0.2558566339614625	0.6270561495434511	0.25369488816638286	0.18607818	0.6095794	0.18024164	0.04202982	0.6322551	0.10242137	-0.03838291	0.5107748	0.09807018	0.31149602	0.6353394	0.50696933	1
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, as an Intermediate Metabolizer for CYP2D6 with an activity score of 1.0, the individual may have reduced metabolism of clomipramine, which is primarily metabolized by CYP2D6. This may lead to higher plasma concentrations and increased risk of adverse effects. However, as a Rapid Metabolizer for CYP2C19, the individual may have enhanced metabolism of clomipramine's active metabolite, desmethylclomipramine, which may counterbalance the reduced CYP2D6 activity. Close monitoring of therapeutic response and adverse effects is recommended, with consideration of dosage adjustments or alternative therapies if necessary.	0.11073195	0.32090554	0.21002282	tensor(-0.1254)	tensor(0.3626)	tensor(0.0742)	0.7710993466512605	0.6306777081288418	0.7025733812371764	0.69586796	0.54665554	0.6362271	0.82753843	0.62802845	0.6699458	0.79126036	0.61783284	0.6200737	0.7291017	0.65249133	0.67646736	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, this individual would be expected to have reduced metabolism of clomipramine, a substrate of both CYP2D6 and CYP2C19. As an Intermediate Metabolizer for CYP2D6 and Poor Metabolizer for CYP2C19, they may be at increased risk of adverse effects, such as anticholinergic side effects, seizures, and cardiac arrhythmias, due to elevated plasma concentrations of clomipramine. Therefore, the clinical guidance would be to consider a lower starting dose of clomipramine, with close monitoring of therapeutic response and adverse effects, and potential consideration of alternative medications or therapeutic strategies.	-0.034123126	0.20239674	0.07546971	tensor(-0.1132)	tensor(0.4556)	tensor(0.1123)	0.7414363039423645	0.6632711846006757	0.7480804256560305	0.5750952	0.51847726	0.7117508	0.64873075	0.62035984	0.7710818	0.5896212	0.6882573	0.64531374	0.5773257	0.7247862	0.6043611	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	"Based on the pharmacogenomics results, for an individual who is classified as ""No Result"" for CYP2D6 activity score and a Rapid Metabolizer for CYP2C19, the clinical guidance for taking clomipramine would be to exercise caution and monitor closely for adverse effects. This is because clomipramine is a substrate of both CYP2D6 and CYP2C19, and the lack of CYP2D6 activity score information may mask potential poor metabolizer status, while rapid metabolism by CYP2C19 may increase the risk of adverse effects. Close monitoring of therapy and potential dose adjustments may be necessary to ensure optimal treatment outcomes."	0.13164803	0.21016814	0.17217806	tensor(-0.1530)	tensor(0.3551)	tensor(0.0264)	0.5876533651685872	0.6562661777615808	0.5018103514888926	0.69314504	0.54915744	0.56276697	0.6027487	0.67472345	0.49649364	0.53295	0.6159361	0.46035483	0.5940384	0.6868715	0.50482476	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, individuals who are Poor Metabolizers (PMs) of CYP2D6 and Normal Metabolizers (NMs) of CYP2C19 may require dosage adjustments when taking clomipramine. As CYP2D6 is a significant metabolizer of clomipramine, PMs may experience increased exposure to the medication, which can lead to increased risk of adverse effects. Therefore, a reduced starting dose and close monitoring for adverse effects, such as sedation, anticholinergic effects, and QTc prolongation, are recommended.	-0.009164489	0.30841616	0.13268353	tensor(-0.1175)	tensor(0.4197)	tensor(0.0927)	0.7696149425031079	0.6667548289285476	0.8124264535817022	0.61452794	0.52194166	0.6849572	0.6471048	0.6053692	0.78371185	0.58336276	0.6264527	0.68522066	0.60560775	0.60674596	0.6287826	1
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual who is an ultrarapid metabolizer (UM) for CYP2C19 may require alternative antiplatelet therapy instead of clopidogrel, as they may not achieve adequate platelet inhibition due to increased metabolism of clopidogrel. This is because UMs may have reduced exposure to the active metabolite of clopidogrel, potentially leading to decreased efficacy. Alternative therapies, such as prasugrel or ticagrelor, may be considered in these individuals.	-0.30373767	-0.00036616597	-0.17180331	tensor(-0.1223)	tensor(0.2767)	tensor(0.0474)	0.22760544197911267	0.5394078131080756	0.24547226682608553	0.16935675	0.52749014	0.2045186	0.11645732	0.5577926	0.12299797	0.0159547	0.5600489	0.102987535	0.2883812	0.5944028	0.48022106	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2C19 may not respond adequately to clopidogrel, a prodrug that requires CYP2C19-mediated activation. As a result, UMs may be at increased risk of therapeutic failure and cardiovascular events. The CPIC recommends considering alternative antiplatelet therapies, such as prasugrel or ticagrelor, which are not dependent on CYP2C19 metabolism, or increasing the clopidogrel dose, with close monitoring, in UM patients.	-0.3611262	0.005183453	-0.20914607	tensor(-0.2114)	tensor(0.2771)	tensor(-0.0149)	0.23037578263677924	0.5471974280502326	0.24547226682608553	0.09196238	0.4215303	0.2045186	0.087021165	0.48893052	0.12299797	0.009239831	0.5729163	0.102987535	0.30412602	0.61759675	0.48022106	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2C19 should avoid taking clopidogrel, as they may not achieve adequate platelet inhibition due to increased metabolism of the prodrug. Instead, alternative antiplatelet agents, such as prasugrel or ticagrelor, may be considered. Additionally, genotype-guided therapy may involve increasing the clopidogrel dose, but this approach requires further study to determine its efficacy and safety.	-0.14152645	0.03825073	-0.05592518	tensor(-0.1104)	tensor(0.3153)	tensor(0.0689)	0.641949507090538	0.5839962499869127	0.6984734717610787	0.5565095	0.5969041	0.6804736	0.51244104	0.54636496	0.7268292	0.61479896	0.61671585	0.776168	0.5709252	0.6349916	0.62266123	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For an individual who is a Normal Metabolizer (NM) for CYP2C19, the clinical guidance for taking clopidogrel is to follow the standard dosing regimen, as they are expected to metabolize clopidogrel effectively and respond to its antiplatelet effects. No dosage adjustment is necessary, and the patient can be treated with standard clopidogrel therapy, typically 75 mg/day. Regular monitoring of platelet function and clinical response is still recommended to ensure adequate antiplatelet effect.	-0.023373589	0.37316132	0.1475912	tensor(-0.0592)	tensor(0.2664)	tensor(0.0851)	0.7022710359190051	0.6592078567275872	0.6984734717610787	0.6675495	0.6347276	0.6804736	0.70888364	0.67986906	0.7268292	0.75210017	0.63931084	0.776168	0.7659976	0.63217866	0.62266123	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	Based on the evidence, for an individual who is an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score ≥3.75, the clinical guidance is to exercise extreme caution or avoid codeine therapy altogether. This is because UM individuals can rapidly convert codeine to morphine, leading to increased risk of opioid toxicity, respiratory depression, and even death. Alternative analgesics or opioids with a lower risk of toxicity should be considered in these patients.	0.04440647	0.2653388	0.14798534	tensor(-0.0957)	tensor(0.3266)	tensor(0.0799)	0.6255433138431182	0.539919575647223	0.6066041809764519	0.67578244	0.5191917	0.71214277	0.6503552	0.5411417	0.73497224	0.62423885	0.5199957	0.706485	0.6661172	0.64917076	0.6865053	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For an individual who is a Poor Metabolizer (PM) of CYP2D6 with an activity score of 0.0, clinical guidance suggests that they should avoid using codeine or use it with extreme caution due to the high risk of inadequate pain relief and potential adverse effects. This is because CYP2D6 is responsible for converting codeine to its active metabolite, morphine, and PMs are unable to perform this conversion, resulting in reduced analgesic efficacy. Alternative analgesics or non-opioid pain management strategies should be considered in these individuals.	0.026143434	0.30646914	0.15380125	tensor(-0.1207)	tensor(0.3056)	tensor(0.0575)	0.6179442527734346	0.563165724305644	0.6699545203053665	0.6761696	0.5830409	0.6902888	0.65728015	0.5526991	0.71534896	0.6423175	0.5612816	0.69900346	0.64967734	0.62068367	0.6586961	0
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Use codeine label recommended age- or weight-specific dosing.	['Avoid codeine. Take an alternate therapy.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Proceed taking codeine as normal. There is no recommendation.	Based on the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient who is a Normal Metabolizer with a CYP2D6 activity score of 1.25 is expected to have normal CYP2D6 enzyme activity. This individual can be expected to metabolize codeine normally, and standard dosing is likely to be effective. However, it is essential to monitor for signs of opioid toxicity or inadequate analgesia and adjust the dose accordingly.	-0.14610665	0.11150578	-0.028999189	tensor(-0.1647)	tensor(0.3398)	tensor(0.0387)	0.4418283784305833	0.49178119834041345	0.6189481994666263	0.36725962	0.38471213	0.5129045	0.5318344	0.56581867	0.61016905	0.5334285	0.49572384	0.63897043	0.5184005	0.6169705	0.68377954	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥5.0, clinical guidance suggests that codeine should be avoided or used with extreme caution due to the high risk of adverse effects, including respiratory depression and opioid toxicity. This is because UMs rapidly convert codeine to morphine, leading to increased opioid levels and potentially life-threatening complications. Alternative pain management options should be considered, and if codeine is deemed necessary, close monitoring and dose reduction are essential.	0.08369625	0.32960317	0.19781668	tensor(-0.1134)	tensor(0.3585)	tensor(0.0813)	0.6558828128568234	0.5728926181408569	0.6066041809764519	0.7073895	0.54576993	0.71214277	0.67957526	0.56566584	0.73497224	0.71131706	0.598427	0.706485	0.66335225	0.6315656	0.6865053	0
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, specifically those with class I or II deficiency (CNSHA, severe or moderate deficiency), should avoid taking dapsone due to the high risk of hemolytic anemia. Dapsone, a sulfone antibiotic, can trigger severe hemolysis in G6PD-deficient individuals, which can lead to life-threatening complications. Alternative antibiotics should be considered, and if dapsone is deemed necessary, close monitoring of hemoglobin levels and methemoglobinemia is crucial.	-0.27836767	0.07560899	-0.12811007	tensor(-0.0713)	tensor(0.2795)	tensor(0.0677)	0.21140790633900958	0.626258903113717	0.29397114268302765	0.28569335	0.5689555	0.35577685	0.15246682	0.6029684	0.26590234	0.16015902	0.4444554	0.26635018	0.42753932	0.6229745	0.51896954	1
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and therefore, dapsone therapy should be approached with caution. It is recommended to monitor for hemolytic anemia and methemoglobinemia, and to consider alternative treatments if possible. Additionally, a G6PD activity assay may be considered to clarify the individual's G6PD status before initiating dapsone therapy.	0.14110339	0.35242662	0.24097148	tensor(-0.0460)	tensor(0.4050)	tensor(0.1436)	0.7078405380769631	0.5894885998009065	0.3441258186006137	0.60079885	0.5919339	0.3123187	0.661877	0.63431495	0.31147724	0.73957956	0.41931581	0.20376977	0.6304559	0.54923016	0.43416855	0
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take dapsone without dose adjustment or special monitoring, as they are not at increased risk of hemolytic anemia. However, it is still essential to monitor for signs of hemolysis, such as anemia, jaundice, or dark urine, as dapsone can cause hemolysis in individuals with unknown or untested G6PD status. Routine G6PD testing is recommended before initiating dapsone therapy to identify individuals who may be at increased risk of hemolytic anemia.	-0.13892587	0.1947603	0.007081629	tensor(-0.1290)	tensor(0.2935)	tensor(0.0460)	0.6323809987943774	0.6494657229193038	0.36059165435853874	0.5321716	0.66133314	0.27750307	0.47497654	0.65714705	0.21654668	0.46115205	0.50531554	0.14750078	0.5295416	0.5386583	0.37921315	0
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking dapsone, a sulfone antibiotic, due to the increased risk of hemolytic anemia. This is because dapsone can cause oxidative stress, which can exacerbate G6PD deficiency and lead to hemolytic anemia. Therefore, alternative therapies should be considered for G6PD-deficient patients who require antibiotic treatment.	-0.29109865	0.03932367	-0.14931986	tensor(-0.0784)	tensor(0.3087)	tensor(0.0568)	0.2048153172997379	0.6430688916381285	0.29397114268302765	0.32733414	0.57030404	0.35577685	0.1345831	0.55390966	0.26590234	0.15303808	0.45334157	0.26635018	0.43716967	0.5958578	0.51896954	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	Based on the pharmacogenomic results, individuals with Uncertain Susceptibility for RYR1 and No Result for CACNA1S can still receive desflurane for anesthesia, but close monitoring for malignant hyperthermia (MH) is recommended. Although the results do not indicate a clear susceptibility to MH, the uncertain status suggests a possible risk, and vigilant monitoring can help ensure early detection and treatment of any potential MH crisis. Anesthesia providers should follow standard MH monitoring and treatment protocols.	0.09889705	0.21138665	0.15519758	tensor(-0.0995)	tensor(0.3016)	tensor(0.0715)	0.6480736779932244	0.5947902559456695	0.390436768457001	0.68384564	0.46166217	0.38977265	0.61143464	0.41287667	0.30585182	0.46904933	0.4329104	0.29088077	0.66569394	0.5272702	0.37354237	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	Based on the pharmacogenomics data, individuals with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 mutations are at increased risk of malignant hyperthermia (MH) when exposed to volatile anesthetics like desflurane. Therefore, it is recommended to avoid using desflurane in these individuals, and instead, consider alternative anesthetics or take precautions to monitor for MH symptoms. The absence of a result for CACNA1S does not affect this guidance, as RYR1 is the primary genetic contributor to MHS.	0.26648456	0.2820572	0.2763655	tensor(-0.0806)	tensor(0.2532)	tensor(0.0664)	0.7811603929023235	0.529618960014183	0.4317797302234162	0.7843388	0.52424866	0.5230363	0.7232054	0.4637278	0.37056965	0.79585266	0.46586475	0.40256345	0.70424247	0.5209015	0.541851	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	Based on the Pharmacogenomics Knowledgebase (PharmGKB) guidelines, individuals with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 mutations are at increased risk of malignant hyperthermia (MH) when exposed to volatile anesthetics like desflurane. Therefore, it is recommended to avoid desflurane and other triggering agents in these individuals. The uncertain susceptibility for CACNA1S does not alter this recommendation, and alternative anesthetics should be considered to minimize the risk of MH.	0.20905788	0.2584338	0.23555988	tensor(-0.0755)	tensor(0.2576)	tensor(0.0713)	0.732034939419418	0.5075033251366431	0.419364478183047	0.6821201	0.47530794	0.5072	0.70678604	0.46556112	0.3943191	0.73036575	0.46363324	0.4080393	0.6919627	0.55136555	0.5519968	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	"Based on the pharmacogenomic profile, there is no specific clinical guidance for desflurane use in individuals with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S. RYR1 and CACNA1S genes are associated with malignant hyperthermia, a rare but life-threatening reaction to certain anesthetics, including desflurane. However, in the absence of a positive result for either gene, the risk of malignant hyperthermia is not significantly increased, and desflurane can be used with standard monitoring and precautions."	0.08784348	0.22224663	0.1540617	tensor(-0.1133)	tensor(0.2869)	tensor(0.0488)	0.6905078637357908	0.5952833523064538	0.403769364440083	0.6889518	0.48655063	0.37993827	0.6947862	0.5432436	0.3032765	0.60994136	0.49593455	0.33309272	0.74571747	0.525563	0.3783121	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2D6 with an activity score ≥3.5 may require a dose reduction of desipramine, a CYP2D6 substrate, to minimize the risk of therapeutic failure. UMs may metabolize desipramine too quickly, leading to subtherapeutic levels, and a reduced dose may be necessary to achieve optimal response. Close monitoring of response and potential dose adjustments are recommended to ensure efficacy and minimize adverse effects.	0.10794154	0.16185443	0.13687709	tensor(-0.1293)	tensor(0.4248)	tensor(0.0910)	0.6287054946993406	0.6046200315697429	0.5463523755692661	0.6703637	0.4702999	0.47636613	0.6588317	0.53674644	0.40268764	0.62372047	0.5442508	0.44125998	0.5835182	0.5419269	0.41513193	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid desipramine. Take an alternate therapy.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Proceed taking desipramine as normal. There is no recommendation.	Based on the pharmacogenomics data, a patient who is a Normal Metabolizer with a CYP2D6 activity score of 1.75 is expected to metabolize desipramine normally. As desipramine is primarily metabolized by CYP2D6, the normal metabolizer status suggests that the patient is likely to metabolize the drug at a normal rate, and no dosage adjustment is necessary. However, close monitoring of therapeutic response and adverse effects is still recommended, as desipramine has a narrow therapeutic index and individual variability in response may still occur.	-0.22528666	0.012504728	-0.11672945	tensor(-0.0886)	tensor(0.2878)	tensor(0.0671)	0.3941425808157868	0.6489896974525308	0.5051425573422825	0.23964112	0.46012926	0.354074	0.21823928	0.5746218	0.27297944	0.29220048	0.5562706	0.38281348	0.36233988	0.5982564	0.5717378	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	Based on the clinical guidance, an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score of 2.75 may require a lower dose of desipramine, a tricyclic antidepressant primarily metabolized by CYP2D6, to avoid increased risk of adverse effects. The UM phenotype is associated with increased enzyme activity, which may lead to rapid metabolism and reduced efficacy of desipramine. Therefore, a reduced starting dose and close monitoring of therapeutic response and adverse effects are recommended to individualize treatment and minimize potential risks.	0.16147186	0.19410565	0.18000856	tensor(-0.1026)	tensor(0.4065)	tensor(0.1042)	0.6585960311709435	0.6033846964260585	0.5463523755692661	0.6840122	0.52188903	0.47636613	0.613064	0.5267169	0.40268764	0.5890623	0.53743917	0.44125998	0.5574327	0.5288187	0.41513193	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥6.0, the clinical guidance for taking desipramine would be to exercise extreme caution and consider alternative medications. Desipramine is primarily metabolized by CYP2D6, and UM individuals may metabolize it too quickly, leading to reduced efficacy or increased risk of side effects. The patient's healthcare provider should closely monitor their response to desipramine and consider reducing the dose or switching to a different medication to ensure optimal treatment outcomes.	0.11882795	0.20303921	0.16204678	tensor(-0.1033)	tensor(0.3674)	tensor(0.0864)	0.6016724880188203	0.6405657206675092	0.5463523755692661	0.70894974	0.6202135	0.47636613	0.6660334	0.6253564	0.40268764	0.6025805	0.6422979	0.44125998	0.56763846	0.5719816	0.41513193	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For individuals who are rapid metabolizers of CYP2C19, the clinical guidance for taking dexlansoprazole is to exercise caution and consider alternative proton pump inhibitors (PPIs) or dose adjustments. Rapid metabolizers may experience reduced efficacy of dexlansoprazole due to increased metabolism, which may lead to subtherapeutic levels and decreased acid suppression. Close monitoring of treatment response and potential dose adjustments may be necessary to ensure optimal therapeutic outcomes.	-0.014482837	0.08476966	0.035897836	tensor(-0.0072)	tensor(0.3946)	tensor(0.1659)	0.42473196310501066	0.6968284401086843	0.43456237852129564	0.49516585	0.6297964	0.44420385	0.44355017	0.569588	0.53292537	0.38199773	0.5865619	0.3973433	0.4073204	0.72214526	0.4159245	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are likely poor metabolizers (PMs) for CYP2C19 may require a dose reduction of dexlansoprazole, a proton pump inhibitor, to minimize the risk of adverse effects such as nausea, diarrhea, and headache. The CPIC recommends a starting dose of 30 mg daily, which is half the usual recommended dose, and close monitoring for adverse effects. Additionally, alternative proton pump inhibitors that are not dependent on CYP2C19 metabolism, such as pantoprazole or rabeprazole, may be considered.	-0.10556696	0.19006991	0.026693312	tensor(-0.1215)	tensor(0.4278)	tensor(0.0977)	0.4501859462185625	0.649949110976021	0.42714149472543356	0.42344162	0.5690057	0.4377094	0.4498045	0.5789919	0.5257376	0.46989304	0.59452206	0.44189915	0.4431233	0.6414584	0.40391704	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2C19 may require higher doses of dexlansoprazole to achieve therapeutic response, as they may metabolize the drug more quickly. However, the optimal dose adjustment for UMs has not been established, and close monitoring of therapeutic response and adverse effects is recommended. Additionally, alternative proton pump inhibitors that are not metabolized by CYP2C19, such as pantoprazole or rabeprazole, may be considered.	-0.1690509	0.12227809	-0.039265543	tensor(-0.1038)	tensor(0.4110)	tensor(0.1012)	0.4205655333305567	0.65839397585732	0.4190311347285449	0.44088292	0.51948637	0.51334107	0.35126138	0.49328706	0.5667941	0.39974746	0.5548269	0.4981389	0.39833957	0.6891355	0.383801	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid dexlansoprazole. Take an alternate therapy.', 'Take dexlansoprazole with a reduced dose.', 'Take dexlansoprazole with an increased dose.']	Proceed taking dexlansoprazole as normal. There is no recommendation.	Based on the evidence, for an individual who is indeterminate for CYP2C19, the clinical guidance for taking dexlansoprazole is to initiate therapy with a standard dose and monitor for efficacy and potential adverse effects. Since CYP2C19 is involved in the metabolism of dexlansoprazole, indeterminate status may imply reduced enzyme activity, which could lead to increased exposure to the drug. However, the impact of indeterminate CYP2C19 status on dexlansoprazole pharmacokinetics and pharmacodynamics is not well established, and further research is needed to inform personalized dosing recommendations.	-0.32474294	0.035428762	-0.17366244	tensor(-0.0629)	tensor(0.4358)	tensor(0.1348)	0.25502793947906016	0.6279579255081041	0.27774156674259937	0.12797241	0.5926085	0.2127639	0.04289779	0.62258303	0.11258603	-0.0019825064	0.5601553	0.100801915	0.304448	0.5893254	0.4491609	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking dibekacin as normal. There is no recommendation.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Avoid dibekacin. Take an alternate therapy.	Based on the available evidence, individuals with the mitochondrial DNA variant m.1555A>G or m.1494C>T in the MT-RNR1 gene are at increased risk of aminoglycoside-induced hearing loss. Due to dibekacin being an aminoglycoside antibiotic, it is recommended to avoid or use with caution in patients with these MT-RNR1 variants, as they may be more susceptible to ototoxicity. Alternative antibiotics should be considered, and close monitoring of hearing function is advised if dibekacin is deemed necessary.	-0.010497271	0.13770677	0.061821885	tensor(-0.1405)	tensor(0.2607)	tensor(0.0130)	0.6057578969692549	0.3964417273291745	0.29113802833973196	0.6662228	0.45139873	0.51720965	0.6807714	0.41803178	0.37425783	0.6643616	0.47497624	0.412967	0.5990004	0.5004384	0.46054223	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	Based on the available evidence, for individuals with a normal risk of aminoglycoside-induced hearing loss (i.e., not carrying the m.1555A>G or m.1494C>T variants in the MT-RNR1 gene), there are no specific contraindications or warnings for using dibekacin, a type of aminoglycoside antibiotic. However, it is still important to closely monitor patients for signs of ototoxicity and nephrotoxicity, as these are potential side effects of aminoglycosides. Additionally, clinicians should follow standard dosing and monitoring guidelines for dibekacin to minimize the risk of adverse effects.	-0.06497903	0.17873411	0.047315218	tensor(-0.1583)	tensor(0.3042)	tensor(0.0247)	0.5421117966444331	0.45102703781099546	0.34441559903633584	0.52729726	0.59338474	0.4988395	0.72501326	0.49876255	0.43198147	0.7201365	0.5211483	0.45650932	0.54767567	0.5211753	0.51453567	0
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (particularly the m.1555A>G or m.1494C>T variants) are at increased risk of aminoglycoside-induced hearing loss. Given this uncertainty, it is recommended to avoid or use with caution aminoglycosides, including dibekacin, in these individuals, especially if they have a history of hearing loss or are at increased risk of ototoxicity. If dibekacin is necessary, close monitoring of hearing function and kidney function is advised.	-0.0839737	0.10637076	0.0062835678	tensor(-0.1627)	tensor(0.3067)	tensor(0.0295)	0.5491999281182041	0.3861938981416039	0.34441559903633584	0.5280152	0.41716832	0.4988395	0.62240857	0.49503577	0.43198147	0.63542753	0.48682427	0.45650932	0.5564957	0.4724261	0.51453567	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For an individual who is normal for G6PD (glucose-6-phosphate dehydrogenase), there are no specific clinical precautions or contraindications for taking dimercaprol, a chelating agent used to treat heavy metal poisoning. Dimercaprol is not known to trigger hemolytic anemia in individuals with normal G6PD activity, and its use is not expected to be affected by G6PD status. Therefore, standard dosing and administration guidelines for dimercaprol can be followed in individuals with normal G6PD activity.	-0.04219739	0.24845555	0.08887301	tensor(-0.1130)	tensor(0.2748)	tensor(0.0530)	0.588667330186585	0.7031295690141566	0.3795383134150187	0.5024977	0.6430093	0.32292318	0.410902	0.6544135	0.27374294	0.38211265	0.5522495	0.114939235	0.5601265	0.5676637	0.38091448	1
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient for medication management purposes. This means that dimercaprol, which can cause hemolysis in G6PD-deficient individuals, should be used with caution or avoided in patients with an indeterminate G6PD status, and alternative treatments should be considered. Close monitoring for signs of hemolysis is recommended if dimercaprol is used in these individuals.	0.09037614	0.27404052	0.17826922	tensor(-0.1028)	tensor(0.3642)	tensor(0.0906)	0.6625285221846868	0.5945298645440028	0.38006521897235573	0.56071	0.6280843	0.34927732	0.6264498	0.66586584	0.3710474	0.5937228	0.49433923	0.16605222	0.53784364	0.5309043	0.43853614	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with Class I or II deficiency (including those with Class NSA, formerly known as CNSHA), should avoid using dimercaprol (British anti-Lewisite, BAL) due to the increased risk of hemolytic anemia. This is because dimercaprol can exacerbate G6PD deficiency, leading to severe and potentially life-threatening hemolysis. Therefore, alternative chelation agents should be considered in these individuals.	-0.11451612	0.084070556	-0.020951428	tensor(-0.1745)	tensor(0.3226)	tensor(0.0262)	0.4743156458912963	0.6035129021882866	0.4810664052955647	0.43081474	0.6221438	0.5438092	0.4939868	0.54010457	0.49818894	0.45260182	0.5111457	0.33236513	0.51578474	0.5361117	0.5197642	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid using dimercaprol (British anti-Lewisite, BAL) due to the increased risk of hemolysis. This is because dimercaprol can exacerbate the existing G6PD deficiency, leading to severe hemolytic anemia. Alternative chelating agents, such as succimer or DMSA, should be considered in patients with G6PD deficiency who require chelation therapy.	-0.07250914	0.14502077	0.029090172	tensor(-0.1134)	tensor(0.3462)	tensor(0.0772)	0.6205292571577692	0.597787572596613	0.42762257653878666	0.6275534	0.6355018	0.4823958	0.59880954	0.58835655	0.44676057	0.57514364	0.51006806	0.322733	0.60252076	0.5056362	0.44501558	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	Based on the pharmacogenomic profile, individuals who are Intermediate Metabolizers of CYP2D6 (activity score = 0.25) and Rapid Metabolizers of CYP2C19 may require closer monitoring and potential dose adjustments when taking doxepin. This is because doxepin is primarily metabolized by CYP2D6, and Intermediate Metabolizers may have reduced enzyme activity, leading to increased plasma concentrations and potential increased risk of adverse effects. Additionally, as Rapid Metabolizers of CYP2C19, they may have increased clearance of doxepin, which could lead to reduced efficacy.	0.12572086	0.24731156	0.18613744	tensor(-0.1187)	tensor(0.3097)	tensor(0.0613)	0.7918148985769308	0.6056841637788613	0.7011422112226695	0.7139994	0.5047211	0.6517085	0.82898086	0.60908663	0.66101384	0.75289315	0.48303598	0.6373031	0.7125983	0.62042725	0.6283634	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Avoid doxepin. Take an alternate therapy.']	Take doxepin with an altered dose.	Based on the pharmacogenomic profile, the clinical guidance for an individual who is an Intermediate Metabolizer (IM) with an activity score of 0.75 for CYP2D6 and a Normal Metabolizer (NM) for CYP2C19, considering doxepin treatment, would be to exercise caution and closely monitor for adverse effects. As doxepin is primarily metabolized by CYP2D6, the IM status may lead to reduced metabolism and increased plasma concentrations, potentially increasing the risk of side effects. Therefore, a lower starting dose and titration may be necessary to achieve optimal therapeutic response while minimizing adverse events.	-0.109979875	0.20094562	0.028021205	tensor(-0.1368)	tensor(0.2868)	tensor(0.0410)	0.5227239164137115	0.6444302120035644	0.44005762710218765	0.45513538	0.490704	0.30628258	0.44088864	0.4676273	0.41851646	0.42520237	0.5515659	0.40561783	0.5761204	0.6289421	0.5770765	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	"Based on the provided pharmacogenomic results, a person with ""No Result"" and activity score = ""No Result"" for CYP2D6 and a ""Rapid Metabolizer"" phenotype for CYP2C19 may not require dosage adjustments for doxepin. Doxepin is primarily metabolized by CYP2C19, and as a Rapid Metabolizer, they may be more efficient at metabolizing the drug, potentially leading to lower serum concentrations. However, close monitoring of therapeutic response and adverse effects is still recommended due to the lack of CYP2D6 activity score, as doxepin is also a substrate of CYP2D6."	0.11419547	0.22388127	0.16919734	tensor(-0.1377)	tensor(0.2681)	tensor(0.0188)	0.5050809860779952	0.586959782152374	0.42608267570239006	0.6227914	0.48829746	0.5338148	0.5370257	0.66054344	0.44516784	0.4690461	0.5911533	0.37179604	0.5218458	0.61096317	0.4935106	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	Based on the pharmacogenomic profile, individuals who are Poor Metabolizers (PM) of CYP2D6 with an activity score of 0.0 and Normal Metabolizers (NM) of CYP2C19 may require alternative treatment or close monitoring when taking doxepin. As doxepin is primarily metabolized by CYP2D6, the PM phenotype may lead to increased doxepin concentrations and increased risk of adverse effects. Therefore, clinicians may consider reducing the initial dose or titrating the dose more slowly to minimize the risk of toxicity.	-0.0053325333	0.26977587	0.119983494	tensor(-0.1051)	tensor(0.3906)	tensor(0.0976)	0.710868649061547	0.6347190363906557	0.8111897095817729	0.5931638	0.5738392	0.63147306	0.584866	0.6074353	0.72896135	0.55906993	0.54393464	0.6893397	0.5849711	0.66558504	0.7160461	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid doxorubicin due to the increased risk of hemolytic anemia. This is because doxorubicin can exacerbate G6PD deficiency, leading to severe hemolysis and potentially life-threatening complications. As a result, alternative chemotherapy regimens should be considered, and G6PD testing is recommended prior to doxorubicin administration, especially in individuals of African, Mediterranean, or Southeast Asian descent, who are more likely to be G6PD deficient.	-0.065377496	0.1512231	0.03587872	tensor(-0.1970)	tensor(0.2615)	tensor(-0.0095)	0.6398543601007306	0.5374791652292095	0.3963212398906257	0.6612721	0.64514905	0.40489972	0.5970824	0.57393897	0.2950699	0.62244684	0.48874173	0.31134716	0.5804158	0.5647673	0.41379267	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and alternative therapies to doxorubicin should be considered to minimize the risk of hemolytic anemia. If doxorubicin is necessary, close monitoring of hematologic parameters and signs of hemolysis is recommended. In addition, a G6PD activity assay may be considered to further guide treatment decisions.	0.15453345	0.34594542	0.24588995	tensor(-0.1041)	tensor(0.2731)	tensor(0.0583)	0.676459116301835	0.5814481992060018	0.3072699961178852	0.6022198	0.5673053	0.25542292	0.6722509	0.53953296	0.22188735	0.6533649	0.46242017	0.17969483	0.61125565	0.54854935	0.4325015	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Based on the pharmacogenomic literature, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II variant (CNSHA, Class I being the most severe) are at increased risk of hemolytic anemia when treated with doxorubicin. Clinical guidance recommends that G6PD-deficient patients should avoid doxorubicin or be closely monitored for hemolysis, as the risk of severe hemolytic anemia outweighs the potential benefits of treatment. Alternative anthracycline formulations or chemotherapeutic agents may be considered in these patients to minimize the risk of hemolytic complications.	-0.06303424	0.16556683	0.043151617	tensor(-0.1838)	tensor(0.2988)	tensor(0.0119)	0.4286338986462983	0.5240168248646664	0.42336196007230653	0.49655247	0.44476387	0.5096324	0.4661094	0.5186316	0.40256256	0.52572054	0.4620089	0.38538122	0.5614208	0.5320012	0.51508474	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For an individual with normal G6PD activity, there are no specific clinical precautions or dose adjustments recommended for doxorubicin administration. Doxorubicin is not a substrate for G6PD, and G6PD deficiency is not a known risk factor for doxorubicin-induced toxicity. Therefore, the standard dosing and administration guidelines for doxorubicin can be followed in patients with normal G6PD activity.	0.0138562545	0.19244315	0.09940861	tensor(-0.1035)	tensor(0.2046)	tensor(0.0324)	0.6116016623373894	0.6560213707775295	0.3576318893917693	0.50798005	0.6766673	0.29035413	0.46659818	0.62078476	0.19486314	0.45102006	0.5847547	0.073940426	0.55866003	0.55436313	0.3743035	1
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2B6 may require higher doses of efavirenz to achieve adequate therapeutic concentrations. The CPIC recommends considering an alternative antiretroviral therapy or increasing the efavirenz dose by 50-100% in UM individuals, while closely monitoring for efficacy and toxicity. However, the optimal dosing strategy for UM individuals has not been established and requires further study.	-0.09344707	0.16558434	0.024722561	tensor(-0.0662)	tensor(0.4589)	tensor(0.1475)	0.6713543247778652	0.5946872739090064	0.7784018211483095	0.6252217	0.48450926	0.71709216	0.59383225	0.51546735	0.7967887	0.6538252	0.5271762	0.74131835	0.6123515	0.5700017	0.7126894	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are rapid metabolizers of CYP2B6 (i.e., CYP2B6 *1/*1 or *1/*4 genotype) may require higher doses of efavirenz to achieve adequate therapeutic levels. However, the optimal dosing strategy is unclear, and therapeutic drug monitoring is recommended to ensure adequate exposure. Close monitoring for efficacy and toxicity is also advised, as rapid metabolizers may be at increased risk of virologic failure or adverse effects.	-0.14214039	0.2102576	0.010611548	tensor(-0.1404)	tensor(0.3573)	tensor(0.0481)	0.629587880688222	0.5703848451287377	0.7784018211483095	0.5756482	0.40964574	0.71709216	0.65809685	0.5862796	0.7967887	0.7299847	0.5806694	0.74131835	0.6239054	0.58767474	0.7126894	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	No recommendation	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for CYP2B6 (i.e., have a genotype that cannot be classified as normal metabolizer, intermediate metabolizer, or poor metabolizer) should be treated as intermediate metabolizers. For efavirenz, which is primarily metabolized by CYP2B6, the CPIC recommends to use the standard efavirenz dose, but to monitor for adverse effects and consider alternative therapies if the patient experiences significant toxicity. Additionally, clinicians should be aware that the indeterminate genotype may be associated with increased risk of central nervous system side effects.	-0.33819094	-0.015102269	-0.2000979	tensor(-0.1206)	tensor(0.3778)	tensor(0.0825)	0.24106201264120472	0.5997025005403339	0.2601762400633709	0.17545147	0.36995837	0.19286856	0.067754716	0.4882722	0.09100999	0.01812291	0.5389906	0.18560685	0.2925358	0.5857702	0.44998935	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal metabolizers for CYP2B6 (i.e., *1/*1 or *1/*4 genotype) do not require dosage adjustments when taking efavirenz, as they are expected to metabolize the drug normally. Efavirenz can be prescribed at the standard recommended dose, and no additional monitoring or testing is necessary. However, it is essential to continue monitoring for efavirenz-related adverse effects and adjust treatment as needed, regardless of CYP2B6 genotype.	-0.10386472	0.2287612	0.04233546	tensor(-0.1013)	tensor(0.3311)	tensor(0.0725)	0.6412755523122087	0.6556688302601322	0.7784018211483095	0.54841596	0.5764174	0.71709216	0.6339609	0.58550733	0.7967887	0.7020817	0.60470176	0.74131835	0.6649122	0.6468091	0.7126894	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	Based on pharmacogenomics guidelines, an individual with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S should exercise caution when taking enflurane, a volatile anesthetic known to trigger malignant hyperthermia (MH) in susceptible individuals. Due to the increased risk of MH, it is recommended to consider alternative anesthetics and to take precautions such as monitoring for MH signs and having dantrolene readily available. Additionally, a thorough medical history and family history of MH should be taken into account before administering enflurane.	0.09894356	0.19811215	0.14913483	tensor(-0.0904)	tensor(0.2809)	tensor(0.0616)	0.6693435048936887	0.5989673825409665	0.39375071704208997	0.6690848	0.51271737	0.49679354	0.719999	0.5442214	0.3708457	0.7211149	0.5422145	0.4438302	0.6823677	0.57949567	0.5388381	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	Based on the genetic test results, the individual has no known mutations associated with Malignant Hyperthermia (MH) susceptibility in the RYR1 gene, but may have a mutation in the CACNA1S gene, which is also associated with MH susceptibility. Enflurane, a volatile anesthetic, can trigger MH in susceptible individuals. Therefore, the clinical guidance would be to exercise caution and consider alternative anesthetics or take precautions to monitor for MH symptoms, such as increased temperature, muscle rigidity, and cardiac arrhythmias, when administering enflurane to this individual.	0.14435259	0.22712974	0.18685153	tensor(-0.1066)	tensor(0.2893)	tensor(0.0439)	0.6780106274817865	0.48003374431768825	0.4171039982278967	0.66126865	0.40109882	0.5283713	0.7906623	0.42358282	0.34597188	0.7952657	0.5458338	0.42322895	0.667907	0.6107256	0.53563297	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	Based on the pharmacogenomics data, individuals with Malignant Hyperthermia Susceptibility (MHS) for RYR1 are at high risk of developing malignant hyperthermia (MH) when exposed to certain anesthetics, including enflurane. Given this susceptibility, it is recommended to avoid using enflurane in these individuals and instead opt for alternative anesthetics that are safe in MHS patients. The Uncertain Susceptibility for CACNA1S does not alter this recommendation, as RYR1 is the primary genetic determinant of MH risk.	0.18082894	0.21703966	0.20104906	tensor(-0.0852)	tensor(0.2755)	tensor(0.0716)	0.6786682207860101	0.48998381300390975	0.39375071704208997	0.6962402	0.5283506	0.49679354	0.63884544	0.41254288	0.3708457	0.69740754	0.4652287	0.4438302	0.6436978	0.5388281	0.5388381	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid enflurane. Take an alternate therapy.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Proceed taking enflurane as normal. There is no recommendation.	"Based on the pharmacogenomic results, there is no specific clinical guidance for the use of enflurane in an individual with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S. Enflurane is not typically associated with malignant hyperthermia (MH) susceptibility, which is the primary concern related to RYR1 and CACNA1S variants. Therefore, the use of enflurane in this individual is not contraindicated based on these pharmacogenomic results."	0.10555585	0.19445227	0.15098147	tensor(-0.1250)	tensor(0.2854)	tensor(0.0486)	0.6598651206421862	0.5818720815309395	0.42388661924590887	0.72901374	0.5953136	0.39443707	0.6543023	0.52795935	0.33410165	0.58757305	0.46853653	0.3475659	0.745828	0.5461407	0.38253376	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	Based on the pharmacogenomics literature, for individuals who are rapid metabolizers of CYP2C19, the clinical guidance for taking escitalopram is to consider a higher initial dose and closer monitoring for efficacy, as they may metabolize the medication more quickly, leading to potentially reduced therapeutic effects. The CPIC (Clinical Pharmacogenetics Implementation Consortium) guideline recommends an initial dose of 20-30 mg/day, which is higher than the usual starting dose of 10 mg/day. Additionally, clinicians should be prepared to adjust the dose upward based on patient response.	0.05702745	0.23632836	0.14297473	tensor(-0.0854)	tensor(0.4747)	tensor(0.1375)	0.6399056105869686	0.6067153134265371	0.5731055623629697	0.6216999	0.48853484	0.53349537	0.6552128	0.62747353	0.39764553	0.61469907	0.5487959	0.5593752	0.667226	0.6045153	0.58349496	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are likely poor metabolizers (PMs) for CYP2C19 may require a reduced dose of escitalopram, as they may be at increased risk of adverse effects due to elevated plasma concentrations. The recommended dose reduction is 25-50% of the standard dose, with close monitoring for efficacy and toxicity. Additionally, alternative selective serotonin reuptake inhibitors (SSRIs) that are not metabolized by CYP2C19, such as sertraline or fluoxetine, may be considered.	0.14840998	0.3334016	0.2369748	tensor(-0.1038)	tensor(0.5080)	tensor(0.1351)	0.8008073630365717	0.6362113971255986	0.6570056368964114	0.7411721	0.5066385	0.5416116	0.8128021	0.56254303	0.5543577	0.8579358	0.6664365	0.6272641	0.77998537	0.63119084	0.62601334	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2C19 may require closer monitoring and potentially higher doses of escitalopram, as they may metabolize the medication too quickly, leading to reduced efficacy. However, the evidence is limited, and the optimal dosing strategy for CYP2C19 UMs taking escitalopram is not well established. Therefore, clinicians should consider therapeutic drug monitoring and adjust the dose based on clinical response.	0.10189616	0.2414777	0.17042954	tensor(-0.0763)	tensor(0.3577)	tensor(0.0854)	0.7100522689042154	0.6099323065320772	0.6397901110963181	0.61794156	0.49109042	0.54551125	0.67538613	0.52515644	0.54818684	0.7221662	0.5395211	0.64080864	0.7161722	0.60680187	0.6448732	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an indeterminate result for CYP2C19 genotype does not provide sufficient information to guide escitalopram therapy. Therefore, the prescribing clinician should make treatment decisions based on clinical judgment and patient response, without considering the CYP2C19 genotype. It is essential to monitor the patient's response to escitalopram and adjust the dosage or switch to an alternative medication if necessary, regardless of the indeterminate CYP2C19 genotype result.	-0.3013075	-0.010119089	-0.17371213	tensor(-0.0719)	tensor(0.4398)	tensor(0.1372)	0.2656186213224421	0.5645821771117397	0.2523203129015917	0.17927009	0.54751176	0.15122843	0.008822932	0.5467879	0.059175212	-0.0332861	0.50685316	0.09631811	0.3451693	0.65853417	0.50393635	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For an individual with an intermediate metabolizer (IM) phenotype and a dihydropyrimidine dehydrogenase (DPYD) activity score of 1.5, clinical guidance suggests that they may be at increased risk of fluorouracil (5-FU) toxicity due to reduced DPYD enzyme activity. Consideration should be given to reducing the initial dose of 5-FU by 25-50% and closely monitoring for adverse effects, such as neutropenia, diarrhea, and hand-foot syndrome. Additionally, frequent monitoring of complete blood counts and liver function tests is recommended to minimize the risk of severe toxicity.	-0.03158536	0.24508645	0.09411424	tensor(-0.1414)	tensor(0.2546)	tensor(0.0268)	0.5001081204606912	0.5692522792851348	0.4094049378869563	0.42825475	0.41542193	0.35275745	0.45063007	0.3981365	0.37727413	0.39545664	0.5073344	0.37770218	0.5317235	0.6097661	0.4631441	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Avoid fluorouracil. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are poor metabolizers (PM) of dihydropyrimidine dehydrogenase (DPYD) with an activity score of 0.0 are at increased risk of severe toxicity, including fatal outcomes, when treated with fluorouracil (5-FU). Therefore, it is recommended to avoid 5-FU treatment in these individuals or to consider alternative therapies. If 5-FU must be used, close monitoring for toxicity and a reduced starting dose are advised.	-0.032713413	0.25593147	0.09767334	tensor(-0.0975)	tensor(0.4121)	tensor(0.1058)	0.610559528210296	0.5329816055923785	0.6125587496349988	0.43580776	0.40056324	0.6707052	0.6013406	0.4724928	0.78131837	0.62113035	0.5880199	0.70820034	0.6481656	0.67765254	0.74395347	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	Based on the pharmacogenomics data, an individual with an intermediate metabolizer (IM) phenotype and a dihydropyrimidine dehydrogenase (DPYD) activity score of 1.0 is at increased risk of fluorouracil (5-FU) toxicity. Clinical guidance suggests that the dose of 5-FU should be reduced by 25-50% to minimize the risk of severe adverse reactions, such as neutropenia, diarrhea, and hand-foot syndrome. Additionally, close monitoring of toxicity and consideration of alternative therapies should be undertaken.	0.036000192	0.10014991	0.06997057	tensor(-0.1060)	tensor(0.3519)	tensor(0.0843)	0.5615283025166924	0.5891540749804676	0.42455619048286536	0.51260537	0.4035956	0.3938515	0.46881384	0.38235745	0.440214	0.3601057	0.5109825	0.34650558	0.5325988	0.6710886	0.38689178	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid fluorouracil. Take an alternate therapy.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Proceed taking fluorouracil as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient with a DPYD activity score of 2.0, indicating normal DPD enzyme activity, can be considered a normal metabolizer of fluorouracil (5-FU). For these patients, the recommended dosage of 5-FU is the standard dose, without any adjustments. However, it is still important to monitor for potential toxicities, as other factors can influence 5-FU metabolism and toxicity.	-0.046208005	0.22980435	0.07909456	tensor(-0.0859)	tensor(0.2949)	tensor(0.0759)	0.43157962563044805	0.594854093300089	0.39802843566083945	0.5064978	0.4823656	0.4569574	0.49438268	0.5200182	0.38284436	0.4562184	0.5823919	0.47354296	0.4551779	0.6311257	0.51059556	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Based on the pharmacogenomic profile, as a Normal Metabolizer with a CYP2C9 activity score of 2.0, the clinical guidance for taking flurbiprofen would be to follow the standard dosage and administration guidelines. This is because CYP2C9 is not a major metabolizing enzyme for flurbiprofen, and the Normal Metabolizer status indicates average enzyme activity. Therefore, no dosage adjustments or special precautions are necessary for this individual.	-0.07533707	0.15058099	0.029678874	tensor(-0.0359)	tensor(0.3956)	tensor(0.1362)	0.38697884860463483	0.6883796801317393	0.4536957170877273	0.36115164	0.4825865	0.42103952	0.3743753	0.48988116	0.29781064	0.33120728	0.5731947	0.39376393	0.38166985	0.66786164	0.49455476	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Based on the Pharmacogenomics Knowledgebase (PharmGKB) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 1.5 for CYP2C9 may experience reduced metabolism of flurbiprofen, which is primarily metabolized by CYP2C9. This may lead to increased exposure to flurbiprofen and potentially increased risk of adverse effects, such as gastrointestinal toxicity. Therefore, clinicians may consider initiating flurbiprofen at a lower dose and monitoring for adverse effects in this individual.	-0.11673171	0.15768282	0.0072281673	tensor(-0.0407)	tensor(0.5031)	tensor(0.1782)	0.39989693129100723	0.5687796004115846	0.4536957170877273	0.29888165	0.3678357	0.42103952	0.28545347	0.41442448	0.29781064	0.26356682	0.4972008	0.39376393	0.41446552	0.6193833	0.49455476	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual with an indeterminate CYP2C9 genotype, clinical guidance suggests exercising caution when initiating flurbiprofen therapy, as CYP2C9 is involved in the metabolism of flurbiprofen. Although the impact of an indeterminate genotype on flurbiprofen metabolism is unclear, it may be associated with altered pharmacokinetics, potentially leading to increased risk of adverse effects or reduced efficacy. Close monitoring of therapeutic response and adverse effects is recommended, with consideration of alternative medications if necessary.	-0.3199538	-0.00822295	-0.18539697	tensor(-0.0042)	tensor(0.4040)	tensor(0.1714)	0.2277209702205382	0.5898174834718858	0.26894609042038753	0.09884152	0.42583585	0.16508034	0.035041716	0.42399442	0.07259886	-0.023698427	0.5184791	0.12626259	0.2708411	0.5637536	0.4454888	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	Based on the pharmacogenomic profile, an individual with an intermediate metabolizer status and an activity score of 1.0 for CYP2C9 may experience reduced metabolism of flurbiprofen, which is primarily metabolized by CYP2C9. As a result, clinical guidance suggests that this individual may be at increased risk of flurbiprofen toxicity or adverse effects, such as gastrointestinal bleeding or renal impairment, and may require close monitoring or dose adjustment. Additionally, alternative medications with different metabolic pathways may be considered to minimize potential risks.	-0.03662537	0.08619674	0.024434581	tensor(-0.0647)	tensor(0.4356)	tensor(0.1308)	0.4131138541583117	0.5969319713464674	0.45767482249585295	0.36262384	0.3750197	0.4119753	0.31126574	0.40153882	0.2570167	0.30991885	0.51822954	0.36928746	0.45143613	0.65574056	0.43776777	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	Based on the pharmacogenomics profile, individuals with Indeterminate CYP2C9 and Possible Decreased Function SLCO1B1 may have altered fluvastatin pharmacokinetics. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends that these individuals may require a reduced fluvastatin dose, as CYP2C9 is involved in fluvastatin metabolism and SLCO1B1 is responsible for its hepatic uptake. However, the evidence is limited, and genotype-based dosing recommendations are not well established; therefore, close monitoring of response and potential adverse effects is advised.	0.17739558	0.24030507	0.21044867	tensor(-0.1565)	tensor(0.3588)	tensor(0.0431)	0.8071031850386594	0.5527317904816869	0.6581908418127803	0.7619089	0.46173397	0.5900206	0.80773556	0.5278797	0.63342106	0.71359205	0.44591752	0.53294355	0.7762735	0.61839217	0.6265347	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	n/a	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	"Based on the pharmacogenomic results, the clinical guidance for taking fluvastatin would be to proceed with caution and close monitoring. The ""No Result"" for CYP2C9 and ""Indeterminate"" for SLCO1B1 genotypes do not provide clear guidance on the metabolism and transport of fluvastatin, respectively. As fluvastatin is primarily metabolized by CYP2C9 and transported by OATP1B1 (encoded by SLCO1B1), the lack of clear guidance may warrant closer monitoring of efficacy and toxicity, with potential consideration of alternative statin therapies."	-0.4381597	-0.27954316	-0.36284953	tensor(-0.1852)	tensor(0.3295)	tensor(0.0206)	0.13288591773433236	0.6409874799945129	0.13930049749562554	0.19846603	0.6217325	0.1278527	0.013909534	0.63293844	0.057927463	-0.010855247	0.5595202	0.030814985	0.39040893	0.63309187	0.38841003	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	Based on the pharmacogenomic profile, a Normal Metabolizer with an activity score of 2.0 for CYP2C9 suggests normal metabolism of fluvastatin, which is primarily metabolized by CYP2C9. However, the Decreased Function of SLCO1B1, which is involved in the hepatic uptake of fluvastatin, may increase the risk of myotoxicity. Therefore, the clinical guidance would be to initiate fluvastatin at a lower dose and monitor for muscle toxicity, with a possible need for dose adjustment or alternative statin therapy.	0.064907335	0.19080378	0.12731245	tensor(-0.0752)	tensor(0.4627)	tensor(0.1380)	0.6836561584534625	0.5992883910823646	0.7185622262621105	0.44133204	0.4041105	0.5516847	0.5517993	0.5699349	0.5439941	0.55570626	0.51422364	0.54269004	0.62779444	0.6457784	0.61407274	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	"Based on the pharmacogenomics results, the clinical guidance for fluvastatin therapy would be to proceed with caution and close monitoring. The ""No Result"" for CYP2C9 suggests that the patient's metabolism of fluvastatin, which is partially metabolized by CYP2C9, may not be significantly affected. However, the ""Possible Decreased Function"" for SLCO1B1, which is involved in statin uptake, may increase the risk of myotoxicity, and therefore, regular monitoring of creatine kinase levels and muscle symptoms is recommended."	0.16360131	0.24417071	0.20502713	tensor(-0.1351)	tensor(0.2639)	tensor(0.0343)	0.8155711424016882	0.6153093110810363	0.6725543731496858	0.73323715	0.6165397	0.5615837	0.7726349	0.6246645	0.6088624	0.6515432	0.5030665	0.5392756	0.72318524	0.6496584	0.63070095	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer (IM) with a CYP2D6 activity score of 0.5, clinical guidance suggests that they may require closer monitoring and potential dose adjustments when taking fluvoxamine, a strong inhibitor of CYP1A2 and a moderate inhibitor of CYP2C19, CYP2C9, and CYP3A4. As fluvoxamine is primarily metabolized by CYP1A2, the IM phenotype is not expected to significantly impact its pharmacokinetics. However, the patient's CYP2D6 status may affect the metabolism of other co-administered medications that are CYP2D6 substrates.	-0.3082808	0.14672352	-0.1261541	tensor(-0.1583)	tensor(0.3583)	tensor(0.0377)	0.3667934751558262	0.6018262448744819	0.5087177848392922	0.4206257	0.5265681	0.46638277	0.31386325	0.5330903	0.4553759	0.35037273	0.38446394	0.5153168	0.351031	0.5642753	0.6195968	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2D6 with an activity score of 4.0 may require reduced dosages of fluvoxamine, a CYP2D6 substrate, to avoid decreased efficacy. The UM phenotype may lead to increased metabolism and clearance of fluvoxamine, resulting in reduced systemic exposure. Therefore, clinicians should consider initiating therapy with a lower dose and closely monitoring the patient's response to fluvoxamine to avoid subtherapeutic effects.	-0.28275883	-0.03373596	-0.17053173	tensor(-0.0755)	tensor(0.4750)	tensor(0.1439)	0.26490667044518457	0.5808081405882063	0.2899874767362205	0.28077132	0.5069874	0.25900793	0.21336108	0.49115178	0.17823517	0.07481985	0.42193592	0.115871325	0.29790708	0.6108587	0.47693428	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥3.75) may require a decreased dose of fluvoxamine, as they may not achieve adequate concentrations of the medication. This is because fluvoxamine is a substrate of CYP2D6 and ultrarapid metabolizers may metabolize it too quickly, leading to reduced efficacy. As a result, clinicians should consider reducing the fluvoxamine dose by 25-50% in these individuals and closely monitoring their response to treatment.	-0.2907127	0.006163091	-0.1608586	tensor(-0.1053)	tensor(0.4050)	tensor(0.0965)	0.26327496471882844	0.5995270897865101	0.2899874767362205	0.3117169	0.5242825	0.25900793	0.22427656	0.5605275	0.17823517	0.0682652	0.48824847	0.115871325	0.28781557	0.60698956	0.47693428	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	Based on the pharmacogenomics data, an individual with an intermediate metabolizer phenotype and a CYP2D6 activity score of 0.25 may have reduced metabolism of fluvoxamine, which is a substrate of CYP2D6. Clinical guidance suggests that fluvoxamine dosage should be reduced by 25-50% to minimize the risk of adverse events, such as increased serotonin levels and potential serotonin syndrome. Close monitoring of therapeutic response and adverse effects is recommended to adjust the dosage accordingly.	-0.1697543	0.17977981	-0.018577376	tensor(-0.0579)	tensor(0.3953)	tensor(0.1229)	0.38585223752113706	0.5975453600627803	0.5087177848392922	0.333126	0.504694	0.46638277	0.35020527	0.61824965	0.4553759	0.38373777	0.49209484	0.5153168	0.50048715	0.6397527	0.6195968	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Avoid fosphenytoin. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, patients who are HLA-B*15:02 positive should avoid using fosphenytoin due to the increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). This is because HLA-B*15:02 is a strong predictor of hypersensitivity reactions to fosphenytoin, and the risk of severe cutaneous adverse reactions is significantly higher in carriers of this allele. Alternative anticonvulsants should be considered for these patients to minimize the risk of adverse events.	-0.064665034	0.24814562	0.07466413	tensor(-0.1247)	tensor(0.3133)	tensor(0.0389)	0.6082829513245279	0.6316635680097135	0.62467502454801	0.6171341	0.60879076	0.6344921	0.6212339	0.5475002	0.6528358	0.50763094	0.58790964	0.7296763	0.6111182	0.62758654	0.63661844	1
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with no HLA-B result (i.e., HLA-B genotype is unknown or not tested) can still be treated with fosphenytoin, but they should be closely monitored for signs of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). This is because the presence of HLA-B*15:02 is a strong predictor of SJS/TEN risk with fosphenytoin, but its absence does not rule out the risk entirely. Genetic testing for HLA-B*15:02 is recommended if possible, but it is not a requirement for fosphenytoin use.	0.16606547	0.16883062	0.16989894	tensor(-0.1158)	tensor(0.2938)	tensor(0.0485)	0.6852805467240806	0.5574918782892181	0.5393677939614699	0.47249442	0.34376743	0.56399983	0.5386111	0.39197367	0.5396722	0.6040261	0.3712844	0.4893951	0.6805393	0.5475516	0.50082487	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	"For an individual with ""No HLA-B Result"" for HLA-B, the clinical guidance is to use fosphenytoin with caution, as they may still be at risk for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), although the exact risk is unknown. However, the presence of HLA-B*15:02 is a strong predictor of SJS/TEN in patients of Asian ancestry, and its absence does not rule out the risk of these severe cutaneous adverse reactions. Therefore, close monitoring for signs of hypersensitivity reactions is recommended when initiating fosphenytoin therapy."	0.19021657	0.19831996	0.19662908	tensor(-0.0859)	tensor(0.3831)	tensor(0.0855)	0.6803348251119377	0.5038511828276908	0.5393677939614699	0.59231216	0.42844465	0.56399983	0.5371998	0.39831454	0.5396722	0.59525174	0.4043339	0.4893951	0.6948208	0.49555176	0.50082487	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid fosphenytoin. Take an alternate therapy.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Proceed taking fosphenytoin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are HLA-B*15:02 positive are at increased risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis when treated with fosphenytoin. Therefore, it is recommended to avoid fosphenytoin in patients who are HLA-B*15:02 positive, and instead consider alternative anticonvulsant medications. If fosphenytoin is necessary, close monitoring for signs of hypersensitivity reactions is advised.	0.084262386	0.08746407	0.08855381	tensor(-0.0646)	tensor(0.4426)	tensor(0.1433)	0.5626480589390116	0.6049613700767201	0.4854435189546359	0.48735437	0.59967875	0.50106055	0.46440187	0.58389825	0.46350196	0.46784127	0.5219919	0.50379306	0.41709024	0.62403756	0.48077327	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking furazolidone, an antibiotic, due to the risk of hemolytic anemia. This is because furazolidone is known to cause hemolysis in G6PD-deficient individuals, which can lead to severe anemia, jaundice, and even acute kidney injury. As such, alternative antibiotic options should be considered for patients with G6PD deficiency.	-0.040372595	0.15167591	0.0507604	tensor(-0.0746)	tensor(0.3931)	tensor(0.1199)	0.6040515631943939	0.5282784927169383	0.3673568029827368	0.6070252	0.59573174	0.31215417	0.5989349	0.5566101	0.19990589	0.5917375	0.5052983	0.2689577	0.5529241	0.59686506	0.47191042	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with indeterminate G6PD status should be treated as G6PD deficient for therapeutic purposes. Therefore, furazolidone, a medication known to cause hemolysis in G6PD-deficient individuals, should be avoided or used with caution in individuals with indeterminate G6PD status, and alternative therapies should be considered. Close monitoring for signs of hemolysis is recommended if furazolidone is prescribed.	0.11009579	0.28222448	0.19300996	tensor(-0.0746)	tensor(0.4041)	tensor(0.1235)	0.6247326706803799	0.5650350617473878	0.31772665795822214	0.52007854	0.5899657	0.24991748	0.5997986	0.55643046	0.18044579	0.5844693	0.5081024	0.16970645	0.5524258	0.6159039	0.43953186	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a class I or II deficiency (such as those with CNSHA, or Class II deficiency) should avoid taking furazolidone, a monoamine oxidase inhibitor, due to the increased risk of hemolytic anemia. This is because furazolidone can exacerbate the underlying G6PD deficiency, leading to severe hemolysis and potentially life-threatening complications. As an alternative, clinicians should consider prescribing alternative medications that do not pose a similar risk.	-0.12218731	0.10033612	-0.018852487	tensor(-0.1201)	tensor(0.4261)	tensor(0.0981)	0.43549097770322803	0.5699214818897423	0.3852225420033478	0.43775198	0.6137283	0.46253023	0.46497002	0.5636746	0.34670883	0.49461466	0.54210156	0.37166706	0.48229417	0.6148922	0.4752877	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take furazolidone, an antibiotic, without any specific dosage adjustments or precautions. This is because furazolidone is not expected to cause hemolytic anemia in individuals with normal G6PD activity. Therefore, no special consideration is needed for G6PD-normal individuals taking furazolidone.	-0.06288408	0.21668679	0.063650176	tensor(-0.0739)	tensor(0.3639)	tensor(0.1058)	0.6311378012251299	0.6546160465769253	0.3155028951555039	0.48941338	0.64378446	0.20622349	0.43804833	0.6072858	0.102348834	0.40162185	0.57339644	0.06839856	0.5565839	0.63311166	0.3956626	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking gentamicin as normal. There is no recommendation.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Avoid gentamicin. Take an alternate therapy.	Individuals with the mitochondrial MT-RNR1 variant are at increased risk of aminoglycoside-induced hearing loss, including gentamicin. The clinical guidance is to avoid or use gentamicin with caution in these individuals, considering alternative antibiotics when possible. If gentamicin is necessary, close monitoring of auditory function and serum concentrations is recommended to minimize the risk of hearing loss.	0.15692884	0.2193531	0.18980052	tensor(-0.0447)	tensor(0.1958)	tensor(0.0596)	0.662712224444392	0.5481451913450964	0.5240998004794737	0.6985101	0.59583676	0.575579	0.72261363	0.5823566	0.5485149	0.67494386	0.533553	0.47309843	0.6460669	0.6429882	0.60315484	0
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals with a normal risk genotype for MT-RNR1, the clinical guidance is to use gentamicin according to the standard dosing and monitoring guidelines, as they are not at increased risk of aminoglycoside-induced hearing loss. No specific modifications to gentamicin therapy are recommended, and the usual precautions to minimize the risk of hearing loss, such as monitoring serum concentrations and avoiding excessive doses, should be followed. Regular audiometric monitoring is still recommended to detect any potential ototoxicity.	0.052779518	0.25134975	0.14697027	tensor(-0.0921)	tensor(0.2870)	tensor(0.0614)	0.6636446303216839	0.6453949143579018	0.5417102465590716	0.69280076	0.6615396	0.56117374	0.7247134	0.61923736	0.5567209	0.6890609	0.5620446	0.5107628	0.6286851	0.58401215	0.62111604	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (particularly the m.1555A>G or m.1494C>T variants) are at increased risk of aminoglycoside-induced hearing loss, including gentamicin. However, the evidence is not yet sufficient to support a contraindication to gentamicin use in these individuals. Instead, CPIC recommends caution and close monitoring of hearing function, especially in patients with pre-existing hearing loss or other risk factors, and consideration of alternative antibiotics when possible.	-0.093243554	0.14428945	0.016356237	tensor(-0.1903)	tensor(0.3007)	tensor(0.0079)	0.5489651173374882	0.549840502690572	0.5417102465590716	0.43839234	0.42545095	0.56117374	0.6231079	0.50940347	0.5567209	0.676985	0.53225183	0.5107628	0.56497175	0.5542647	0.62111604	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid glyburide due to increased risk of hemolytic anemia. G6PD deficiency can impair the metabolism of glyburide, leading to increased formation of reactive oxygen species that can cause hemolysis. As a result, alternative sulfonylureas or antidiabetic agents should be considered for patients with G6PD deficiency.	-0.048820917	0.1487081	0.04458642	tensor(-0.0730)	tensor(0.3710)	tensor(0.1135)	0.6122205373909516	0.516525356325745	0.3980268352881108	0.60189855	0.56287104	0.50869673	0.5884205	0.55361295	0.47483635	0.6701194	0.55506575	0.46649092	0.614624	0.53664786	0.498027	0
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for glucose-6-phosphate dehydrogenase (G6PD) deficiency can likely take glyburide without increased risk of hemolytic anemia, as glyburide is not typically associated with hemolysis in G6PD-deficient individuals. However, it is recommended to monitor for signs and symptoms of hemolysis, such as anemia, fatigue, and dark urine, especially in individuals with a family history of G6PD deficiency or those of African, Mediterranean, or Southeast Asian descent. Additionally, alternative sulfonylureas without a risk of hemolysis, such as glipizide or glimepiride, could be considered.	-0.053093385	0.22536576	0.073103435	tensor(-0.1538)	tensor(0.3081)	tensor(0.0363)	0.5749206839586694	0.5692477990279124	0.349256330212684	0.476195	0.6215493	0.35664847	0.61263	0.6379133	0.387123	0.63173175	0.6039783	0.35245866	0.52405095	0.511869	0.47997203	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	"For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a class I or II deficiency (classified as CNSHA, or ""Class I, II, or III"" in some sources), the clinical guidance is to use glyburide with caution due to the increased risk of hemolytic anemia. It is recommended to monitor for signs of hemolysis, such as anemia, fatigue, and dark urine, and to discontinue glyburide if hemolysis occurs. Alternative sulfonylureas, such as glipizide or glimepiride, may be considered as they are less likely to cause hemolytic anemia in G6PD-deficient individuals."	-0.09587378	0.19565059	0.034929536	tensor(-0.1223)	tensor(0.3531)	tensor(0.0733)	0.4238346971943013	0.5429889438452825	0.4271683469412071	0.5430008	0.5716685	0.5571215	0.5425295	0.6493804	0.47607183	0.45472658	0.5882968	0.3938367	0.54998785	0.48761913	0.48714405	0
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For an individual who is normal for glucose-6-phosphate dehydrogenase (G6PD), there are no specific clinical concerns or restrictions regarding the use of glyburide, a sulfonylurea medication for type 2 diabetes. Glyburide is not known to cause hemolytic anemia, a concern for individuals with G6PD deficiency, and can be used as per standard clinical guidelines. Therefore, normal G6PD status does not impact glyburide therapy, and dosing can be titrated based on glycemic response and other clinical factors.	-0.057808027	0.25889543	0.083090216	tensor(-0.0679)	tensor(0.3083)	tensor(0.0948)	0.6162996158221999	0.5937269553094565	0.35271780208970166	0.50989175	0.6299137	0.3268034	0.46035287	0.64666265	0.2738237	0.4001565	0.58766717	0.24943726	0.56710875	0.5411154	0.44064677	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Based on the pharmacogenomics profile, the clinical guidance for an individual with Malignant Hyperthermia Susceptibility (MHS) for RYR1 and Uncertain Susceptibility for CACNA1S would be to avoid halothane due to the high risk of malignant hyperthermia (MH). The RYR1 variant is strongly associated with MHS, and halothane is a known triggering agent for MH. Therefore, alternative anesthetics should be considered to minimize the risk of this life-threatening adverse reaction.	0.18545745	0.22843988	0.20894201	tensor(-0.0932)	tensor(0.2464)	tensor(0.0388)	0.702062693943159	0.5068899730293654	0.439550449810415	0.7020951	0.54810834	0.57533854	0.772486	0.5245028	0.50871634	0.7250895	0.46252486	0.4248627	0.67982215	0.5658918	0.5738699	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Based on the genetic profile, individuals with Malignant Hyperthermia Susceptibility (MHS) associated with RYR1 and CACNA1S mutations are at increased risk of developing malignant hyperthermia (MH) when exposed to certain anesthetics, including halothane. Clinical guidance recommends that these individuals avoid halothane and other triggering anesthetics, opting instead for alternative anesthetics that are less likely to trigger MH. Additionally, a thorough pre-anesthetic evaluation and preparation, including a family history and genetic testing, should be performed to ensure the safest possible anesthesia care.	0.13242745	0.1878811	0.16203786	tensor(-0.1290)	tensor(0.2353)	tensor(0.0122)	0.7276716792108773	0.4850499035048427	0.439550449810415	0.7291579	0.52709496	0.57533854	0.78941923	0.5284057	0.50871634	0.76447725	0.48807114	0.4248627	0.6815169	0.56704146	0.5738699	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid halothane. Take an alternate therapy.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Proceed taking halothane as normal. There is no recommendation.	Based on the pharmacogenomics results, an individual with Uncertain Susceptibility for RYR1 and No Result for CACNA1S should exercise caution when considering the use of halothane anesthesia. Although the RYR1 result is uncertain, it may still indicate an increased risk of malignant hyperthermia (MH), a rare but life-threatening reaction to halothane. Therefore, alternative anesthetics may be considered, and the anesthesiologist should take necessary precautions to monitor for signs of MH during surgery.	0.13946594	0.27422455	0.20582494	tensor(-0.0701)	tensor(0.3533)	tensor(0.1094)	0.7100164312342966	0.5492713406259764	0.4305505515098672	0.73462135	0.5000529	0.45458028	0.714038	0.5224239	0.43798286	0.57480454	0.493197	0.3440171	0.721604	0.51607543	0.4221218	0
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	"Based on current evidence, a patient with a ""No Result"" for RYR1 and Malignant Hyperthermia Susceptibility (MHS) for CACNA1S should still be considered at risk for malignant hyperthermia (MH) when exposed to halothane, a known MH-triggering anesthetic. This is because a ""No Result"" does not rule out the presence of a variant that may still confer risk. Therefore, standard MH precautions and monitoring should be taken when administering halothane to this individual."	0.14798059	0.17952076	0.1660228	tensor(-0.1365)	tensor(0.2594)	tensor(0.0154)	0.7026148768779138	0.4891475493635886	0.460420494639617	0.79770344	0.58240694	0.6118899	0.81925285	0.5869766	0.4742661	0.7541589	0.54794014	0.4053989	0.74336046	0.51798975	0.56504685	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2D6, with an activity score ≥5.0, may metabolize hydrocodone too quickly, leading to reduced efficacy or increased risk of toxicity. Therefore, the CPIC recommends considering an alternative opioid or closely monitoring the patient for efficacy and adverse effects, as well as adjusting the dose or dosing interval as needed. Additionally, UMs may require more frequent dosing to achieve adequate pain control.	-0.07467656	0.27619278	0.07873892	tensor(-0.1238)	tensor(0.4060)	tensor(0.0892)	0.5051631503595256	0.5275993180534226	0.6102162761904872	0.4131932	0.47554204	0.55567604	0.6404655	0.5613912	0.7285884	0.54756874	0.57485235	0.70235753	0.57458115	0.61650527	0.7356111	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For an individual who is an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score of 2.5, clinical guidance suggests that they may metabolize hydrocodone more rapidly and extensively, potentially leading to decreased efficacy or increased risk of toxicity due to rapid formation of opioid metabolites. As a result, it is recommended to consider alternative analgesics or closely monitor for efficacy and adverse effects, with potential dose adjustments or more frequent dosing intervals to achieve optimal pain management. Additionally, genotype-based dosing recommendations may be necessary to ensure safe and effective treatment.	-0.01313587	0.30880225	0.1303314	tensor(-0.0898)	tensor(0.3507)	tensor(0.0951)	0.5451704560787537	0.5471234747853723	0.6102162761904872	0.34031537	0.473006	0.55567604	0.6706083	0.57337725	0.7285884	0.5869751	0.5381857	0.70235753	0.5242574	0.5673553	0.7356111	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	Use hydrocodone label recommended age- or weight-specific dosing.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	Based on the clinical guidance from the Clinical Pharmacogenetics Implementation Consortium (CPIC), a patient who is a Normal Metabolizer (NM) with a CYP2D6 activity score of 1.5 is expected to metabolize hydrocodone normally. As a result, the recommended dose and dosing interval of hydrocodone are unlikely to need adjustment, and standard prescribing guidelines can be followed. However, it is essential to monitor the patient's response to therapy and adjust the dose as needed to achieve adequate pain control while minimizing adverse effects.	-0.08918853	0.12657623	0.011592846	tensor(-0.1184)	tensor(0.3145)	tensor(0.0593)	0.594898703921864	0.6214167463796192	0.6633386887195895	0.58690864	0.49240226	0.56259805	0.601399	0.58894134	0.6689284	0.6036573	0.59624726	0.63510936	0.5726926	0.6616935	0.70890653	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	Based on the clinical evidence, individuals who are ultrarapid metabolizers (UMs) of CYP2D6 with an activity score ≥6.0 may require reduced dosages of hydrocodone due to increased conversion to its active metabolite, hydromorphone, which can lead to increased risk of adverse effects such as respiratory depression and overdose. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend that UMs of CYP2D6 may require a 25-50% reduction in hydrocodone dosage, with close monitoring for efficacy and adverse effects. Additionally, alternative analgesics may be considered to minimize the risk of adverse outcomes.	-0.032667406	0.30748484	0.117428124	tensor(-0.1168)	tensor(0.3805)	tensor(0.0835)	0.5460721601789938	0.5458607293833178	0.6102162761904872	0.45028627	0.509706	0.55567604	0.64933693	0.5359076	0.7285884	0.5782915	0.5667987	0.70235753	0.5546729	0.5653262	0.7356111	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are variable for glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at increased risk of hemolytic anemia when taking hydroxychloroquine. However, the evidence is limited, and the risk is likely to be low. As a result, CPIC recommends caution and close monitoring for hemolysis, but does not recommend avoiding hydroxychloroquine in these individuals.	-0.111839436	0.1630061	0.012340829	tensor(-0.0852)	tensor(0.3502)	tensor(0.0980)	0.5976732058483332	0.5309244566259264	0.33955265938283596	0.5147463	0.5142089	0.3887062	0.5088277	0.59335494	0.2883553	0.5178064	0.61912996	0.24293713	0.5400779	0.5175178	0.4296599	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	According to current clinical guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can safely take hydroxychloroquine, as they are not at increased risk of hemolytic anemia, a rare but potential side effect of this medication. No dose adjustments or special precautions are recommended for G6PD-normal individuals taking hydroxychloroquine. Regular monitoring for signs of hemolysis, such as dark urine or jaundice, is still recommended, but the risk is considered low in G6PD-normal individuals.	-0.11831625	0.13504367	-0.0026130986	tensor(-0.0813)	tensor(0.3445)	tensor(0.0987)	0.6253626257015565	0.6089379514941511	0.28768019585306626	0.4983357	0.71827507	0.2588156	0.42924666	0.73063356	0.1573301	0.3573752	0.6532838	0.07277118	0.61498743	0.5868492	0.3968069	1
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, the clinical guidance is to exercise caution when considering hydroxychloroquine therapy, as they may be at increased risk of hemolytic anemia. However, the available evidence suggests that the risk is likely lower than in individuals with a known G6PD deficiency. Close monitoring of hematological parameters, particularly during the initial treatment period, is recommended to detect any potential adverse reactions.	0.09079531	0.25275484	0.16923837	tensor(-0.0319)	tensor(0.4260)	tensor(0.1604)	0.6434783276970716	0.526518881839228	0.30411562367564293	0.5180405	0.5718101	0.2795874	0.6349942	0.5639225	0.24634303	0.58794904	0.5511203	0.15418531	0.5939182	0.54151624	0.43756366	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should exercise caution when taking hydroxychloroquine, as it may increase the risk of hemolytic anemia. The CPIC recommends that G6PD-deficient individuals be closely monitored for signs of hemolysis, such as anemia, fatigue, and dark urine, when taking hydroxychloroquine. In some cases, alternative treatments may be considered, especially in severe G6PD deficiency or with a history of hemolytic anemia.	-0.09134272	0.11174835	0.0042004283	tensor(-0.0821)	tensor(0.3844)	tensor(0.1117)	0.6088368810683596	0.5103755012862231	0.33955265938283596	0.5709824	0.5995284	0.3887062	0.5536382	0.6140579	0.2883553	0.54667366	0.6246116	0.24293713	0.5099639	0.5055014	0.4296599	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	Based on the pharmacogenomics data, as a Normal Metabolizer with an activity score of 2.0 for CYP2C9, the clinical guidance for taking ibuprofen is as follows: You are expected to metabolize ibuprofen normally, and no dosage adjustment is required. You can take ibuprofen at the standard recommended dose and frequency, and monitoring for adverse effects is not necessary due to CYP2C9 genotype. However, it's essential to follow the recommended dosage and consult with a healthcare professional if you experience any unusual side effects or have concerns.	-0.059417997	0.19943494	0.05897802	tensor(-0.0365)	tensor(0.4135)	tensor(0.1452)	0.40765844558625425	0.6306710067124006	0.47434012075240656	0.42018622	0.5659728	0.39356413	0.36355042	0.5332121	0.2775328	0.39443874	0.55252004	0.3557187	0.41532964	0.6503028	0.47965077	1
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer (IM) with an activity score of 1.5 for CYP2C9, the clinical guidance suggests that they may experience reduced metabolism of ibuprofen, which may lead to increased plasma concentrations and potentially increased risk of adverse effects. As a result, it is recommended to initiate therapy with a lower dose of ibuprofen and closely monitor for signs of toxicity, such as gastrointestinal upset or bleeding. Additionally, the patient should be informed of the potential for altered response to ibuprofen and the need for close monitoring.	-0.087578684	0.1739889	0.031645928	tensor(-0.0504)	tensor(0.4831)	tensor(0.1572)	0.5179352715081729	0.5221937804961438	0.47434012075240656	0.3811913	0.45489356	0.39356413	0.36846995	0.48573792	0.2775328	0.3773941	0.531026	0.3557187	0.41238686	0.55621004	0.47965077	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For an individual who is indeterminate for CYP2C9, clinical guidance suggests that they can likely take ibuprofen as usual, as CYP2C9 is not a primary enzyme involved in ibuprofen metabolism. However, it's essential to monitor for potential adverse effects, such as gastrointestinal bleeding or renal impairment, as CYP2C9 may play a minor role in ibuprofen metabolism. Additionally, consideration of other genetic and non-genetic factors that may influence ibuprofen response or toxicity is recommended.	-0.31605047	0.0088014025	-0.1768055	tensor(-0.0312)	tensor(0.3288)	tensor(0.1263)	0.257748048102674	0.5857415119566891	0.26014175292499875	0.11569807	0.55396444	0.12163701	0.035567228	0.44626492	0.043806147	-0.019747159	0.52537143	0.09934662	0.28579384	0.5768724	0.47328937	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	Based on the Pharmacogenomics Knowledgebase (PharmGKB) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 1.0 for CYP2C9 is expected to have reduced enzyme activity. This may lead to increased exposure to ibuprofen, which is primarily metabolized by CYP2C9. As a result, the clinical guidance suggests that these individuals may require a lower dose of ibuprofen to avoid adverse effects, such as gastrointestinal bleeding, and should be monitored for increased sensitivity to the drug.	-0.037852336	0.093124375	0.026843673	tensor(-0.0742)	tensor(0.4550)	tensor(0.1291)	0.4352845448596663	0.4198434675344071	0.47619327010627704	0.3431785	0.35988972	0.38559103	0.2549583	0.34841278	0.24466251	0.3224956	0.46429548	0.33813602	0.4076263	0.55412084	0.42126685	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	Based on the pharmacogenomics profile, an individual who is an Ultrarapid Metabolizer (UM) for CYP2D6 (activity score ≥3.25) and an Intermediate Metabolizer (IM) for CYP2C19 may require dosage adjustments when taking imipramine. As a UM for CYP2D6, they may metabolize imipramine too quickly, leading to reduced efficacy or increased risk of adverse effects, and may require a higher dose. Additionally, as an IM for CYP2C19, they may have reduced metabolism of imipramine, which could increase the risk of adverse effects, and close monitoring of therapeutic response and adverse effects is recommended.	-0.06558581	0.26184574	0.07925754	tensor(-0.1526)	tensor(0.3753)	tensor(0.0586)	0.7252973151744482	0.610939738407469	0.7400162423309369	0.59564996	0.44095156	0.68123335	0.63284254	0.57008576	0.7389349	0.47865707	0.491822	0.5607455	0.56130356	0.55561525	0.6112069	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid imipramine. Take an alternate therapy.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Proceed taking imipramine as normal. There is no recommendation.	Based on the pharmacogenomic profile, as a Normal Metabolizer with an activity score of 2.25 for CYP2D6, the individual is expected to metabolize imipramine normally. However, as an Intermediate Metabolizer for CYP2C19, they may have reduced metabolism of imipramine, which could lead to higher plasma concentrations and increased risk of adverse effects. Clinical guidance would suggest starting with a lower dose of imipramine and closely monitoring for adverse effects, such as drowsiness, dizziness, and anticholinergic effects, with potential dose adjustments based on therapeutic response and tolerability.	-0.18591753	0.22645812	-0.0132702645	tensor(-0.0869)	tensor(0.4204)	tensor(0.1180)	0.43849356563489045	0.6349784420211777	0.5309065817909071	0.2589272	0.463778	0.44453612	0.30680376	0.60710424	0.42729184	0.35127437	0.6115939	0.49763578	0.4694112	0.6353651	0.6318137	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥4.0) may require lower doses of imipramine, a tricyclic antidepressant primarily metabolized by CYP2D6, to avoid increased risk of adverse effects. Close monitoring of therapeutic response and adverse effects is recommended. Additionally, in the absence of CYP2C19 genotyping results, clinicians should consider imipramine's potential for inhibition of CYP2C19 and adjust dosing accordingly to minimize potential drug-drug interactions.	0.20256165	0.22131442	0.21419394	tensor(-0.0993)	tensor(0.3283)	tensor(0.0562)	0.6940162620329905	0.6557344302834541	0.5317135249942968	0.6272043	0.480824	0.4796846	0.57863104	0.49481225	0.42694318	0.57910556	0.56133705	0.4305113	0.641381	0.629796	0.42369863	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, as an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score of 3.0, the individual may metabolize imipramine more quickly, potentially leading to reduced efficacy or increased risk of adverse effects. Considering the Indeterminate result for CYP2C19, which also contributes to imipramine metabolism, close therapeutic drug monitoring is recommended to ensure optimal dosing and minimize potential toxicity. The clinician may need to consider alternative therapies or adjust the imipramine dosage based on the patient's response and adverse effect profile.	0.1451315	0.20550473	0.17705588	tensor(-0.1016)	tensor(0.3039)	tensor(0.0602)	0.6091700440408493	0.6171243935349388	0.5317135249942968	0.608988	0.46974105	0.4796846	0.607928	0.53639406	0.42694318	0.5556661	0.5738052	0.4305113	0.6000355	0.6259418	0.42369863	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	Based on the pharmacogenomics profile, individuals with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S are at increased risk of malignant hyperthermia (MH) when exposed to volatile anesthetics like isoflurane. As a result, clinical guidance recommends careful consideration and close monitoring when administering isoflurane to these individuals, and alternative anesthetics may be preferred. Additionally, a thorough medical history and family history of MH should be obtained, and preparations for MH treatment should be made available.	0.16141294	0.1887636	0.17737558	tensor(-0.1557)	tensor(0.1232)	tensor(-0.0415)	0.6855184309652761	0.5516019379189567	0.3766365308909913	0.67691827	0.4721429	0.47739962	0.74291575	0.5166864	0.3792879	0.7210508	0.46819875	0.38819194	0.65479255	0.61955696	0.5353766	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	"According to the Pharmacogenomics Knowledgebase (PharmGKB), a ""No Result"" for RYR1 and Malignant Hyperthermia Susceptibility (MHS) indicates that the individual does not have a known variant associated with MHS. Additionally, the CACNA1S gene is also associated with MHS, but in this case, the individual's genotype is not reported. Therefore, there is no specific clinical guidance for isoflurane use in this individual, and standard anesthesia precautions and monitoring should be followed."	0.19110769	0.18850505	0.19219176	tensor(-0.0923)	tensor(0.2687)	tensor(0.0645)	0.6168583908511569	0.44258405888278873	0.3987591625365293	0.50049424	0.222278	0.51547456	0.71440583	0.56303245	0.35079083	0.6638797	0.45228	0.37099385	0.6043001	0.5018592	0.5316622	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	According to the Pharmacogenomics Knowledgebase (PharmGKB) and the Malignant Hyperthermia Association of the United States (MHAUS), individuals with a diagnosis of Malignant Hyperthermia Susceptibility (MHS) due to a variant in the RYR1 gene should avoid triggering anesthetics, including isoflurane, as they can trigger a malignant hyperthermia (MH) crisis. The uncertain susceptibility for CACNA1S does not alter this guidance, as RYR1 is the primary genetic risk factor for MHS. Therefore, alternative anesthetics should be considered, and precautions should be taken to ensure rapid treatment of an MH crisis if it were to occur.	0.14248498	0.1856542	0.16617483	tensor(-0.2374)	tensor(0.1293)	tensor(-0.0817)	0.6825319219869017	0.4399073481137841	0.3766365308909913	0.71014684	0.5530824	0.47739962	0.7482465	0.5015871	0.3792879	0.735499	0.40825555	0.38819194	0.65316826	0.5710694	0.5353766	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid isoflurane. Take an alternate therapy.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Proceed taking isoflurane as normal. There is no recommendation.	"Based on the available evidence, a patient with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S is not at increased risk for malignant hyperthermia (MH) associated with isoflurane anesthesia. The American Society of Anesthesiologists recommends that patients with uncertain susceptibility to MH can still receive isoflurane, but with careful monitoring and preparation for potential MH crisis. However, it is essential to discuss the patient's individual situation with an anesthesiologist to determine the best course of action."	0.026723498	0.16861336	0.09627804	tensor(-0.1798)	tensor(0.1793)	tensor(-0.0255)	0.6438472633164923	0.5290569991670584	0.4239299331007022	0.6988825	0.4986643	0.40739372	0.62930536	0.44929987	0.33031934	0.506842	0.48926908	0.3553096	0.68121254	0.553787	0.4108436	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Use ivacaftor according to the product label	['Avoid ivacaftor. Take an alternate therapy.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Proceed taking ivacaftor as normal. There is no recommendation.	According to the Cystic Fibrosis Foundation and the FDA, ivacaftor is recommended for cystic fibrosis (CF) patients aged 6 months and older who have at least one copy of the G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene. These patients are considered ivacaftor-responsive and may benefit from treatment with ivacaftor, which has been shown to improve lung function, reduce exacerbations, and improve quality of life. Dosing is typically 150 mg orally every 12 hours, with or without food.	-0.23191959	0.3011217	-0.022669494	tensor(-0.2129)	tensor(0.2989)	tensor(-0.0128)	0.6396309573058032	0.601317363222397	0.7670214781579747	0.60835195	0.52642405	0.6941758	0.59501934	0.64743984	0.7759698	0.4184563	0.61585516	0.44867808	0.64888245	0.46523774	0.70768344	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Ivacaftor is not recommended	['Proceed taking ivacaftor as normal. There is no recommendation.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Avoid ivacaftor. Take an alternate therapy.	According to the Cystic Fibrosis Foundation and the American Thoracic Society, ivacaftor is not recommended for patients with cystic fibrosis (CF) who are non-responders, as they are unlikely to benefit from treatment. Non-responders are typically defined as those with a change in percent predicted forced expiratory volume in 1 second (ppFEV1) of <5% or a sweat chloride reduction of <30 mmol/L after ivacaftor treatment. In such cases, alternative treatment options should be explored, and ivacaftor therapy should be discontinued to avoid unnecessary medication burden and potential side effects.	-0.17649181	0.50968707	0.079479	tensor(-0.1363)	tensor(0.2827)	tensor(0.0377)	0.6708577083031548	0.5804942283519545	0.7428704288527176	0.680535	0.5764516	0.7654093	0.6047022	0.61177886	0.75782347	0.51249564	0.6567924	0.66114455	0.69791937	0.6751243	0.7280906	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking kanamycin as normal. There is no recommendation.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Avoid kanamycin. Take an alternate therapy.	For individuals with the m.1555A>G or m.1494C>T variants in the MT-RNR1 gene, which confer an increased risk of aminoglycoside-induced hearing loss, clinical guidance suggests avoiding kanamycin due to its high risk of ototoxicity. If kanamycin is deemed necessary, close monitoring of auditory function and serum concentrations is recommended to minimize the risk of hearing loss. Alternative antibiotics with lower ototoxic potential should be considered whenever possible.	0.06557954	0.21659885	0.13918857	tensor(-0.1299)	tensor(0.2867)	tensor(0.0352)	0.6743213948657116	0.576452253513845	0.4343070696020012	0.7588332	0.60691005	0.5684394	0.7570869	0.61720455	0.5099516	0.73478985	0.49168873	0.4549284	0.651953	0.64780104	0.5694706	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For an individual with a normal risk of aminoglycoside-induced hearing loss due to a wild-type MT-RNR1 genotype, the clinical guidance is to use kanamycin with caution and close monitoring for ototoxicity. This is because kanamycin, like other aminoglycosides, can still cause hearing loss in individuals without a genetic predisposition. Regular audiometric testing and careful evaluation of potential ototoxicity symptoms are recommended to minimize the risk of hearing loss.	0.06927373	0.18437855	0.12679408	tensor(-0.0520)	tensor(0.3068)	tensor(0.1047)	0.6226797414334015	0.5593063976749132	0.4447664254714316	0.57586694	0.59854704	0.560374	0.6620986	0.6502936	0.54688895	0.67075723	0.45129997	0.52928793	0.56392753	0.5163777	0.5961292	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (particularly the m.1555A>G or m.1494C>T variants) are at increased risk of aminoglycoside-induced hearing loss, including with kanamycin. In these cases, the CPIC recommends considering alternative antibiotics or monitoring for ototoxicity with regular audiograms, especially in patients with pre-existing hearing loss or other risk factors. However, the evidence is not yet sufficient to recommend universal genetic testing for MT-RNR1 prior to kanamycin administration.	-0.0767832	0.17149411	0.03725249	tensor(-0.1515)	tensor(0.3199)	tensor(0.0418)	0.5512407294042291	0.5311561375187873	0.4447664254714316	0.4780638	0.41371056	0.560374	0.5983259	0.50789046	0.54688895	0.6618004	0.4174227	0.52928793	0.5194565	0.538536	0.5961292	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are rapid metabolizers of CYP2C19 may require higher doses of lansoprazole to achieve therapeutic effects due to increased metabolism of the drug. However, the optimal dosing strategy has not been established, and clinicians should closely monitor treatment response and adjust the dose as needed. Additionally, alternative proton pump inhibitors that are not CYP2C19 substrates, such as pantoprazole or rabeprazole, may be considered.	-0.041322757	0.08586739	0.021688197	tensor(-0.0487)	tensor(0.3847)	tensor(0.1309)	0.45786818851882743	0.6716030220899836	0.4571874024966373	0.48665166	0.57777345	0.4252373	0.40336746	0.51905257	0.5098257	0.37801957	0.5429751	0.4069917	0.41018942	0.6629333	0.41472074	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are likely poor metabolizers (PMs) for CYP2C19 may require alternative proton pump inhibitor (PPI) therapy, as lansoprazole is a CYP2C19 substrate. Lansoprazole dosing may need to be reduced or alternative PPIs such as rabeprazole or pantoprazole, which are less dependent on CYP2C19, may be considered. Close monitoring for adverse effects, such as gastrointestinal symptoms, is recommended in CYP2C19 PMs taking lansoprazole.	-0.18413675	0.047734622	-0.077524625	tensor(-0.0799)	tensor(0.3466)	tensor(0.1004)	0.3382854719925294	0.6356559202004992	0.4210090733969492	0.36891264	0.5362083	0.42745245	0.32858872	0.52756214	0.50445116	0.3280271	0.55938697	0.4396712	0.36368	0.61757326	0.37784943	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2C19 may require higher doses of lansoprazole, a proton pump inhibitor (PPI), to achieve adequate therapeutic response. This is because UMs may metabolize lansoprazole too quickly, resulting in reduced efficacy. The CPIC recommends considering a dose increase of up to 2-3 times the standard dose, with close monitoring of therapeutic response and adverse effects.	-0.15897012	0.16008277	-0.018684413	tensor(-0.1149)	tensor(0.3381)	tensor(0.0735)	0.41812666089141176	0.6695567486312634	0.39885158636818724	0.39889777	0.52671564	0.49366963	0.39346546	0.5018601	0.5537985	0.42172918	0.53271097	0.48328146	0.43897784	0.6986069	0.35912442	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid lansoprazole. Take an alternate therapy.', 'Take lansoprazole with a reduced dose.', 'Take lansoprazole with an increased dose.']	Proceed taking lansoprazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for CYP2C19 (i.e., have a genotype that does not clearly classify as extensive, intermediate, or poor metabolizer) can be treated similarly to extensive metabolizers with regards to lansoprazole dosing. No specific dosage adjustments are recommended, and the standard dose of lansoprazole can be used. However, clinicians should be aware that the individual's response to the medication may vary, and monitoring for efficacy and toxicity is still warranted.	-0.3185842	0.06524835	-0.15946795	tensor(-0.1140)	tensor(0.3558)	tensor(0.0785)	0.2707857359780433	0.6256790028097162	0.2921613700922261	0.11845974	0.5406002	0.19737782	0.079205506	0.62242675	0.09397242	-0.0138934525	0.57905924	0.110937074	0.36026537	0.6057682	0.46315637	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal metabolizers of CYP2C9 with an activity score of 2.0 are expected to metabolize lornoxicam, a CYP2C9 substrate, normally. Therefore, no dosage adjustment is recommended, and standard dosing of lornoxicam can be used. However, it is essential to monitor the patient for efficacy and toxicity, as individual responses to lornoxicam may vary.	-0.09316324	0.16912177	0.02629256	tensor(-0.0585)	tensor(0.3461)	tensor(0.1146)	0.39694977909117574	0.6850891663317047	0.452334357646321	0.42294723	0.6076603	0.41502437	0.44065166	0.5876589	0.366958	0.44425902	0.57598716	0.45434287	0.46045288	0.66387314	0.49890026	1
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with a CYP2C9 intermediate metabolizer genotype and an activity score of 1.5 is likely to have reduced enzyme activity. For lornoxicam, a CYP2C9 substrate, this may lead to increased exposure and potentially increased risk of adverse effects, such as gastrointestinal bleeding. Therefore, clinicians may consider alternative medications or close monitoring for adverse effects when prescribing lornoxicam to individuals with this genotype.	-0.12242367	0.1110582	-0.014669643	tensor(-0.0936)	tensor(0.3900)	tensor(0.1056)	0.37864977858323756	0.5669934082980823	0.452334357646321	0.31430224	0.46170345	0.41502437	0.31084132	0.5179925	0.366958	0.33440098	0.55023724	0.45434287	0.36452892	0.56710505	0.49890026	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate CYP2C9 genotype, which is typically associated with reduced enzyme activity, may require dose adjustment or alternative medications when taking lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID) metabolized by CYP2C9. As lornoxicam is primarily metabolized by CYP2C9, reduced enzyme activity may lead to increased drug concentrations and potentially increased risk of adverse effects. Therefore, clinicians should consider monitoring for adverse effects and adjusting the dose or switching to an alternative NSAID if necessary.	-0.3774049	0.030328639	-0.21280508	tensor(-0.1371)	tensor(0.3983)	tensor(0.0726)	0.24256506688795768	0.628169243023025	0.28538900180946636	0.10435433	0.4681913	0.30926386	0.0529137	0.49052382	0.20892292	-0.0061438475	0.5440316	0.14792292	0.2822858	0.6435519	0.43689218	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	Based on the pharmacogenomics data, as an Intermediate Metabolizer with an activity score of 1.0 for CYP2C9, the clinical guidance for taking lornoxicam would be to monitor for potential increased risk of adverse effects, such as gastrointestinal bleeding or cardiovascular events, due to reduced metabolism of lornoxicam. Dose adjustments may be necessary, and close monitoring of therapeutic response and adverse events is recommended. Additionally, alternative medications with a more favorable pharmacogenomic profile may be considered.	0.032301527	0.114156745	0.07458283	tensor(-0.0705)	tensor(0.4255)	tensor(0.1263)	0.44946198340650517	0.6736828275897718	0.4664440878681671	0.45966634	0.5585499	0.5035275	0.38047796	0.60805845	0.42515695	0.38148037	0.5811437	0.4258482	0.49112454	0.6855266	0.4612326	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	According to clinical guidelines, individuals with normal function of the SLCO1B1 gene, which codes for the organic anion transporting polypeptide 1B1 (OATP1B1), are not expected to have altered pharmacokinetics of lovastatin, a statin medication. Therefore, no dosage adjustment or special monitoring is recommended for lovastatin in individuals with normal SLCO1B1 function. Standard dosing and monitoring for lovastatin can be followed in these individuals.	-0.15998547	0.15720929	-0.020402864	tensor(-0.1224)	tensor(0.2793)	tensor(0.0482)	0.32451570208024577	0.5979911142850879	0.35179844288183243	0.32663125	0.601288	0.4318498	0.4154432	0.626169	0.3690482	0.3035551	0.5747397	0.33563986	0.43637332	0.6281751	0.6248803	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with increased function of SLCO1B1 (e.g., *1A/*1A genotype) may require higher doses of lovastatin to achieve optimal therapeutic response, as they may have increased uptake of the medication in the liver. However, the evidence for this recommendation is moderate, and the optimal dosing strategy has not been established. Close monitoring of serum cholesterol levels and potential adjustment of dosage may be necessary to achieve therapeutic goals.	-0.10402319	0.1698573	0.019865513	tensor(-0.1136)	tensor(0.3158)	tensor(0.0613)	0.3876651580977574	0.576885665561657	0.35179844288183243	0.4738408	0.43737417	0.4318498	0.4544206	0.6271537	0.3690482	0.44070822	0.6083593	0.33563986	0.51149386	0.5981774	0.6248803	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for SLCO1B1 (i.e., have a genotype that is not clearly associated with normal or reduced function) should be treated similarly to those with normal function, as the clinical significance of the indeterminate genotype is unclear. Therefore, lovastatin can be initiated at a standard dose, but close monitoring for myotoxicity is recommended, especially at higher doses. Additionally, consideration of alternative statins with lower risk of myotoxicity may be warranted.	-0.28011858	-0.012498593	-0.16084166	tensor(-0.1121)	tensor(0.4003)	tensor(0.0872)	0.24788654970961907	0.6109621800918827	0.2514619861194599	0.13213013	0.427115	0.2111122	0.07442032	0.6443275	0.102388866	0.010949649	0.51305026	0.12969117	0.28836858	0.6091305	0.48885432	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	['Proceed taking lovastatin as normal. There is no recommendation.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Avoid lovastatin. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a Possible Decreased Function for SLCO1B1 (e.g., *1B/*5 or *1B/*15) may have reduced uptake of lovastatin, which may lead to decreased efficacy. However, the clinical impact is likely to be small, and no specific dosage adjustment is recommended. Nevertheless, close monitoring of lipid levels and potential adjustments to the lovastatin dose or alternative statin therapy may be considered on a case-by-case basis.	-0.023741385	0.08186538	0.029546605	tensor(-0.1230)	tensor(0.3282)	tensor(0.0502)	0.6563214027751472	0.5991760084392338	0.6802116213222643	0.6135737	0.58796304	0.7266848	0.6678403	0.6572396	0.7880298	0.6605882	0.59083503	0.6099594	0.5398374	0.5947937	0.62536454	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid mafenide, a topical antibiotic, due to the increased risk of hemolytic anemia. This is because mafenide can cause oxidative stress, which can exacerbate the G6PD deficiency and lead to hemolysis. Alternative antibiotics should be considered for these individuals to minimize the risk of adverse reactions.	-0.08683287	0.14526449	0.020618593	tensor(-0.1050)	tensor(0.3848)	tensor(0.0959)	0.6058382328628412	0.5372888988446269	0.3936736211603061	0.6018866	0.59723264	0.44782764	0.57536054	0.5656834	0.33643657	0.57192385	0.56342375	0.3574572	0.5303857	0.47463	0.44066045	0
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for glucose-6-phosphate dehydrogenase (G6PD) deficiency should be treated as if they have G6PD deficiency when considering treatment with mafenide, a topical antimicrobial agent that can cause hemolytic anemia in G6PD-deficient individuals. As such, mafenide should be used with caution and close monitoring for hemolytic anemia in individuals with indeterminate G6PD status. Alternative treatments without G6PD-related risks may be considered, especially in patients with a high risk of hemolytic anemia.	0.046718806	0.2910792	0.15999995	tensor(-0.1607)	tensor(0.3716)	tensor(0.0515)	0.5928348331192357	0.570649092898792	0.32712374887775025	0.5664331	0.5286925	0.2604222	0.5807136	0.530467	0.22177052	0.5814107	0.5069965	0.20485654	0.54339695	0.4620093	0.42468384	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II deficiency (CNSHA, Class I being the most severe) should avoid using mafenide, a topical antibiotic, due to the risk of hemolytic anemia. Mafenide is a known oxidant stress inducer, which can exacerbate G6PD deficiency and lead to hemolysis. Therefore, alternative treatments should be considered for these individuals to minimize the risk of adverse effects.	-0.10316332	0.06849681	-0.020865032	tensor(-0.1362)	tensor(0.3675)	tensor(0.0680)	0.41813435432603957	0.5526286850745284	0.4303922450894623	0.43080908	0.6154151	0.5605796	0.43385762	0.5392588	0.458394	0.45389083	0.5300175	0.35717058	0.50701964	0.48802635	0.44123384	0
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	According to established clinical guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can safely take mafenide, a topical antibiotic cream, without concerns about hemolytic anemia. Mafenide is not expected to exacerbate G6PD deficiency, and no dose adjustments are necessary for patients with normal G6PD activity. As a result, mafenide can be prescribed and used as directed in individuals with normal G6PD status.	-0.034631882	0.1946528	0.07200376	tensor(-0.0790)	tensor(0.3118)	tensor(0.0858)	0.6032626286987431	0.620877833490619	0.34789166047007636	0.50959086	0.6399447	0.31268007	0.45628354	0.66345495	0.22123298	0.32818002	0.594712	0.14340995	0.5292247	0.49767357	0.38798466	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with a CYP2C9 activity score of 2.0, clinical guidance suggests that they can take meloxicam at the standard recommended dose, as they are expected to metabolize the drug normally. The normal CYP2C9 activity ensures that meloxicam will be metabolized effectively, reducing the risk of adverse effects or toxicity. Therefore, no dose adjustment is necessary, and the patient can be treated with meloxicam according to the usual guidelines.	-0.048958044	0.20903194	0.06918079	tensor(-0.0587)	tensor(0.3989)	tensor(0.1307)	0.39281521910925665	0.6678098260614916	0.42817305648519965	0.3840512	0.5182166	0.42703682	0.40280125	0.6170868	0.31357118	0.46852773	0.6344051	0.44312397	0.45158124	0.7003259	0.48656842	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	Based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 1.5 for CYP2C9 may require a moderate dose reduction of meloxicam, which is a CYP2C9 substrate. This is because intermediate metabolizers may have reduced enzyme activity, leading to higher meloxicam concentrations and potentially increased risk of adverse effects. The recommended dose adjustment is 25-50% reduction in the usual starting dose, with close monitoring for efficacy and toxicity.	0.00052575173	0.26163357	0.120299764	tensor(-0.0960)	tensor(0.3948)	tensor(0.1055)	0.6927153460365174	0.5789322648603251	0.7086018068277924	0.5176952	0.44795373	0.5321482	0.55244815	0.5367461	0.5373744	0.61046153	0.5334248	0.66062367	0.579338	0.5906813	0.5866608	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual with an indeterminate CYP2C9 genotype, clinical guidance suggests to assume a reduced metabolic capacity, similar to that of intermediate metabolizers. As meloxicam is primarily metabolized by CYP2C9, the indeterminate genotype may lead to increased exposure to meloxicam, potentially increasing the risk of adverse effects, such as gastrointestinal bleeding. Therefore, close monitoring of therapeutic response and adverse effects, as well as consideration of alternative NSAIDs, may be warranted.	-0.27323577	-0.01096798	-0.15586624	tensor(-0.0694)	tensor(0.3517)	tensor(0.1088)	0.23230078535209006	0.5480875336259268	0.2636527752244793	0.08102825	0.46606067	0.1510788	0.05592789	0.52644885	0.068102635	0.028734192	0.55236673	0.16318294	0.28579	0.5698466	0.50212026	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking meloxicam as normal. There is no recommendation.', 'Avoid meloxicam. Take an alternate therapy.']	Take meloxicam with an altered dose.	Based on pharmacogenomic guidelines, an individual who is an intermediate metabolizer (IM) of CYP2C9 with an activity score of 1.0 may require a moderate dose reduction of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) primarily metabolized by CYP2C9. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends that IMs of CYP2C9 may require a 25-50% dose reduction of meloxicam to minimize the risk of adverse effects, such as gastrointestinal toxicity. However, the exact dose adjustment should be individualized based on patient-specific factors, such as age, renal function, and concomitant medications.	0.1686711	0.110444345	0.14143685	tensor(-0.1626)	tensor(0.2885)	tensor(0.0237)	0.7822069371915559	0.667621451248327	0.6811237591642918	0.5276002	0.4966127	0.55235106	0.7532446	0.42193186	0.6455267	0.7461864	0.51467925	0.5818276	0.74481076	0.6687547	0.589614	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	Based on the pharmacogenomic profile, a Normal Metabolizer for TPMT and a Poor Metabolizer for NUDT15, the clinical guidance for mercaptopurine therapy would be to initiate therapy with a reduced dose (e.g., 30-50% of the standard dose) and monitor closely for signs of myelosuppression. This is because NUDT15 poor metabolizers are at increased risk of mercaptopurine-related myelotoxicity, while normal TPMT activity reduces the risk of severe myelosuppression. Close monitoring of complete blood counts and liver function tests is essential to adjust the dose and prevent adverse effects.	0.07609841	0.089909784	0.08566585	tensor(-0.0885)	tensor(0.3396)	tensor(0.0921)	0.7133383916972358	0.6466745964758212	0.6552655532158471	0.6858313	0.534833	0.5157334	0.63611585	0.43342695	0.6298633	0.5863695	0.51713395	0.49740124	0.6323374	0.65998834	0.5484572	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	Based on the evidence, for an individual who is an Intermediate Metabolizer (IM) for both Thiopurine Methyltransferase (TPMT) and Nucleoside Diphosphatase 15 (NUDT15), the clinical guidance for taking mercaptopurine would be to initiate therapy with a reduced dose (e.g., 30-50% of the standard dose) and closely monitor for signs of toxicity, such as myelosuppression. This is because IM status for both enzymes may increase the risk of adverse reactions to mercaptopurine. Additionally, regular monitoring of complete blood counts and liver function tests is recommended to adjust the dose as needed.	0.1354635	-0.0053139436	0.063751094	tensor(-0.1009)	tensor(0.3592)	tensor(0.0903)	0.7794105942715622	0.6687865686259175	0.6721737831472956	0.5661323	0.55514866	0.49899372	0.65956545	0.46493465	0.65702343	0.6884829	0.55743784	0.6289339	0.5883627	0.6806658	0.486486	1
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For an individual who is a Possible Intermediate Metabolizer (IM) for TPMT and a Poor Metabolizer (PM) for NUDT15, the clinical guidance for taking mercaptopurine would be to consider a reduced starting dose and close monitoring for toxicity. This is because the TPMT IM genotype may lead to reduced enzyme activity, increasing the risk of myelosuppression, while the NUDT15 PM genotype is associated with increased risk of mercaptopurine-induced hematotoxicity. A dose reduction of 30-50% may be necessary to minimize the risk of adverse effects.	0.03359597	0.06787132	0.05328303	tensor(-0.0801)	tensor(0.3247)	tensor(0.0926)	0.708223983385597	0.6480722027263486	0.6552655532158471	0.5386952	0.50291103	0.5157334	0.6193125	0.46853873	0.6298633	0.57340926	0.53779525	0.49740124	0.5437578	0.63081086	0.5484572	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	According to clinical guidelines, individuals who are poor metabolizers (PMs) for TPMT and normal metabolizers (NMs) for NUDT15 should receive a reduced initial dose of mercaptopurine, with close monitoring of blood counts and potential dose adjustments. This is because TPMT PMs are at increased risk of myelosuppression, while NUDT15 NM status does not significantly impact mercaptopurine tolerance. The initial dose reduction and close monitoring can help minimize the risk of adverse effects while maintaining therapeutic efficacy.	0.08067772	-0.003184941	0.04010056	tensor(-0.0824)	tensor(0.3308)	tensor(0.0932)	0.7089757634725788	0.6275120891439468	0.699439274416648	0.655795	0.5217195	0.49993914	0.6873762	0.4650185	0.65776473	0.6126293	0.53363353	0.59319097	0.625682	0.63160914	0.587134	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Based on the available evidence, individuals with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S should exercise caution when taking methoxyflurane, as it can trigger malignant hyperthermia (MH) in susceptible individuals. Due to the increased risk of MH, it is recommended that these patients receive alternative anesthetics and be closely monitored for signs of MH during anesthesia. Additionally, a thorough pre-anesthetic evaluation and consultation with an anesthesiologist is strongly advised to develop a personalized anesthesia plan.	0.14468831	0.19352031	0.171097	tensor(-0.0765)	tensor(0.3727)	tensor(0.0884)	0.6878252179931064	0.5784466751221453	0.45413872952243667	0.67896247	0.59763986	0.47491577	0.7712533	0.5589749	0.32962164	0.7301635	0.54532146	0.4165829	0.69479865	0.6291307	0.58532214	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	"Based on the available evidence, there is no specific clinical guidance for methoxyflurane use in individuals with a ""No Result"" for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S. However, as methoxyflurane is an anesthetic agent that can trigger malignant hyperthermia, caution is advised, and careful monitoring is recommended. It is essential to consult with an anesthesiologist or a healthcare professional to discuss individual risk factors and develop a personalized anesthesia plan."	0.1450722	0.16416709	0.15703899	tensor(0.0004)	tensor(0.3681)	tensor(0.1613)	0.6800266674696381	0.590985323887357	0.4692197857678623	0.74409544	0.6139114	0.5205767	0.72387934	0.63992256	0.2994762	0.7204658	0.5443876	0.39242128	0.7159558	0.5865949	0.57530695	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Based on the available evidence, individuals with Malignant Hyperthermia Susceptibility (MHS) associated with RYR1 mutations should avoid methoxyflurane, a known triggering agent, to prevent malignant hyperthermia episodes. The presence of Uncertain Susceptibility for CACNA1S does not alter this recommendation, as CACNA1S is also associated with MHS. Therefore, it is recommended to use alternative anesthetics and to take precautions to prevent malignant hyperthermia episodes in these individuals.	0.18457069	0.22702353	0.20780194	tensor(-0.0687)	tensor(0.3299)	tensor(0.1002)	0.7182499377397278	0.5129802311396657	0.45413872952243667	0.6928237	0.523954	0.47491577	0.72714466	0.41247734	0.32962164	0.7797109	0.47849497	0.4165829	0.67922926	0.60193056	0.58532214	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid methoxyflurane. Take an alternate therapy.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Proceed taking methoxyflurane as normal. There is no recommendation.	"Based on current pharmacogenomics guidelines, individuals with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S may not have an increased risk of malignant hyperthermia (MH) with methoxyflurane administration. However, due to the uncertain susceptibility status for CACNA1S, it is recommended to proceed with caution and monitor for signs of MH, such as hyperthermia, muscle rigidity, and cardiac arrhythmias, during anesthesia. Additionally, a thorough medical history and family history of MH should be taken into consideration before administering methoxyflurane."	0.09991699	0.25840133	0.17683849	tensor(-0.1014)	tensor(0.3531)	tensor(0.0773)	0.6822015785997352	0.6121036957561449	0.41175903798609553	0.69557285	0.511331	0.3822638	0.67524874	0.46455732	0.2715133	0.5749219	0.5230848	0.36154142	0.73500663	0.585394	0.40464923	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid methylene blue due to the risk of hemolytic anemia, as methylene blue can exacerbate G6PD deficiency and lead to hemolysis. The FDA recommends that G6PD-deficient individuals not receive methylene blue, and alternative treatments should be considered. Additionally, genetic testing and counseling may be necessary to identify individuals at risk and ensure safe treatment.	-0.24929763	0.04595274	-0.119290434	tensor(-0.0781)	tensor(0.1577)	tensor(0.0297)	0.20452549665300582	0.5877420691391967	0.30297330394920535	0.30685	0.6160302	0.35005638	0.16641355	0.585909	0.24695739	0.16675058	0.63513297	0.21392979	0.3728461	0.6613257	0.5678415	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and methylene blue should be used with caution or avoided due to the risk of hemolytic anemia. This is because some individuals with an indeterminate result may still have some degree of G6PD deficiency, which could lead to adverse reactions to methylene blue. As a precautionary measure, alternative treatments should be considered, and the patient should be closely monitored for signs of hemolysis if methylene blue is used.	0.055967767	0.27616978	0.15928994	tensor(-0.1138)	tensor(0.3315)	tensor(0.0720)	0.673064580786914	0.5664233790529034	0.35087635499512043	0.5413194	0.63761014	0.28823838	0.5735091	0.6575862	0.25527686	0.5353924	0.65421444	0.22817656	0.53419703	0.5940557	0.43679303	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with class I or II deficiency (CNSHA - Class I, II, or III), the use of methylene blue is contraindicated due to the risk of hemolytic anemia. Methylene blue can trigger hemolysis in G6PD-deficient individuals, leading to severe anemia, jaundice, and even acute kidney injury. Therefore, alternative medications or treatments should be considered, and the use of methylene blue should be avoided in these individuals.	-0.28203028	0.06371351	-0.13470367	tensor(-0.1356)	tensor(0.1743)	tensor(-0.0002)	0.24164440447481889	0.6078368946919516	0.30297330394920535	0.3086494	0.61612344	0.35005638	0.16199961	0.60040325	0.24695739	0.19514592	0.6987442	0.21392979	0.4460052	0.69124043	0.5678415	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, there are no specific contraindications or precautions for taking methylene blue. Methylene blue can be used at the recommended dose without concerns for hemolytic anemia, a risk associated with G6PD deficiency. However, as with any medication, it's essential to follow the recommended dosage and monitor for potential side effects or allergic reactions.	-0.086824566	0.1819708	0.035251666	tensor(-0.0948)	tensor(0.3117)	tensor(0.0733)	0.6061940072029224	0.632887883979294	0.3230369678087114	0.47973585	0.7141861	0.22677493	0.3913019	0.77856296	0.13636027	0.31225654	0.7169649	0.09708099	0.4924243	0.6227471	0.35743833	1
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking nalidixic acid, a quinolone antibiotic, due to the increased risk of hemolytic anemia. This is because nalidixic acid is known to trigger hemolysis in G6PD-deficient individuals, which can lead to severe and potentially life-threatening anemia. Therefore, alternative antibiotics should be considered for these patients to minimize the risk of adverse reactions.	-0.087632746	0.15567626	0.024328947	tensor(-0.0447)	tensor(0.4432)	tensor(0.1575)	0.6013588861288539	0.5457283147512978	0.4058704079536503	0.59129834	0.6210782	0.40840146	0.55800146	0.57085174	0.29296613	0.5089712	0.5302269	0.3382855	0.54745513	0.57148546	0.45840853	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and nalidixic acid should be avoided or used with caution due to the risk of hemolytic anemia. This is because nalidixic acid is a known trigger of hemolysis in individuals with G6PD deficiency, and an indeterminate result may indicate a potential deficiency. Alternative antibiotics should be considered, and close monitoring for signs of hemolysis is recommended if nalidixic acid is used.	0.035462685	0.2691683	0.14429982	tensor(-0.0488)	tensor(0.3959)	tensor(0.1385)	0.650309480203461	0.5889847876182277	0.3563594609236648	0.4795183	0.6894727	0.28526318	0.5807592	0.68941045	0.2615591	0.5469057	0.58973587	0.21358429	0.5291991	0.61112696	0.45210806	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class I or II variant, such as those with Class III G6PD CNSHA variant, are at increased risk of hemolytic anemia when taking nalidixic acid. Therefore, it is recommended to avoid nalidixic acid in these individuals, or to closely monitor for signs of hemolysis if its use is unavoidable. Alternative antibiotic options should be considered to minimize the risk of adverse reactions.	-0.09808267	0.18408	0.029085329	tensor(-0.1002)	tensor(0.4475)	tensor(0.1193)	0.48105993259409735	0.5789294457948324	0.4655954492727313	0.47192726	0.41380063	0.5337533	0.4909313	0.6498623	0.46121514	0.46348622	0.61304504	0.3697019	0.52327484	0.59563893	0.48285532	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	According to clinical guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take nalidixic acid, a quinolone antibiotic, without increased risk of hemolytic anemia. This is because nalidixic acid is not typically associated with hemolysis in G6PD-normal individuals. Therefore, no specific precautions or dose adjustments are necessary for G6PD-normal patients taking nalidixic acid.	-0.08544188	0.17020991	0.031460527	tensor(-0.0164)	tensor(0.3989)	tensor(0.1529)	0.6252436179593293	0.6383795828473564	0.35766173000612805	0.45404434	0.60274804	0.2670876	0.40582156	0.63314754	0.16172875	0.32716098	0.58437353	0.106067315	0.5324732	0.59076947	0.41354752	1
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking neomycin as normal. There is no recommendation.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Avoid neomycin. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant, which confers increased risk of aminoglycoside-induced hearing loss, should be advised to avoid neomycin or use it with caution due to the increased risk of ototoxicity. Alternative antibiotics should be considered, especially for prolonged or high-dose treatment. If neomycin is deemed necessary, close monitoring of auditory function and serum concentrations is recommended to minimize the risk of hearing loss.	0.10133616	0.23121892	0.16551834	tensor(-0.0837)	tensor(0.2619)	tensor(0.0568)	0.7014139454286428	0.5969164842740617	0.4474621363963665	0.7412986	0.6286578	0.5713662	0.74580115	0.62194353	0.5265883	0.76265204	0.5410374	0.48693702	0.6492626	0.64768183	0.54382235	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, the clinical guidance suggests that they can be treated with neomycin without increased risk of ototoxicity. Neomycin can be used at standard doses and durations, with regular monitoring of hearing function. However, it is still important to monitor for signs and symptoms of ototoxicity, as neomycin can still cause hearing loss in some individuals, even if they are at normal risk.	0.0621789	0.27883136	0.16403842	tensor(-0.0596)	tensor(0.3149)	tensor(0.0963)	0.6489515304689084	0.593400137803108	0.48436696088656284	0.64778703	0.5760459	0.5563146	0.67659205	0.6578067	0.57857746	0.7274146	0.5464639	0.5468496	0.58725256	0.50806403	0.5689827	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, the clinical guidance is to exercise caution when considering neomycin treatment. While the evidence is not sufficient to contraindicate neomycin use, patients should be informed of the potential increased risk of ototoxicity and closely monitored for signs of hearing loss or vestibular dysfunction during and after treatment. In addition, alternative antibiotics may be considered when possible, especially for prolonged or high-dose neomycin therapy.	0.022068154	0.19205399	0.1039262	tensor(-0.0552)	tensor(0.3335)	tensor(0.1123)	0.6393021791345703	0.5561298430107015	0.48436696088656284	0.5263901	0.57123184	0.5563146	0.6934292	0.6095821	0.57857746	0.74465674	0.5190874	0.5468496	0.6073436	0.58316267	0.5689827	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking netilmicin as normal. There is no recommendation.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Avoid netilmicin. Take an alternate therapy.	Based on current evidence, individuals with the mitochondrial MT-RNR1 variant are at increased risk of aminoglycoside-induced hearing loss. For netilmicin, a specific aminoglycoside, clinical guidance recommends cautious use or avoidance in patients with the MT-RNR1 variant, particularly in those with pre-existing hearing impairment or kidney disease. Alternative antibiotics should be considered, and audiometric monitoring is recommended for patients who must receive netilmicin despite being at high risk.	0.026800686	0.14781897	0.08702751	tensor(-0.1035)	tensor(0.2984)	tensor(0.0638)	0.6423011868862972	0.524903966729751	0.4514241482485256	0.63239336	0.52146757	0.53816426	0.6952359	0.526388	0.43934253	0.67965674	0.48053002	0.43886867	0.6192255	0.5863475	0.5105371	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype can receive netilmicin as per standard dosing recommendations, without any specific precautions or dose adjustments. No specific monitoring or testing is required beyond standard clinical care. However, it is essential to note that patients should still be monitored for signs and symptoms of ototoxicity, as they can occur even in individuals without a high-risk genotype.	-0.03351367	0.20910862	0.07856142	tensor(-0.1286)	tensor(0.3838)	tensor(0.0727)	0.6115622051176862	0.6141268002326724	0.4298189631282794	0.61342573	0.60136515	0.51884896	0.6288566	0.56446534	0.4979349	0.676912	0.52432984	0.5040965	0.61640465	0.5871074	0.52520496	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	For individuals with an uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, clinical guidance suggests exercising caution when considering netilmicin therapy. The American College of Medical Genetics and Genomics (ACMG) recommends that these individuals be monitored closely for ototoxicity and consider alternative antibiotics when possible. Additionally, audiometric testing and monitoring of hearing function should be performed before, during, and after netilmicin treatment to facilitate early detection of potential hearing loss.	0.0052535557	0.18529339	0.09141029	tensor(-0.0766)	tensor(0.3917)	tensor(0.1180)	0.6218813174788782	0.5887478309626727	0.4298189631282794	0.55528855	0.50172603	0.51884896	0.6632357	0.5488804	0.4979349	0.70147467	0.45766613	0.5040965	0.6726346	0.531883	0.52520496	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Use at standard doses with caution and with close monitoring for anemia	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking nitrofurantoin due to the increased risk of hemolytic anemia. This is because nitrofurantoin can cause oxidative stress, which can exacerbate the underlying G6PD deficiency and lead to hemolysis. As a result, alternative antibiotic therapies should be considered for G6PD-deficient patients.	-0.24000822	-0.034590222	-0.14440973	tensor(-0.0548)	tensor(0.4370)	tensor(0.1483)	0.340594262000693	0.5558053338291105	0.4400267761676549	0.50185907	0.6562722	0.49311423	0.47130376	0.6132732	0.41552055	0.39619783	0.5429573	0.34159386	0.45295435	0.60490435	0.46324143	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and nitrofurantoin should be used with caution or alternative antibiotics considered. This is because G6PD deficiency is associated with increased risk of hemolytic anemia with nitrofurantoin use, and the indeterminate result may indicate partial deficiency or other variants that could still increase this risk. Close monitoring for signs of hemolysis is recommended if nitrofurantoin is used in these individuals.	0.04030039	0.28537133	0.15383565	tensor(-0.0586)	tensor(0.3431)	tensor(0.1135)	0.6021179310433434	0.6013469317755762	0.31366361363325385	0.5696652	0.6278038	0.29920465	0.5996858	0.673741	0.2942435	0.5819255	0.56112003	0.1904601	0.5179045	0.5843766	0.39085028	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Avoid	['Proceed taking nitrofurantoin as normal. There is no recommendation.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Avoid nitrofurantoin. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class III or IV variant, such as those with Class III variant Cantonese (CNSHA), are at increased risk of hemolytic anemia when taking nitrofurantoin. The CPIC recommends that these individuals avoid nitrofurantoin due to the high risk of hemolytic anemia, and alternative antibiotics be considered. If nitrofurantoin is deemed necessary, close monitoring for signs and symptoms of hemolytic anemia is essential.	-0.4021523	0.053564776	-0.22424373	tensor(-0.0960)	tensor(0.3111)	tensor(0.0651)	0.17163271882569459	0.6225898213659473	0.2718393448298181	0.16842948	0.42542866	0.33953944	0.10782154	0.61522126	0.25064933	0.11371975	0.6094104	0.25303125	0.38101968	0.6252029	0.47564763	1
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	According to clinical guidance, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can take nitrofurantoin without concerns related to G6PD deficiency. Nitrofurantoin is not contraindicated in patients with normal G6PD activity, and the risk of hemolytic anemia is low in this population. Therefore, no special precautions or dosage adjustments are necessary for G6PD-normal individuals taking nitrofurantoin.	-0.014219067	0.18534873	0.080175	tensor(-0.0121)	tensor(0.3361)	tensor(0.1373)	0.5919917112898314	0.6586410723686664	0.2946334187916671	0.5537689	0.7239652	0.33706653	0.5028523	0.75491	0.25741306	0.39960852	0.5892562	0.12421556	0.60096794	0.6461053	0.3926811	1
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking norfloxacin due to the increased risk of hemolytic anemia. Norfloxacin is contraindicated in G6PD-deficient individuals, as it can trigger hemolysis and worsen anemia. Alternative antibiotic options should be considered, and healthcare providers should closely monitor patients with G6PD deficiency for signs of hemolytic anemia when prescribing antibiotics.	-0.0807027	0.13762037	0.021176204	tensor(-0.0941)	tensor(0.4363)	tensor(0.1202)	0.6000166256368472	0.54219024406632	0.33625239138291	0.62125754	0.54891896	0.3017979	0.59299326	0.4817997	0.16326211	0.58089507	0.5322691	0.29386216	0.54357684	0.5842546	0.3911967	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and therefore, should avoid taking norfloxacin, a drug that can cause hemolytic anemia in individuals with G6PD deficiency. This is because the indeterminate result may indicate a mild or partial deficiency, and norfloxacin can still pose a risk of hemolysis in these individuals. Alternative antibiotics should be considered to minimize the risk of adverse effects.	0.043302443	0.28098068	0.15381871	tensor(-0.0613)	tensor(0.4704)	tensor(0.1546)	0.6141704629894418	0.5504257678742378	0.26925276324496505	0.43531525	0.55474645	0.15225619	0.5623957	0.48693174	0.079886965	0.5541397	0.51510835	0.16424122	0.51645666	0.56778127	0.39753497	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with class I or II deficiency (such as those with CNSHA, a class II deficiency), are at increased risk of hemolytic anemia when taking norfloxacin. The CPIC recommends avoiding norfloxacin in these individuals, especially if alternative antibiotics are available. If norfloxacin is necessary, close monitoring for signs of hemolytic anemia, such as dark urine, fatigue, and jaundice, is essential.	-0.09643966	0.22514005	0.04575898	tensor(-0.1139)	tensor(0.4022)	tensor(0.0951)	0.44786846406611297	0.5416588010758091	0.398954814435786	0.4673143	0.37169978	0.49613303	0.48145548	0.47265235	0.37678492	0.4931639	0.5925602	0.36633617	0.52456075	0.5847737	0.49247876	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take norfloxacin without any specific precautions or dose adjustments. Norfloxacin is not associated with an increased risk of hemolytic anemia in individuals with normal G6PD activity. Therefore, no special considerations are necessary for G6PD normal individuals taking norfloxacin.	-0.05685748	0.20853336	0.06415554	tensor(-0.0426)	tensor(0.4221)	tensor(0.1515)	0.6207449472279203	0.6333298327325582	0.29465857614047125	0.4695291	0.5972569	0.20621966	0.4260975	0.5148404	0.08644246	0.37781066	0.57869434	0.103041954	0.54720455	0.61241645	0.35793763	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an ultrarapid metabolizer (UM) phenotype and a CYP2D6 activity score ≥3.75 is at increased risk of inadequate response to nortriptyline due to rapid metabolism. The CPIC recommends considering an alternative medication or increasing the dose of nortriptyline, while closely monitoring the patient's response and adjusting the dose as needed to avoid therapeutic failure. Additionally, the patient should be informed of the potential for inadequate response and the need for close monitoring.	0.052244566	0.15301916	0.10323976	tensor(-0.1316)	tensor(0.3648)	tensor(0.0705)	0.6398078615027	0.6015822684850028	0.5309204208738215	0.6580641	0.53009874	0.5505053	0.63161284	0.5948696	0.5560613	0.6370307	0.5428409	0.49246567	0.6215881	0.6269809	0.555814	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid nortriptyline. Take an alternate therapy.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Proceed taking nortriptyline as normal. There is no recommendation.	For an individual who is a Normal Metabolizer with a CYP2D6 activity score of 1.75, the clinical guidance for taking nortriptyline is to initiate therapy with a standard dose and monitor for efficacy and adverse effects. This is because the activity score suggests normal CYP2D6 function, which is the primary enzyme responsible for nortriptyline metabolism, and therefore, no dosage adjustments are necessary. However, close monitoring is still recommended due to the potential for individual variability in response to nortriptyline.	-0.20749609	0.2798878	-0.011156798	tensor(-0.0650)	tensor(0.4354)	tensor(0.1327)	0.47437104602084323	0.650603873237011	0.48023408111107846	0.47871798	0.5165457	0.4240283	0.40592033	0.67408997	0.3588726	0.40569526	0.5615372	0.36522415	0.45982003	0.6282397	0.55969626	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score of 2.75, clinical guidance suggests that they may require lower doses of nortriptyline, a tricyclic antidepressant primarily metabolized by CYP2D6, to avoid increased risk of adverse effects. Due to their enhanced CYP2D6 activity, they may metabolize nortriptyline more rapidly, leading to lower plasma concentrations and potentially reduced efficacy. Therefore, close monitoring of therapeutic response and potential dose reductions may be necessary to optimize treatment outcomes.	0.19745505	0.22632699	0.21405798	tensor(-0.0961)	tensor(0.3942)	tensor(0.1046)	0.7097090409172057	0.6292308343976278	0.5309204208738215	0.75499505	0.5804768	0.5505053	0.8145202	0.57172745	0.5560613	0.7588152	0.52828455	0.49246567	0.68084353	0.5947909	0.555814	0
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2D6, with an activity score ≥4.0, may require lower doses of nortriptyline due to increased metabolism and potential reduced efficacy. The CPIC recommends considering a 25-50% reduction in the usual starting dose of nortriptyline, with close monitoring for efficacy and toxicity. Additionally, alternative medications not primarily metabolized by CYP2D6 may be considered to minimize the impact of ultrarapid metabolism.	0.12689301	0.20800579	0.16864763	tensor(-0.1156)	tensor(0.4092)	tensor(0.0961)	0.6598091442539574	0.6302022602924032	0.5309204208738215	0.71354717	0.5341947	0.5505053	0.7007997	0.5826379	0.5560613	0.69650674	0.48405558	0.49246567	0.6207838	0.5864879	0.555814	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid using ofloxacin due to the increased risk of hemolytic anemia. Ofloxacin, a fluoroquinolone antibiotic, is known to cause hemolysis in G6PD-deficient patients, and its use may exacerbate the condition. Therefore, alternative antibiotics should be considered for these individuals to minimize the risk of adverse reactions.	-0.08732923	0.13648213	0.016753674	tensor(-0.1444)	tensor(0.3195)	tensor(0.0467)	0.5258941790897957	0.52654858300837	0.3131991277529827	0.560811	0.6116876	0.397889	0.5158553	0.59534657	0.27511027	0.532946	0.51006335	0.28796577	0.4837637	0.55000085	0.357518	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with indeterminate G6PD status should be treated as G6PD deficient, as the genotype may not accurately predict enzyme activity. Therefore, ofloxacin, which carries a risk of hemolytic anemia in G6PD-deficient individuals, should be used with caution and close monitoring for signs of hemolysis. Alternative antibiotics with a lower risk of hemolysis may be considered, especially in patients with a high risk of complications.	0.0768717	0.3386612	0.19745186	tensor(-0.1414)	tensor(0.2581)	tensor(0.0280)	0.6215173650892174	0.5351053729223223	0.23731217617803552	0.6449524	0.49195024	0.24203877	0.60719544	0.6334162	0.17011733	0.60147786	0.5007552	0.1809522	0.5530726	0.5408012	0.42305574	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with class I (severe) deficiency such as those with the CNSHA variant, should avoid ofloxacin due to the increased risk of hemolytic anemia. Ofloxacin is a contraindicated medication in G6PD-deficient individuals, and alternative antibiotics should be considered. Close monitoring for signs of hemolysis is recommended if ofloxacin is deemed necessary and no alternative is available.	-0.052799456	0.2377037	0.07809912	tensor(-0.1579)	tensor(0.3363)	tensor(0.0425)	0.42630865997845063	0.5203713204010961	0.4219714816114772	0.4712963	0.55021614	0.5038507	0.47356406	0.6046759	0.40975153	0.55495095	0.5619731	0.4176293	0.5244289	0.5625209	0.51761067	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For an individual with normal G6PD (glucose-6-phosphate dehydrogenase) activity, there are no specific contraindications or dosage adjustments recommended for ofloxacin use. Ofloxacin is not typically associated with hemolytic anemia, a concern for individuals with G6PD deficiency. Therefore, normal G6PD individuals can take ofloxacin as directed by their healthcare provider, following standard dosing and monitoring guidelines.	-0.034572076	0.17420974	0.06359742	tensor(-0.1148)	tensor(0.2902)	tensor(0.0487)	0.5502493517132484	0.6132093374105811	0.2504531598232545	0.51956004	0.6224289	0.2995282	0.47147933	0.64368016	0.18758342	0.36943582	0.51007825	0.06641618	0.50749445	0.5940434	0.32797045	1
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2C19 may require higher doses of omeprazole to achieve adequate therapeutic response, as they may metabolize the drug too quickly. However, the optimal dosing strategy for CYP2C19 UMs has not been established, and close monitoring of therapeutic response and potential adverse effects is recommended. Additionally, alternative proton pump inhibitors that are less dependent on CYP2C19 metabolism, such as pantoprazole or rabeprazole, may be considered.	-0.16693908	0.09833135	-0.047077443	tensor(-0.1085)	tensor(0.3182)	tensor(0.0679)	0.3708050917232253	0.5896070549027336	0.38031617462564243	0.45860964	0.5518267	0.47826907	0.35022554	0.49563247	0.531712	0.3320249	0.48813516	0.49863356	0.34913826	0.60428125	0.354102	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	According to clinical guidelines, individuals who are likely poor metabolizers (LPMs) for CYP2C19 should be treated with caution when taking omeprazole, as they may experience increased plasma concentrations and risk of adverse effects. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends considering alternative proton pump inhibitors (PPIs) that are not CYP2C19 substrates, such as lansoprazole or pantoprazole, or reducing the dose of omeprazole in LPMs. Additionally, close monitoring for adverse effects, such as gastrointestinal symptoms and hypomagnesemia, is recommended.	-0.12180246	0.08785197	-0.02371221	tensor(-0.0745)	tensor(0.3255)	tensor(0.0883)	0.3213324784077235	0.6016784951766608	0.4134758955960719	0.33623883	0.58613694	0.39692506	0.30909368	0.5537775	0.47483686	0.29312563	0.5491646	0.45883602	0.38609806	0.64810205	0.3992009	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For an individual who is a Likely Intermediate Metabolizer (IM) for CYP2C19, the clinical guidance for taking omeprazole is to initiate therapy with a reduced dose, as IMs may have decreased metabolism and increased plasma concentrations of omeprazole. Monitoring for adverse effects, such as gastrointestinal disturbances, headache, and dizziness, is recommended. Additionally, therapeutic drug monitoring may be considered to optimize dosing and minimize potential toxicities.	-0.002949654	0.15956618	0.075629376	tensor(-0.0227)	tensor(0.3987)	tensor(0.1572)	0.4834244873384966	0.6758488775988968	0.4134758955960719	0.48613995	0.60963416	0.39692506	0.39346576	0.56229824	0.47483686	0.39289975	0.5415335	0.45883602	0.49162856	0.67762506	0.3992009	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid omeprazole. Take an alternate therapy.', 'Take omeprazole with a reduced dose.', 'Take omeprazole with an increased dose.']	Proceed taking omeprazole as normal. There is no recommendation.	For an individual who is indeterminate for CYP2C19, clinical guidance suggests that they may have reduced or increased metabolism of omeprazole, which may lead to variable response or toxicity. As a result, close monitoring of therapeutic response and potential adverse effects is recommended, and dosage adjustments may be necessary to achieve optimal acid suppression. Additionally, consideration of alternative proton pump inhibitors (PPIs) that are less dependent on CYP2C19 metabolism, such as pantoprazole or rabeprazole, may be warranted.	-0.27769366	-0.010676581	-0.15860605	tensor(-0.0554)	tensor(0.3578)	tensor(0.1208)	0.24557781711559046	0.5716283517702516	0.24972268204827422	0.12235277	0.57188326	0.21290499	0.062460233	0.5552946	0.106184766	-0.035868507	0.5767333	0.08981355	0.3171059	0.5698561	0.49077046	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥6.0, the clinical guidance for taking ondansetron is to use with caution and close monitoring due to the potential for reduced efficacy. This is because ondansetron is primarily metabolized by CYP2D6, and UM individuals may metabolize the drug too quickly, leading to decreased therapeutic effect. Dose adjustment or alternative antiemetic therapy may be necessary to achieve optimal outcomes.	0.019700993	0.25842562	0.13051732	tensor(-0.0877)	tensor(0.3799)	tensor(0.1064)	0.5161807980827142	0.6549978751456899	0.4930524198583804	0.5777516	0.6051005	0.569965	0.7381411	0.6008723	0.42662913	0.7027129	0.6046615	0.5408177	0.58326393	0.574015	0.5406571	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid ondansetron. Take an alternate therapy.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Proceed taking ondansetron as normal. There is no recommendation.	Based on the pharmacogenomics data, a Normal Metabolizer with a CYP2D6 activity score of 1.75 is expected to have normal enzyme activity. For ondansetron, which is primarily metabolized by CYP2D6, the clinical guidance suggests that no dosage adjustment is necessary, and standard dosing can be used. However, it is essential to monitor the patient for efficacy and adverse effects, as ondansetron's therapeutic response may still vary due to individual factors beyond CYP2D6 genotype.	-0.16336209	0.19508338	-0.008869525	tensor(-0.0641)	tensor(0.3744)	tensor(0.1116)	0.39774316682822997	0.6087579002279917	0.5503771033069789	0.32349047	0.56189543	0.5308615	0.355446	0.57200885	0.5381755	0.3472768	0.57347465	0.5120067	0.4642803	0.62776375	0.6186217	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	Based on the pharmacogenomic profile, an individual with an ultrarapid metabolizer (UM) phenotype and a CYP2D6 activity score of 2.75 is expected to metabolize ondansetron more rapidly than average. Clinical guidance suggests that this individual may require higher doses of ondansetron to achieve therapeutic efficacy, as the rapid metabolism may lead to reduced systemic exposure and potentially decreased anti-emetic effects. Close monitoring of treatment response and potential dose adjustments may be necessary to optimize therapy.	-0.03688518	0.15738107	0.055194907	tensor(-0.0715)	tensor(0.4011)	tensor(0.1245)	0.48749094600149473	0.5715880024796892	0.4930524198583804	0.47508395	0.48761633	0.569965	0.6712335	0.55754584	0.42662913	0.61947167	0.61400115	0.5408177	0.5437793	0.5875156	0.5406571	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥ 5.0) may require a reduced dose of ondansetron, as they may metabolize the drug too quickly, leading to reduced efficacy. The CPIC guidelines suggest considering a 25-50% increase in the usual dose of ondansetron, with close monitoring of therapeutic response and adverse effects. However, the optimal dose adjustment has not been established and may require individualized titration.	-0.044272028	0.22584069	0.07872172	tensor(-0.0737)	tensor(0.4709)	tensor(0.1459)	0.4993876871966213	0.6236333110662188	0.4930524198583804	0.5724833	0.5762471	0.569965	0.7207833	0.564426	0.42662913	0.6740028	0.58059573	0.5408177	0.5272322	0.55904096	0.5406571	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	['Proceed taking oxcarbazepine as normal. There is no recommendation.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Avoid oxcarbazepine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, patients who are HLA-B*15:02 positive are at increased risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when taking oxcarbazepine. As a result, CPIC recommends avoiding oxcarbazepine in HLA-B*15:02-positive patients, especially in those of Asian ancestry, where the allele is more common. Alternative anticonvulsant medications should be considered to minimize the risk of severe cutaneous adverse reactions.	-0.06946402	0.41490412	0.13072489	tensor(-0.1352)	tensor(0.3031)	tensor(0.0409)	0.6304076879387683	0.6294296391409637	0.7048617397194842	0.5466173	0.5685322	0.685753	0.6208805	0.5524848	0.7577337	0.56654495	0.49539948	0.7757302	0.6044368	0.62444925	0.6866951	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are HLA-B*15:02 positive are at increased risk of developing Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) when taking oxcarbazepine. Therefore, oxcarbazepine is contraindicated in HLA-B*15:02-positive individuals, and alternative medications should be considered. Additionally, HLA-B*15:02 screening is recommended prior to initiating oxcarbazepine therapy in individuals of Southeast Asian ancestry, as they are more likely to carry this allele.	0.09164055	0.13838696	0.11718563	tensor(-0.1282)	tensor(0.3641)	tensor(0.0727)	0.6604035400864526	0.5969575308833003	0.5472377564472066	0.5758455	0.60160667	0.57381165	0.54261494	0.5160736	0.5987657	0.5238076	0.42258412	0.55886954	0.49494132	0.57298416	0.54892606	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, the clinical guidance is to proceed with oxcarbazepine therapy as usual, as the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is significantly lower in HLA-B*15:02-negative patients. The FDA recommends genetic testing for HLA-B*15:02 in patients with ancestry from areas where HLA-B*15:02 is prevalent (e.g., Asian populations), but a negative result does not preclude oxcarbazepine use. Close monitoring for signs of hypersensitivity reactions is still recommended, as SJS and TEN can occur in HLA-B*15:02-negative patients, albeit at a lower frequency.	-0.22447158	0.29006594	-0.020453833	tensor(-0.2022)	tensor(0.3586)	tensor(0.0168)	0.5898627059068383	0.6142172985777828	0.7788660104160574	0.5377425	0.57883334	0.78823286	0.4887269	0.5442928	0.89219457	0.3395866	0.37715223	0.8279687	0.54750556	0.5280919	0.80462366	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, the clinical guidance is that they can safely take oxcarbazepine without an increased risk of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). This is because the HLA-B*15:02 allele is associated with an increased risk of SJS/TEN in patients taking oxcarbazepine, and the absence of this allele suggests a lower risk of this adverse reaction. Therefore, oxcarbazepine can be prescribed to HLA-B*15:02 negative individuals without genotype-based restrictions.	-0.15592559	0.30918646	0.035154313	tensor(-0.1298)	tensor(0.3785)	tensor(0.0762)	0.6046918929203221	0.6342166744300184	0.7788660104160574	0.53672355	0.6385899	0.78823286	0.51070637	0.5700039	0.89219457	0.45068812	0.47494838	0.8279687	0.590959	0.5730697	0.80462366	1
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UMs) of CYP2C19 may require higher doses of pantoprazole to achieve optimal therapeutic effects. This is because UMs may metabolize pantoprazole more quickly, leading to reduced drug exposure and potentially decreased efficacy. The CPIC recommends considering a dose increase of 1.5-2 times the standard dose, with close monitoring of response and potential adverse effects.	-0.115848064	0.17069046	0.012801342	tensor(-0.1179)	tensor(0.2987)	tensor(0.0580)	0.40425852082027053	0.682649592014906	0.3810550288730285	0.42162493	0.5484494	0.5056187	0.40935093	0.5234679	0.5532805	0.4392755	0.53482366	0.47421473	0.47158015	0.69043654	0.37573257	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are likely poor metabolizers (PMs) for CYP2C19 may require dose reduction or alternative therapy when taking pantoprazole, as they may experience increased exposure to the active metabolite and enhanced antiplatelet effects. The CPIC recommends considering a 50% dose reduction of pantoprazole in CYP2C19 PMs to minimize the risk of adverse effects. Additionally, clinicians should closely monitor patients for signs of toxicity, such as gastrointestinal bleeding or thrombocytopenia.	-0.047605198	0.18557559	0.060543053	tensor(-0.0944)	tensor(0.3701)	tensor(0.0985)	0.3779752566566392	0.6871296789305751	0.4206355504109669	0.41771492	0.5980591	0.42378712	0.40072626	0.5419601	0.5355277	0.41500098	0.5353872	0.42420053	0.4793762	0.6755034	0.42951134	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For an individual who is an Intermediate Metabolizer (IM) for CYP2C19, clinical guidance suggests that they may require a higher dose of pantoprazole, a proton pump inhibitor (PPI) primarily metabolized by CYP2C19, to achieve optimal therapeutic effects. This is because IMs may have reduced metabolic activity, leading to higher plasma concentrations and potentially increased risk of adverse effects. However, the exact dosage adjustment is not well established and may require close monitoring of therapeutic response and potential side effects.	-0.071717955	0.09312309	0.0077424534	tensor(-0.1121)	tensor(0.3107)	tensor(0.0661)	0.39752390835555135	0.671938005181294	0.4206355504109669	0.3886311	0.5910939	0.42378712	0.36341816	0.5231477	0.5355277	0.4073408	0.5064597	0.42420053	0.43234548	0.6751187	0.42951134	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid pantoprazole. Take an alternate therapy.', 'Take pantoprazole with a reduced dose.', 'Take pantoprazole with an increased dose.']	Proceed taking pantoprazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate CYP2C19 genotype are likely to have impaired pantoprazole metabolism, but the impact on proton pump inhibitor (PPI) efficacy and safety is unclear. As a result, no specific dosage adjustments are recommended, and clinicians should monitor patients for efficacy and toxicity, considering alternative PPIs if necessary. Close clinical observation and titration of pantoprazole dosage based on patient response is advised.	-0.27311262	0.0682964	-0.12707354	tensor(-0.0814)	tensor(0.3312)	tensor(0.0940)	0.26052898775761674	0.6281584659701112	0.25398627898560994	0.12616678	0.5143526	0.23273724	0.03515432	0.53762215	0.12085304	-0.026283614	0.5636983	0.11063561	0.36768872	0.6134501	0.45487145	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking paromomycin as normal. There is no recommendation.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Avoid paromomycin. Take an alternate therapy.	Based on the evidence, individuals with the mitochondrial MT-RNR1 variant are at increased risk of aminoglycoside-induced hearing loss. Considering paromomycin is an aminoglycoside antibiotic, clinical guidance suggests that these individuals should be counseled about the increased risk of ototoxicity and closely monitored for hearing loss during and after treatment. Alternatively, when possible, clinicians may consider alternative antibiotics with lower risk of ototoxicity.	0.1127841	0.18283695	0.1493707	tensor(-0.0642)	tensor(0.4166)	tensor(0.1341)	0.6541411891390125	0.5524702704890766	0.4390956109579199	0.62793446	0.5372648	0.58393806	0.69543886	0.57680506	0.50874466	0.7287299	0.45801625	0.46796888	0.62420005	0.65984535	0.531438	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	Based on the available evidence, for an individual with a normal risk of aminoglycoside-induced hearing loss due to MT-RNR1, the clinical guidance suggests that paromomycin can be used with caution. However, it is recommended to closely monitor auditory function and adjust the dosage or duration of therapy as needed to minimize the risk of ototoxicity. Additionally, alternative antibiotics should be considered if possible, especially in patients with pre-existing hearing impairment or other risk factors for ototoxicity.	0.028179219	0.19268739	0.10766828	tensor(-0.0571)	tensor(0.4407)	tensor(0.1479)	0.650776649397367	0.6168620396827831	0.48321734635695385	0.62911296	0.61072177	0.54317784	0.75498956	0.6370509	0.55598813	0.769675	0.51229805	0.5189444	0.6486422	0.5785496	0.59631217	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (mt1555A>G or mt1494C>T) are at increased risk of aminoglycoside-induced hearing loss. Although paromomycin is not a typical aminoglycoside, it shares a similar mechanism of action and may also increase the risk of hearing loss in these individuals. As a result, clinicians should exercise caution and consider alternative antibiotics or closely monitor hearing function in patients with the MT-RNR1 variant who require paromomycin therapy.	-0.07690109	0.13679667	0.023098024	tensor(-0.1096)	tensor(0.4093)	tensor(0.1005)	0.5551210976320379	0.5262099943592697	0.48321734635695385	0.47588363	0.43179974	0.54317784	0.6232217	0.55604094	0.55598813	0.6962742	0.45240688	0.5189444	0.50720406	0.5288852	0.59631217	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2D6 with an activity score ≥6.0 may require a reduced dose of paroxetine, as they may metabolize the medication too quickly, potentially leading to reduced efficacy. The CPIC recommends a 50% reduction in the initial dose of paroxetine, with close monitoring for efficacy and adverse effects. Additionally, alternative medications with lower CYP2D6 metabolism may be considered to minimize the risk of inadequate response.	-0.052837923	0.3565604	0.12210333	tensor(-0.1092)	tensor(0.4093)	tensor(0.1008)	0.4950448569387716	0.6098551533813847	0.35736980874923496	0.5132103	0.48811468	0.46759406	0.6425907	0.605814	0.30278403	0.6592756	0.558699	0.36861268	0.51473075	0.6457985	0.48488787	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid paroxetine. Take an alternate therapy.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Proceed taking paroxetine as normal. There is no recommendation.	Based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with a Normal Metabolizer phenotype and an activity score of 1.75 for CYP2D6 can be expected to metabolize paroxetine normally. As such, the recommended dosage of paroxetine is not adjusted, and the patient can be initiated on a standard dose. However, it is essential to monitor the patient's response to treatment and adjust the dose as needed based on clinical efficacy and tolerability.	-0.16683774	0.15167706	-0.026880754	tensor(-0.0844)	tensor(0.3522)	tensor(0.0943)	0.4516010151995208	0.6218840163472523	0.4847171683471587	0.3131369	0.5714365	0.4003561	0.3684901	0.6232578	0.31609526	0.4733712	0.55641997	0.4318051	0.5116009	0.6581723	0.58868575	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an Ultrarapid Metabolizer (UM) phenotype and an activity score of 2.75 for CYP2D6 may require a dose reduction of paroxetine, a CYP2D6 substrate, to avoid potential adverse effects. This is because UM individuals may metabolize paroxetine more rapidly, leading to decreased efficacy or increased risk of adverse effects at usual doses. A 25-50% dose reduction of paroxetine may be considered to achieve optimal therapeutic response.	-0.08349798	0.30057445	0.08179201	tensor(-0.1186)	tensor(0.3161)	tensor(0.0626)	0.4754671932620856	0.5886662089200773	0.35736980874923496	0.5213891	0.45937857	0.46759406	0.59639436	0.57611597	0.30278403	0.6224575	0.5414118	0.36861268	0.5045358	0.6143697	0.48488787	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥5.0, clinical guidance recommends exercising caution when taking paroxetine, a CYP2D6 substrate. Due to increased enzyme activity, paroxetine may be metabolized too quickly, leading to reduced efficacy or increased risk of adverse effects. Consideration should be given to alternative medications or close monitoring of therapeutic response and side effects, with potential dose adjustments or alternative therapies as needed.	-0.040350743	0.35407993	0.12952188	tensor(-0.1017)	tensor(0.3534)	tensor(0.0878)	0.5111426797910864	0.6231722882300655	0.35736980874923496	0.54568833	0.5658382	0.46759406	0.6968988	0.6160748	0.30278403	0.60459805	0.6261755	0.36861268	0.52087295	0.6379605	0.48488787	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	According to the FDA label and clinical guidelines, pegloticase is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis and methemoglobinemia. This is because pegloticase can cause oxidative stress, which can exacerbate G6PD deficiency and lead to severe hemolytic reactions. Therefore, G6PD deficiency should be screened for before initiating pegloticase therapy, and alternative treatments should be considered for patients with a deficiency.	-0.28330082	0.036718715	-0.14501016	tensor(-0.0617)	tensor(0.2952)	tensor(0.0712)	0.22390841272740986	0.6473107021053908	0.2836595974636578	0.28176796	0.603868	0.34201807	0.15598679	0.6386057	0.22254765	0.0955987	0.63589704	0.21276401	0.41114596	0.6714127	0.5131165	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	According to the FDA label and clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or those with unknown G6PD status (indeterminate) should not receive pegloticase due to the risk of hemolysis and methemoglobinemia. This is because pegloticase can cause oxidative stress, which can exacerbate G6PD deficiency. As a precaution, G6PD testing is recommended prior to initiating pegloticase therapy, and alternative treatments should be considered for individuals with G6PD deficiency or indeterminate status.	0.07090952	0.25575113	0.15927236	tensor(-0.0916)	tensor(0.3590)	tensor(0.0966)	0.5867203164585054	0.604054528888554	0.38408358809821735	0.46970537	0.6511155	0.3297883	0.65547895	0.6663748	0.34201604	0.6700498	0.5846379	0.33425763	0.55811715	0.5376647	0.45537958	0
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II variant (CNSHA: Class I/II) should be counseled to avoid pegloticase due to the increased risk of hemolysis and methemoglobinemia. Pegloticase, a urate-lowering therapy, may exacerbate G6PD deficiency, leading to severe adverse reactions. As a result, alternative treatment options should be considered for these individuals.	-0.32121193	0.043055367	-0.16865642	tensor(-0.1376)	tensor(0.3332)	tensor(0.0482)	0.22284504613771627	0.6476946718660788	0.2836595974636578	0.29670036	0.5713657	0.34201807	0.104890905	0.5665659	0.22254765	0.122145966	0.57744575	0.21276401	0.42344376	0.6862293	0.5131165	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD), there are no specific contraindications or dose adjustments recommended for pegloticase, a recombinant uricase enzyme used to treat refractory chronic gout. This is because pegloticase is not expected to exacerbate G6PD deficiency, and the risk of hemolytic anemia is low in individuals with normal G6PD activity. Therefore, pegloticase can be used in G6PD-normal individuals without specific precautions or monitoring beyond the usual recommended safety monitoring.	-0.07781554	0.16416568	0.03368727	tensor(-0.0988)	tensor(0.3016)	tensor(0.0656)	0.5790364148028586	0.6686167305777141	0.3661061005617193	0.51309574	0.6690015	0.30338058	0.33518875	0.65759563	0.21096012	0.40184185	0.5954787	0.1031822	0.5491383	0.5994731	0.38962558	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II variant, such as those with Class NSA (CNSHA), are at increased risk of hemolytic anemia when taking phenazopyridine. As a result, phenazopyridine should be avoided or used with caution in these individuals, and alternative treatments should be considered. Additionally, close monitoring for signs of hemolytic anemia is recommended if phenazopyridine is prescribed.	-0.06579756	0.26390585	0.07989542	tensor(-0.0708)	tensor(0.3851)	tensor(0.1198)	0.4354849093116623	0.5873218924853667	0.4148487116043359	0.4566278	0.42598012	0.56215477	0.482405	0.560169	0.48105702	0.48023552	0.5318178	0.3691482	0.51349884	0.58099335	0.5044628	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can take phenazopyridine without any specific dosage adjustment or monitoring. This is because phenazopyridine is not expected to cause hemolytic anemia in individuals with normal G6PD activity. Therefore, no special precautions or considerations are necessary for G6PD-normal individuals taking phenazopyridine.	-0.06870811	0.1944542	0.0513175	tensor(-0.0450)	tensor(0.3489)	tensor(0.1180)	0.6520841041653465	0.6602282363881575	0.35273842910118525	0.49897903	0.69599825	0.27729583	0.46741542	0.6895688	0.19127893	0.45908415	0.5952971	0.1322071	0.56874084	0.6259838	0.4017263	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	"According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are classified as ""Variable"" for G6PD (glucose-6-phosphate dehydrogenase) deficiency may be at increased risk of hemolytic anemia when taking oxidant drugs like phenazopyridine. As a result, it is recommended to exercise caution and closely monitor for signs of hemolysis when prescribing phenazopyridine to these individuals. Additionally, alternative medications without oxidant properties may be considered to minimize the risk of adverse effects."	-0.13009557	0.16159728	0.00034863403	tensor(-0.0840)	tensor(0.3825)	tensor(0.1098)	0.6209986513655703	0.5758613337327668	0.39552156204494643	0.5267003	0.45226595	0.42807305	0.5487623	0.54700744	0.3633053	0.60280156	0.48025018	0.34324947	0.5511601	0.5673764	0.46290568	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient for glucose-6-phosphate dehydrogenase (G6PD) should use phenazopyridine with caution due to the risk of hemolytic anemia. It is recommended to monitor for signs of hemolysis, such as dark urine, fatigue, and jaundice, and to consider alternative agents if possible. If phenazopyridine is necessary, the patient should be closely monitored for adverse effects and consider a reduced dose or duration of treatment.	-0.116588645	0.16213995	0.009043332	tensor(-0.0550)	tensor(0.5052)	tensor(0.1579)	0.6345832819963051	0.5988573485003151	0.39552156204494643	0.63192827	0.630919	0.42807305	0.6345087	0.64583164	0.3633053	0.64578646	0.58302003	0.34324947	0.5576245	0.58370364	0.46290568	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, the clinical guidance is to consider them as not being at increased risk for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) associated with phenytoin use. Therefore, HLA-B*15:02 negativity does not contraindicate the use of phenytoin, and the medication can be prescribed and monitored as usual. However, it is still important to monitor for signs of hypersensitivity reactions, as SJS/TEN can still occur in HLA-B*15:02 negative individuals, albeit at a lower frequency.	0.22511196	0.29833478	0.26294434	tensor(-0.1667)	tensor(0.3203)	tensor(0.0276)	0.8139241868448966	0.6012467053193769	0.5679442729686351	0.6989528	0.56464833	0.58998376	0.8139383	0.55198306	0.6464528	0.75839984	0.39338225	0.5625798	0.8497187	0.55029273	0.528282	1
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	For individuals with no HLA-B result (i.e., unknown HLA-B status), clinical guidance recommends exercising caution when prescribing phenytoin, as they may still be at risk of developing Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). In such cases, close monitoring for signs of hypersensitivity reactions is advised, and alternative anticonvulsants may be considered, especially in patients with a history of adverse reactions to phenytoin or those of Asian ancestry. Additionally, genetic testing for HLA-B*15:02, if possible, may help inform prescribing decisions.	0.1530813	0.18713433	0.17233084	tensor(-0.1118)	tensor(0.3166)	tensor(0.0597)	0.7683320615887426	0.5495016289442141	0.610073804101925	0.6268379	0.3781993	0.63090664	0.6550512	0.4634074	0.70149153	0.6991634	0.45232216	0.5399993	0.68407506	0.54963106	0.51266736	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	For an individual with no HLA-B result, the clinical guidance is to exercise caution when prescribing phenytoin, as they may still be at risk of developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), which are severe cutaneous adverse reactions associated with HLA-B*15:02. In this scenario, close monitoring for signs of hypersensitivity reactions is recommended, and alternative therapies may be considered. However, HLA-B genotyping is still recommended if possible, as it can help identify individuals at highest risk of SJS/TEN.	0.1645833	0.17783064	0.17361452	tensor(-0.1375)	tensor(0.3972)	tensor(0.0608)	0.7573804926718893	0.5162531439263844	0.611153531855402	0.65028775	0.42089593	0.62042993	0.6332462	0.38694376	0.6949401	0.6108804	0.38225615	0.53821397	0.7199009	0.49995163	0.5138016	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	For individuals who are HLA-B*15:02 positive, the clinical guidance is to avoid using phenytoin due to the increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are severe cutaneous adverse reactions. The FDA recommends genetic testing for HLA-B*15:02 in individuals of Asian ancestry, as they are at higher risk of carrying this allele, and suggests that alternative therapies be considered in HLA-B*15:02-positive patients. This guidance is based on strong evidence from multiple studies demonstrating a significant association between HLA-B*15:02 and the risk of SJS/TEN with phenytoin use.	0.041446082	0.14758456	0.094910264	tensor(-0.1860)	tensor(0.3646)	tensor(0.0307)	0.6492853373964433	0.5509855514111103	0.5605895166290633	0.5656164	0.6065377	0.59851664	0.5524026	0.48715144	0.67357403	0.45451903	0.38007754	0.6002432	0.4498189	0.5009854	0.50846344	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	Based on the clinical guidance, a Normal Metabolizer with a CYP2C9 activity score of 2.0 is expected to metabolize piroxicam normally. Therefore, no dosage adjustment is recommended, and the standard dosing regimen for piroxicam can be followed. However, it is essential to monitor the patient for adverse effects and therapeutic response, as individual variability in response to piroxicam may still occur.	0.0033758527	0.19658588	0.09514281	tensor(-0.0125)	tensor(0.2939)	tensor(0.1214)	0.39941439885308855	0.6789518464477905	0.46930572455869957	0.43672636	0.67855245	0.35982746	0.4798809	0.6570962	0.29022616	0.42372337	0.5614412	0.43487886	0.4316695	0.66023725	0.50485027	1
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	Based on the pharmacogenomics data, an individual with an intermediate metabolizer status and an activity score of 1.5 for CYP2C9 may require dose adjustment when taking piroxicam. The CYP2C9 enzyme is responsible for metabolizing piroxicam, and intermediate metabolizers may experience reduced enzyme activity, leading to increased piroxicam concentrations and potentially increased risk of adverse effects. Therefore, clinicians may consider initiating therapy with a lower dose of piroxicam and closely monitoring the patient for signs of toxicity, such as gastrointestinal bleeding or renal impairment.	-0.07745637	0.21296902	0.0531384	tensor(-0.0619)	tensor(0.4138)	tensor(0.1286)	0.3937109728713594	0.5848395502930513	0.46930572455869957	0.34962276	0.47559664	0.35982746	0.29905015	0.55614114	0.29022616	0.3244055	0.48058185	0.43487886	0.43606368	0.5920794	0.50485027	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For an individual who is indeterminate for CYP2C9, the clinical guidance for taking piroxicam is to exercise caution and monitor for adverse effects, as piroxicam is metabolized by CYP2C9 and altered enzyme activity may impact its pharmacokinetics. A conservative approach may involve starting with a lower dose and titrating up as needed, while closely monitoring for signs of toxicity, such as gastrointestinal bleeding or renal impairment. Additionally, alternative medications with fewer CYP2C9-dependent pharmacokinetics may be considered if possible.	-0.31115416	0.024917306	-0.16789857	tensor(-0.0927)	tensor(0.4676)	tensor(0.1077)	0.24811403567552354	0.669250675781289	0.2766569239238709	0.16061383	0.6442918	0.27695686	0.08968863	0.64228475	0.18642671	-0.04780014	0.5382859	0.11296725	0.29187945	0.6274991	0.4543677	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking piroxicam as normal. There is no recommendation.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Avoid piroxicam. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer (IM) with an activity score of 1.0 for CYP2C9, the clinical guidance for taking piroxicam is to exercise caution and consider alternative medications or close monitoring. This is because piroxicam is primarily metabolized by CYP2C9, and IMs may have reduced metabolic capacity, potentially leading to increased plasma concentrations and elevated risk of adverse effects. A recommended dosage adjustment is not specified, but clinicians should be aware of the potential for increased sensitivity to piroxicam in these individuals.	0.04166244	0.15099777	0.096584365	tensor(-0.0851)	tensor(0.3424)	tensor(0.0815)	0.5862652396920971	0.6562640298873894	0.5328882864948475	0.6493259	0.62210274	0.48932475	0.6621955	0.6276553	0.34184462	0.55001765	0.5315114	0.4166794	0.5998305	0.6237824	0.54451865	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with increased function of SLCO1B1 (e.g., *1A/*1A genotype) are expected to have increased uptake of pitavastatin in the liver, resulting in higher systemic exposure and potentially increased efficacy. However, the clinical significance of this interaction is currently unclear, and no specific dosage adjustments are recommended. Nevertheless, close monitoring of lipid profiles and potential side effects is advised to ensure optimal therapeutic outcomes.	-0.12810004	0.14711513	-0.0039561554	tensor(-0.1119)	tensor(0.3802)	tensor(0.0816)	0.34807208450170296	0.5451367596269358	0.38739210170308735	0.3994697	0.45841208	0.42072248	0.39142856	0.58437705	0.35659784	0.32116732	0.48979744	0.3807351	0.46037537	0.6037362	0.6209967	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with normal function of SLCO1B1 (i.e., *1A/*1A or *1A/*1B genotype) can be prescribed pitavastatin at standard doses, as they are expected to have normal pitavastatin transport and metabolism. No dose adjustment is recommended for these individuals. However, it is essential to monitor for potential adverse effects, such as myalgia and elevated creatine phosphokinase (CPK) levels, as they can occur even in individuals with normal SLCO1B1 function.	-0.20439474	0.18645503	-0.039564867	tensor(-0.1547)	tensor(0.4011)	tensor(0.0545)	0.4042589163121654	0.6491632036978348	0.38739210170308735	0.47086167	0.5446013	0.42072248	0.48005226	0.6694846	0.35659784	0.43653575	0.53673846	0.3807351	0.5018544	0.66995007	0.6209967	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an indeterminate result for SLCO1B1 does not provide clear guidance for pitavastatin dosing. However, as pitavastatin is not a substrate of OATP1B1, the SLCO1B1 genotype is not expected to have a significant impact on its pharmacokinetics. Therefore, standard dosing of pitavastatin can be used, and no specific adjustments are recommended for an individual with an indeterminate SLCO1B1 result.	-0.2996812	0.062069666	-0.14734802	tensor(-0.0516)	tensor(0.3265)	tensor(0.1108)	0.25162774096122426	0.5764845716253424	0.2614390515982583	0.20964897	0.5789367	0.19101268	0.045844883	0.6594816	0.08467902	-0.009638801	0.4999404	0.087956615	0.27809823	0.5922506	0.45525143	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking pitavastatin as normal. There is no recommendation.', 'Avoid pitavastatin. Take an alternate therapy.']	Take pitavastatin with an altered dose.	Based on the available evidence, individuals with possible decreased function of SLCO1B1 (Organic Anion Transporting Polypeptide 1B1) may have reduced pitavastatin uptake in the liver, leading to increased systemic exposure. Therefore, the clinical guidance for such individuals is to exercise caution when initiating pitavastatin therapy, with close monitoring of response and potential adverse effects, as they may be more susceptible to statin-related muscle toxicity. Additionally, a lower starting dose of pitavastatin may be considered to minimize the risk of adverse effects.	0.13122886	0.055288758	0.09477213	tensor(-0.0407)	tensor(0.3624)	tensor(0.1323)	0.7088644061089406	0.633366849458845	0.6850769222322277	0.61213225	0.57725316	0.6116056	0.6784353	0.5769018	0.7565726	0.570501	0.5329898	0.61485815	0.6218784	0.6765367	0.6247302	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking plazomicin as normal. There is no recommendation.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Avoid plazomicin. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the mitochondrial MT-RNR1 variant (m.1555A>G or m.1494C>T) are at increased risk of aminoglycoside-induced hearing loss. Plazomicin, as a next-generation aminoglycoside, may also pose a risk of ototoxicity in these individuals. Therefore, clinicians should consider alternative antibiotic options or closely monitor patients with this variant for signs of ototoxicity if plazomicin is deemed necessary.	-0.021654991	0.15331823	0.06226698	tensor(-0.1280)	tensor(0.2974)	tensor(0.0378)	0.5751919415057706	0.5499351678652828	0.37925311589773353	0.5415694	0.47287515	0.53406185	0.6626941	0.52635014	0.40404913	0.65327233	0.4993394	0.43501624	0.5665001	0.5707842	0.48188493	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype (i.e., not carrying the m.1555A>G or m.1494C>T variants) can be treated with plazomicin without any specific pharmacogenomic-based dosage adjustments or monitoring recommendations. Plazomicin can be used in these individuals according to the standard dosing regimen, with routine audiometric monitoring as recommended for all patients receiving aminoglycosides. No specific genotype-based warnings or precautions are necessary for this population.	-0.076540135	0.22702903	0.059114367	tensor(-0.1560)	tensor(0.3449)	tensor(0.0355)	0.5382339672870032	0.6229535769374398	0.40090371675239167	0.57707417	0.44936824	0.48164576	0.60148007	0.5357664	0.46355703	0.71699864	0.50638354	0.5253902	0.60295945	0.56147426	0.5398633	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	According to clinical guidelines, individuals with an uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants should exercise caution when considering plazomicin therapy. The FDA recommends audiologic monitoring before, during, and after treatment with plazomicin, especially in patients with a history of hearing loss or those who are at increased risk of ototoxicity. Additionally, alternative antibiotic options should be considered when possible, and the benefits and risks of plazomicin treatment should be carefully weighed in these individuals.	-0.03593131	0.15822318	0.05610523	tensor(-0.0591)	tensor(0.3575)	tensor(0.1183)	0.5259817716196862	0.5959590263524179	0.40090371675239167	0.54245967	0.5575132	0.48164576	0.6696673	0.6031069	0.46355703	0.72316206	0.56105506	0.5253902	0.64623886	0.55452263	0.5398633	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with increased function of SLCO1B1 (e.g., *1A/*1A genotype) may require higher doses of pravastatin to achieve optimal LDL-C reduction, as they may have increased hepatic uptake and clearance of the medication. However, the evidence is limited, and dosage adjustments are not uniformly recommended. Clinicians should consider monitoring LDL-C levels and adjusting pravastatin doses based on individual response.	-0.08512616	0.2592377	0.065718405	tensor(-0.1290)	tensor(0.3096)	tensor(0.0514)	0.4052409904237363	0.5402826849750031	0.3757289009424938	0.4752336	0.41158956	0.41707793	0.45688787	0.54337573	0.34962344	0.43615994	0.5037159	0.37830508	0.4658397	0.5120543	0.622214	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with normal function of the SLCO1B1 gene (c.521CC or c.521CT genotype) can be prescribed pravastatin at standard doses, as they are expected to have normal uptake of pravastatin into hepatocytes. No dosage adjustment is recommended for these individuals. However, it is essential to monitor for muscle toxicity and adjust the dose or discontinue the medication if necessary, as with any statin therapy.	-0.09150323	0.20856622	0.042626627	tensor(-0.1067)	tensor(0.3286)	tensor(0.0644)	0.38070600211595407	0.5763321897869832	0.3757289009424938	0.5063771	0.50479066	0.41707793	0.52361125	0.6691235	0.34962344	0.4552308	0.5868505	0.37830508	0.50534815	0.6171639	0.622214	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an indeterminate result for SLCO1B1 does not provide clear guidance for pravastatin dosing. In such cases, clinicians should consider alternative statins, such as atorvastatin or rosuvastatin, which are not significantly affected by SLCO1B1 genotype. However, if pravastatin is still chosen, close monitoring of muscle toxicity and creatine kinase levels is recommended.	-0.25547528	-0.0073446627	-0.14324807	tensor(-0.0691)	tensor(0.3403)	tensor(0.1055)	0.24883920914519123	0.5463726889445762	0.2686107476932096	0.22406329	0.6329509	0.18586577	0.062183242	0.5702941	0.07904037	0.027655106	0.50569063	0.089790605	0.3379895	0.56990993	0.47989246	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with possible decreased function of SLCO1B1 (e.g., SLCO1B1*4 or SLCO1B1*5 alleles) may have reduced pravastatin efficacy and/or increased risk of myotoxicity due to increased pravastatin exposure. The CPIC recommends considering an alternative statin, such as atorvastatin or rosuvastatin, or initiating pravastatin at a lower dose with close monitoring for efficacy and toxicity. Additionally, clinicians should be aware of the potential for increased risk of myotoxicity and monitor patients closely for muscle-related adverse effects.	0.060272697	0.31072894	0.17612886	tensor(-0.1568)	tensor(0.4416)	tensor(0.0690)	0.6466878906979067	0.5067588836694755	0.6912430173486501	0.5085544	0.4858345	0.56564283	0.5335799	0.57761115	0.5571235	0.51957303	0.52199405	0.52122015	0.6074186	0.55455095	0.6289818	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking primaquine, a medication used to treat and prevent malaria, due to the risk of hemolytic anemia. G6PD deficiency can lead to primaquine-induced hemolysis, which can be severe and even life-threatening. Alternative medications, such as tafenoquine, may be considered for patients with G6PD deficiency, but close monitoring is still necessary to mitigate the risk of adverse effects.	0.0857337	0.0044830726	0.046542004	tensor(-0.0789)	tensor(0.3096)	tensor(0.0700)	0.6829636768893247	0.584137128855448	0.6724824681073586	0.6553497	0.5413095	0.59102464	0.70449966	0.56251496	0.66269284	0.658711	0.5885133	0.58343875	0.5497379	0.6130284	0.5980694	0
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and primaquine should be used with caution or avoided due to the risk of hemolytic anemia. If primaquine is necessary, close monitoring of hemoglobin levels and methemoglobin levels is recommended, and the patient should be counselled on the signs and symptoms of hemolytic anemia. Additionally, a quantitative G6PD assay may be considered to determine the exact level of G6PD enzyme activity.	0.13558325	0.35844502	0.24032314	tensor(-0.0599)	tensor(0.3492)	tensor(0.1145)	0.6763961528631574	0.576492686550798	0.34136369992272403	0.57880086	0.6025633	0.30933174	0.71183926	0.6050864	0.24606328	0.7187013	0.52411705	0.22139983	0.5933711	0.54314804	0.42473283	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	Based on pharmacogenomics guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with class I or II variants (e.g., CNSHA), are at risk of hemolytic anemia when taking primaquine. Therefore, primaquine is contraindicated in these individuals, and alternative treatments for malaria should be considered. In cases where primaquine is deemed essential, close monitoring for hemolysis and anemia is recommended, with consideration of G6PD activity testing and genotype confirmation prior to treatment initiation.	-0.15416028	0.35408875	0.05083367	tensor(-0.0686)	tensor(0.2695)	tensor(0.0748)	0.6460695455617332	0.5923836606767862	0.7518294203479643	0.6577324	0.52591413	0.7079004	0.5603041	0.49198723	0.7809514	0.6170706	0.5311858	0.7572219	0.66535336	0.6290097	0.7526333	0
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can take primaquine at the standard dose and frequency, as they are not at increased risk for hemolytic anemia. No dosage adjustment or special monitoring is required. However, it is still important to monitor for signs and symptoms of hemolytic anemia, as primaquine can cause hemolysis in people with G6PD deficiency.	-0.0969681	0.21294	0.0408293	tensor(-0.0879)	tensor(0.4031)	tensor(0.1066)	0.5796470173121262	0.6520898175933699	0.3422806634857717	0.41840267	0.62529254	0.22781688	0.38393697	0.7259126	0.12922293	0.36397386	0.6277217	0.13366257	0.51911265	0.55488443	0.40272087	1
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the clinical guidance is to exercise caution or avoid quinine therapy due to the increased risk of hemolytic anemia. Quinine can trigger hemolysis in G6PD-deficient individuals, which can lead to severe anemia, jaundice, and even acute kidney injury. Alternative antimalarial agents should be considered, and if quinine is deemed necessary, close monitoring of hematological parameters and signs of hemolysis is essential.	-0.06421992	0.15972108	0.04005545	tensor(-0.0734)	tensor(0.3343)	tensor(0.1005)	0.5942072768130351	0.5810802056981182	0.40341314945507434	0.57469857	0.6142913	0.37275577	0.4488893	0.57725716	0.29598364	0.51020265	0.4947897	0.34505847	0.53160137	0.5422706	0.4272391	0
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient for the purpose of quinine therapy. This means that quinine should be avoided or used with caution in these individuals, as they may be at increased risk of hemolytic anemia. Alternative treatments should be considered, and if quinine is necessary, close monitoring for hemolysis and anemia is recommended.	0.08772348	0.2826088	0.18043543	tensor(-0.0492)	tensor(0.3774)	tensor(0.1319)	0.6407391521508442	0.590607545679448	0.36090126421286484	0.50212413	0.6789214	0.3010217	0.57992697	0.68541765	0.2621999	0.6253475	0.5078585	0.2058315	0.5585596	0.5645841	0.40939176	0
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with Class III (CNSHA) severity, the clinical guidance recommends cautious use of quinine due to the increased risk of hemolytic anemia. Quinine should be used at the lowest effective dose and for the shortest duration necessary, with close monitoring for signs of hemolysis. In addition, alternative treatments should be considered whenever possible to minimize the risk of adverse reactions.	0.01873869	0.32089737	0.15492909	tensor(-0.0932)	tensor(0.3749)	tensor(0.1009)	0.48812955086906096	0.6178734770663827	0.4460725527105968	0.59354323	0.6459124	0.5309316	0.5310439	0.71070147	0.43043858	0.50713617	0.5479156	0.32792756	0.62391424	0.52112633	0.4810313	0
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Based on current evidence, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) can safely take quinine without increased risk of hemolytic anemia. Quinine is not contraindicated in G6PD-normal individuals, and its use is not expected to exacerbate G6PD deficiency. However, it is essential to monitor for signs of hemolysis, as rare cases of quinine-induced hemolysis have been reported in individuals with normal G6PD activity.	-0.041044418	0.20090446	0.07070683	tensor(-0.1072)	tensor(0.2627)	tensor(0.0525)	0.6260256018237228	0.6143455288983151	0.3492633013539158	0.47496065	0.69002825	0.23936793	0.38652802	0.7389008	0.15713121	0.36200958	0.52405655	0.1129773	0.5681337	0.5829773	0.35749537	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should not receive rasburicase due to the risk of severe hemolytic anemia. This is because rasburicase can cause hemolysis in G6PD-deficient individuals, leading to potentially life-threatening complications. Alternative treatments for hyperuricemia, such as allopurinol or febuxostat, should be considered in these patients.	-0.30226988	0.024551524	-0.16201147	tensor(-0.0939)	tensor(0.2880)	tensor(0.0497)	0.23938426894611273	0.6187972853560606	0.2839277760305201	0.31432557	0.5572596	0.37148455	0.16088074	0.6069594	0.24142145	0.101869576	0.57663924	0.19576238	0.39365593	0.6152047	0.514625	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and rasburicase should be used with caution or avoided due to the risk of hemolysis. This is because rasburicase can cause severe hemolysis in G6PD-deficient patients, and the indeterminate status may indicate a partial deficiency. As a result, alternative treatments or close monitoring for hemolysis should be considered for these patients.	0.0780602	0.29429632	0.17980431	tensor(-0.0706)	tensor(0.3819)	tensor(0.1188)	0.65546851903887	0.5793941959130555	0.3553725166493302	0.53359807	0.6409139	0.3348372	0.6479577	0.63342035	0.3250966	0.6665805	0.5381603	0.30013254	0.554205	0.47786438	0.4022239	0
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class I or II variant (including CNSHA) should avoid rasburicase due to the increased risk of hemolytic anemia and methemoglobinemia. Rasburicase, a urate-oxidase enzyme, can exacerbate G6PD deficiency, leading to severe hemolysis. Therefore, alternative treatments for hyperuricemia, such as allopurinol or febuxostat, should be considered in these individuals.	-0.3242567	0.052358408	-0.16769692	tensor(-0.1298)	tensor(0.2941)	tensor(0.0320)	0.24290951407185427	0.6226654465016093	0.2839277760305201	0.3363756	0.58907807	0.37148455	0.124728516	0.5746527	0.24142145	0.09089781	0.5721055	0.19576238	0.38977164	0.5497136	0.514625	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (wild-type G6PD) can receive rasburicase without any specific precautions or dose adjustments. Rasburicase is not expected to cause hemolysis in individuals with normal G6PD activity, and its use is not contraindicated in this population. Therefore, clinicians can administer rasburicase according to the standard dosing recommendations for tumor lysis syndrome in patients with normal G6PD activity.	-0.079480015	0.15598759	0.029385287	tensor(-0.0782)	tensor(0.3293)	tensor(0.0938)	0.6117104471678033	0.6705024378577505	0.37730619282423905	0.49503145	0.6750924	0.3315364	0.38434482	0.6337429	0.21088675	0.37719032	0.55562884	0.08789234	0.5437265	0.57086635	0.37661874	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking ribostamycin as normal. There is no recommendation.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Avoid ribostamycin. Take an alternate therapy.	Based on the available evidence, individuals with the MT-RNR1 variant, which confers an increased risk of aminoglycoside-induced hearing loss, should exercise caution when considering treatment with ribostamycin, a member of the aminoglycoside antibiotic class. Clinical guidance suggests that these individuals should be closely monitored for ototoxicity and that alternative antibiotics be considered, if possible, to minimize the risk of hearing loss. Additionally, audiometric testing and monitoring of renal function may be warranted during and after ribostamycin therapy.	0.0711131	0.18502116	0.12808783	tensor(-0.0785)	tensor(0.3326)	tensor(0.0768)	0.6591389757529714	0.6171239276782647	0.42998007778263236	0.6663098	0.5640313	0.5759598	0.73638374	0.6196672	0.51095366	0.751754	0.5782019	0.48602897	0.6505818	0.6481121	0.5290406	0
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a normal risk of aminoglycoside-induced hearing loss, who are homozygous for the wild-type allele (MT-RNR1 *1/*1) or heterozygous (MT-RNR1 *1/*1555), can receive ribostamycin without any specific precautions or dose adjustments, as they are not at increased risk of hearing loss. However, it is essential to monitor for signs and symptoms of ototoxicity, as recommended for all patients receiving aminoglycosides.	-0.064710915	0.17388283	0.04552057	tensor(-0.1622)	tensor(0.3859)	tensor(0.0493)	0.6017899832060959	0.5801551966882829	0.4588290853702596	0.49588668	0.31391513	0.5580528	0.6374895	0.60123163	0.5625482	0.6699167	0.5376124	0.54661757	0.56593156	0.5639445	0.55963165	0
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	Based on current evidence, for individuals with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, the clinical guidance is to exercise caution when considering ribostamycin therapy. Although ribostamycin is considered to have a lower risk of ototoxicity compared to other aminoglycosides, it is still recommended to monitor auditory function closely and consider alternative antibiotics if possible. Additionally, genetic counseling and further testing may be warranted to better understand the individual's risk profile.	0.011386474	0.15649346	0.08235702	tensor(-0.0540)	tensor(0.3979)	tensor(0.1357)	0.6133185152919556	0.6013729510816579	0.4588290853702596	0.52888924	0.576544	0.5580528	0.65761334	0.5582673	0.5625482	0.7075266	0.47657633	0.54661757	0.60134304	0.5528985	0.55963165	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	Based on the patient's pharmacogenomic profile, they are expected to have normal response to rosuvastatin, as Normal Function for ABCG2 suggests no impact on rosuvastatin efflux, and Increased Function for SLCO1B1 may even enhance rosuvastatin uptake in the liver. Therefore, the recommended dosage and treatment regimen for rosuvastatin can be followed as usual, with regular monitoring of lipid profiles and potential side effects. No specific dose adjustment or alternative therapy is required due to these genetic variations.	0.042044677	0.20435448	0.12059271	tensor(-0.0321)	tensor(0.3565)	tensor(0.1359)	0.6058405708353024	0.5993472156612657	0.6384760880715512	0.55656105	0.5266234	0.57925487	0.76738816	0.676949	0.6854539	0.59848845	0.51757276	0.56083727	0.6407522	0.6556315	0.7288876	1
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	Based on pharmacogenomic data, for an individual with Normal Function for ABCG2 and Decreased Function for SLCO1B1, the clinical guidance for taking rosuvastatin is as follows: Rosuvastatin dose adjustment may not be necessary due to normal ABCG2 function, which is associated with normal rosuvastatin efflux. However, decreased SLCO1B1 function may lead to increased rosuvastatin exposure, and close monitoring of efficacy and toxicity is recommended. Additionally, starting with a lower dose and titrating upwards may be considered to minimize the risk of adverse effects.	0.06871003	0.175883	0.12261596	tensor(-0.0591)	tensor(0.4670)	tensor(0.1463)	0.6456000886310811	0.6016983791262841	0.6818171917651367	0.602281	0.6177761	0.59519106	0.68699217	0.71971685	0.6004795	0.5893052	0.5757709	0.52457887	0.6496817	0.62873054	0.62280756	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	Based on pharmacogenomic guidelines, an individual with decreased function of ABCG2 and normal function of SLCO1B1 may require a reduced dose of rosuvastatin. This is because decreased ABCG2 function can increase the risk of rosuvastatin-induced myotoxicity, while normal SLCO1B1 function does not appear to affect rosuvastatin pharmacokinetics. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends a 50% dose reduction of rosuvastatin in individuals with decreased ABCG2 function to minimize the risk of adverse effects.	-0.020476203	0.23382604	0.096405976	tensor(-0.0907)	tensor(0.3883)	tensor(0.0997)	0.5599683147238245	0.501341461513258	0.6384760880715512	0.50618017	0.5120975	0.57925487	0.65981394	0.5996873	0.6854539	0.5129615	0.4349506	0.56083727	0.57086694	0.53329	0.7288876	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	Based on pharmacogenomic guidelines, an individual with decreased function of ABCG2 and no result for SLCO1B1 may require rosuvastatin dose adjustment. The decreased function of ABCG2 may increase the risk of rosuvastatin-induced myotoxicity, and a lower starting dose (e.g., 5-10 mg/day) with close monitoring of muscle toxicity is recommended. Additionally, genotype-guided dosing may be considered, and the patient's response to therapy should be closely monitored to adjust the dose as needed.	0.13077289	0.37865293	0.24594857	tensor(-0.0769)	tensor(0.3803)	tensor(0.1019)	0.8314419146984715	0.5130197392547566	0.6080700901263998	0.74674004	0.55048436	0.5556931	0.8546059	0.640538	0.67374545	0.7409594	0.48703146	0.5022805	0.82562	0.55421156	0.5781394	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	No recommendation	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	"Based on the pharmacogenomics results, individuals with a ""No Result"" for CYP2B6 and ""Indeterminate"" for CYP2C19 may have impaired metabolism of sertraline, which is primarily metabolized by CYP2C19. As a result, clinical guidance would recommend closer monitoring of sertraline's therapeutic response and potential side effects, with possible consideration of alternative medications or dose adjustments. Additionally, the prescribing clinician should be aware of the increased risk of sertraline toxicity and adjust the treatment plan accordingly."	-0.30352053	-0.0061552944	-0.17373678	tensor(-0.0589)	tensor(0.3542)	tensor(0.1172)	0.24669844638884714	0.5775675201362406	0.2593680525263897	0.11960515	0.5213223	0.18537726	0.057733927	0.6062094	0.12365695	-0.009010937	0.5438782	0.10507219	0.35838053	0.6812503	0.46661776	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	"Based on the pharmacogenomic profile, as an Ultrarapid Metabolizer (UM) for CYP2B6, the individual may metabolize sertraline, a CYP2B6 substrate, more rapidly, potentially leading to reduced efficacy. However, since CYP2C19 is not a significant metabolizer of sertraline, the ""No Result"" for CYP2C19 does not impact sertraline metabolism. Therefore, the clinical guidance would be to monitor the patient's response to sertraline therapy closely, as they may require higher doses or more frequent dosing to achieve therapeutic levels."	-0.20810299	0.21116656	-0.03379724	tensor(-0.0732)	tensor(0.3535)	tensor(0.1056)	0.32431055116734103	0.564128295677022	0.5148237579923572	0.23278566	0.4993575	0.44890946	0.27861553	0.55780196	0.4409128	0.32117254	0.5229285	0.4584697	0.3634242	0.61323893	0.65532905	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	Based on the pharmacogenomic profile, the clinical guidance for an individual who is Indeterminate for CYP2B6 and an Ultrarapid Metabolizer (UM) for CYP2C19 with regards to taking sertraline is as follows:     Sertraline dosing may require close monitoring and potential adjustment, as the CYP2C19 UM genotype may lead to increased metabolism and reduced efficacy of sertraline. However, the impact of the Indeterminate CYP2B6 genotype is unclear, and its effect on sertraline metabolism is not well established. Clinicians should consider regular monitoring of treatment response and serum concentrations to ensure optimal therapeutic outcomes.	-0.21948275	0.1684991	-0.056036167	tensor(-0.1013)	tensor(0.2963)	tensor(0.0631)	0.3784619299854596	0.5973717794247869	0.5148237579923572	0.38170213	0.53064287	0.44890946	0.27457657	0.586479	0.4409128	0.38325414	0.5055217	0.4584697	0.30733684	0.5791383	0.65532905	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	"Based on the pharmacogenomics results, as a Rapid Metabolizer for CYP2B6, the individual may require higher doses of sertraline to achieve therapeutic effects, as CYP2B6 is involved in sertraline metabolism. The ""No Result"" for CYP2C19 is not a concern, as CYP2C19 is not a primary enzyme involved in sertraline metabolism. Therefore, standard sertraline dosing may be initiated, with close monitoring of therapeutic response and potential dose adjustments based on clinical response."	-0.18305662	0.21470988	-0.01529619	tensor(-0.0466)	tensor(0.3539)	tensor(0.1140)	0.36288317102037493	0.5773448421865873	0.5148237579923572	0.26207235	0.550662	0.44890946	0.32583228	0.64251626	0.4409128	0.34126198	0.52306503	0.4584697	0.38800824	0.6056465	0.65532905	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	Based on the genetic test results, the individual is not at increased risk for Malignant Hyperthermia (MH) associated with RYR1 mutations, but may be susceptible to MH due to the CACNA1S variant. Sevoflurane, an anesthetic agent, can trigger MH in susceptible individuals. Therefore, clinical guidance suggests that the anesthesiologist should take precautions, such as monitoring for signs of MH and having a treatment plan in place, when administering sevoflurane to this individual.	0.18228377	0.18533812	0.18621325	tensor(-0.0702)	tensor(0.2850)	tensor(0.0678)	0.6650547365623143	0.5008426046705025	0.4197885345178334	0.7174589	0.47744283	0.52355206	0.7574979	0.50930136	0.34792435	0.7563058	0.5725128	0.39408535	0.6616232	0.5560562	0.5044889	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	According to the Pharmacogenomics Knowledgebase (PharmGKB), individuals who are susceptible to Malignant Hyperthermia (MH) due to variants in RYR1 or CACNA1S are at increased risk of developing MH when exposed to anesthetic agents such as sevoflurane. The clinical guidance is to avoid using sevoflurane and other triggering anesthetics in these individuals, and instead consider alternative anesthetic options. Additionally, precautions should be taken to ensure rapid detection and treatment of MH if it occurs, including having dantrolene readily available and being prepared to provide supportive care.	0.11666296	0.21196203	0.16503948	tensor(-0.0926)	tensor(0.2496)	tensor(0.0530)	0.698351123713881	0.5458487984972069	0.40272085978541355	0.66480017	0.50710666	0.48602018	0.74936	0.55089813	0.36936644	0.7724325	0.4339983	0.4177194	0.6446853	0.6019101	0.50798446	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	Based on the pharmacogenomic testing results, individuals with Uncertain Susceptibility for RYR1 and No Result for CACNA1S may be at increased risk for malignant hyperthermia (MH) when exposed to sevoflurane, a known MH-triggering anesthetic. However, the uncertain susceptibility result for RYR1 does not provide a clear indication of MH risk, and the lack of result for CACNA1S does not provide additional information to inform risk assessment. As a result, standard clinical precautions and monitoring for MH should be taken when administering sevoflurane to these individuals, but no specific genotype-based guidance can be recommended.	0.08346239	0.22787984	0.15415166	tensor(-0.1478)	tensor(0.2511)	tensor(0.0213)	0.6803616397216695	0.5423273967550063	0.4029857316783647	0.6355549	0.39724886	0.39698383	0.65912884	0.4713747	0.29812968	0.5178722	0.46290863	0.28996712	0.5589107	0.40458488	0.3836446	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	"Based on current pharmacogenomic guidelines, an individual with a ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S may not be at increased risk for malignant hyperthermia (MH) when exposed to sevoflurane. However, due to the uncertain susceptibility result for CACNA1S, close monitoring for signs of MH is still recommended during sevoflurane administration. Additionally, a thorough medical history and family history of MH or anesthesia-related adverse events should be considered before administering sevoflurane."	0.12887806	0.2773254	0.2013652	tensor(-0.0937)	tensor(0.2792)	tensor(0.0674)	0.6716366289382595	0.5580344286180696	0.4206143185415405	0.65384805	0.5229942	0.39011076	0.6320323	0.5253918	0.2960167	0.53286135	0.5030533	0.33132276	0.7136304	0.5455449	0.38429147	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For individuals with increased function of SLCO1B1, clinical guidance recommends a reduced starting dose of simvastatin to minimize the risk of myopathy. This is because SLCO1B1 increased function is associated with increased uptake of simvastatin in the liver, leading to higher systemic concentrations and increased risk of muscle toxicity. A starting dose of 5-10 mg/day is recommended, with close monitoring of muscle enzymes and adjustment of dose as needed.	-0.04599893	0.21153133	0.07198044	tensor(-0.0381)	tensor(0.4437)	tensor(0.1567)	0.4210167649108453	0.5413906614675482	0.37105978009374313	0.51429963	0.5686724	0.42194787	0.49703148	0.697242	0.36107668	0.47253534	0.56739175	0.38846934	0.4491802	0.5081892	0.63806295	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For an individual with normal function of the SLCO1B1 gene, which codes for the hepatic uptake transporter OATP1B1, the clinical guidance for taking simvastatin is as follows: No dosage adjustment is recommended, as normal SLCO1B1 function is associated with standard simvastatin pharmacokinetics and response. The usual simvastatin dosing regimen can be initiated, and the patient can be monitored for response and adverse effects as per standard clinical practice.	-0.100725934	0.121748455	0.0027285456	tensor(-0.0933)	tensor(0.3156)	tensor(0.0806)	0.3687389025508497	0.630485560567193	0.37105978009374313	0.39868274	0.6758502	0.42194787	0.47863567	0.69580877	0.36107668	0.40804198	0.52288526	0.38846934	0.45626658	0.58692294	0.63806295	1
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for SLCO1B1 (i.e., have a genotype that is not clearly associated with normal or reduced function) can be treated similarly to those with normal function, as the clinical implications of this genotype are uncertain. Therefore, simvastatin can be initiated at a standard dose, but close monitoring for muscle toxicity is recommended, as indeterminate individuals may still be at increased risk for myotoxicity. Additionally, consideration of alternative statins with lower risk of muscle toxicity, such as pravastatin or fluvastatin, may be warranted.	-0.30677575	-0.013249073	-0.17843856	tensor(-0.1387)	tensor(0.4030)	tensor(0.0682)	0.24306306466131214	0.5648700329445488	0.2567276218623102	0.12653416	0.4292989	0.19626938	0.053418115	0.61270344	0.08749134	0.012306489	0.5319249	0.10325783	0.26012474	0.5681876	0.4805333	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	['Proceed taking simvastatin as normal. There is no recommendation.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Avoid simvastatin. Take an alternate therapy.	"According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a ""Possible Decreased Function"" genotype for SLCO1B1 (e.g., *1B/*15 or *1B/*17) may be at increased risk of simvastatin-induced myotoxicity. As such, the CPIC recommends considering an alternative statin or initiating simvastatin at a lower dose (e.g., 10-20 mg daily) with close monitoring for muscle toxicity. Additionally, the FDA label for simvastatin recommends reducing the dose in patients who are carriers of the SLCO1B1 reduced function allele."	-0.031045934	0.12746717	0.045752864	tensor(-0.1585)	tensor(0.4435)	tensor(0.0748)	0.6609904860866906	0.588440725873909	0.6872677154294964	0.57578903	0.54921925	0.73131627	0.73191893	0.70695513	0.7963201	0.620893	0.57997924	0.57501906	0.6280903	0.6133825	0.6128454	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking streptomycin as normal. There is no recommendation.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Avoid streptomycin. Take an alternate therapy.	According to clinical guidelines, individuals with the mitochondrial MT-RNR1 variant, specifically the m.1555A>G or m.1494C>T mutations, are at increased risk of aminoglycoside-induced hearing loss, including with streptomycin. Therefore, it is recommended to avoid or use with caution streptomycin in these individuals, and alternative antibiotics should be considered when possible. Additionally, audiometric monitoring is recommended for patients who must receive streptomycin to detect early signs of hearing loss.	0.007418799	0.14844598	0.07658442	tensor(-0.1483)	tensor(0.1356)	tensor(-0.0265)	0.6643030937430392	0.5603894130768953	0.4361742156686382	0.6761588	0.54626817	0.5839129	0.690271	0.58980566	0.53661996	0.6472493	0.52770615	0.46000788	0.57545257	0.5802108	0.5538775	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a normal risk of aminoglycoside-induced hearing loss, i.e., those without the m.1555A>G or m.1494C>T variants in the MT-RNR1 gene, can be treated with streptomycin without any adjustments. No specific dosing recommendations or additional monitoring are required for these individuals. However, it is essential to follow standard clinical practice for monitoring hearing function and kidney function, as well as adjusting the dose based on renal function, to minimize the risk of ototoxicity and nephrotoxicity associated with streptomycin use.	-0.0812213	0.17714892	0.0367958	tensor(-0.2060)	tensor(0.2077)	tensor(-0.0454)	0.6626788578437336	0.616905590147602	0.47539959383112923	0.5762844	0.47752193	0.55190474	0.7031164	0.5643845	0.5641262	0.7088729	0.5179194	0.48491383	0.6303935	0.6003114	0.590404	0
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with the MT-RNR1 variant (1555A>G or 1494C>T) are at increased risk of aminoglycoside-induced hearing loss, including with streptomycin. The guidance recommends that these individuals avoid using streptomycin or other aminoglycosides, if possible, and instead consider alternative antibiotics. If streptomycin is necessary, close monitoring for ototoxicity and regular hearing assessments are recommended.	-0.0041963016	0.17874266	0.08317789	tensor(-0.1472)	tensor(0.3192)	tensor(0.0446)	0.5845116477011019	0.5128793144113863	0.47539959383112923	0.49070477	0.5436091	0.55190474	0.6517684	0.5880637	0.5641262	0.68176234	0.47621554	0.48491383	0.5980113	0.56210154	0.590404	0
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	Based on the pharmacogenomics results, individuals with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S are at increased risk of malignant hyperthermia (MH) when exposed to succinylcholine. Clinical guidance recommends exercising extreme caution when considering the use of succinylcholine in these individuals, and alternative anesthetics should be considered whenever possible. If succinylcholine must be used, close monitoring for signs of MH and preparation for immediate treatment are essential.	0.18811215	0.22124079	0.20681478	tensor(-0.0575)	tensor(0.2422)	tensor(0.0648)	0.7633423603851256	0.5633977860413569	0.5006740955787048	0.6967936	0.4985048	0.55130637	0.8111745	0.53087705	0.46792105	0.74475056	0.4809096	0.48707622	0.7112163	0.5874286	0.5373941	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	Based on the genetic test results, this individual does not have a detected variant in the RYR1 gene associated with Malignant Hyperthermia (MH) susceptibility, but does have a variant in the CACNA1S gene, which is also associated with MH susceptibility. According to clinical guidelines, a CACNA1S variant is considered a risk factor for MH, and succinylcholine should be used with caution or avoided in this individual, as it can trigger MH in susceptible patients. Alternative muscle relaxants should be considered, and the anesthesiologist should take appropriate precautions to monitor for MH during anesthesia.	0.22075886	0.28909218	0.25628552	tensor(-0.1142)	tensor(0.3368)	tensor(0.0504)	0.7273808299618185	0.4675688158550189	0.4951781130922272	0.5935506	0.24243481	0.5973257	0.86615455	0.41460976	0.44043863	0.7822858	0.3977614	0.4789548	0.7510158	0.4916101	0.5404216	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	Based on the genetic test results, individuals with Malignant Hyperthermia Susceptibility (MHS) for RYR1 and Uncertain Susceptibility for CACNA1S are considered to be at high risk for malignant hyperthermia (MH) triggered by succinylcholine. The clinical guidance is to avoid the use of succinylcholine in these individuals, as it may trigger a life-threatening MH episode. Instead, alternative muscle relaxants should be used, and a thorough risk assessment and discussion with an anesthesiologist should take place before any surgical procedure.	0.18888263	0.2613989	0.22646278	tensor(-0.0943)	tensor(0.3062)	tensor(0.0590)	0.7841610228666523	0.5209538957404781	0.5006740955787048	0.74099475	0.45974147	0.55130637	0.8521127	0.50895715	0.46792105	0.80628246	0.48028657	0.48707622	0.7449986	0.5929355	0.5373941	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid succinylcholine. Take an alternate therapy.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Proceed taking succinylcholine as normal. There is no recommendation.	"Based on the pharmacogenomic results, the patient with ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S may not be at increased risk for malignant hyperthermia (MH) with succinylcholine administration. However, due to the uncertain susceptibility for CACNA1S, caution should be exercised, and anesthesia providers should be aware of the potential risk of MH. Close monitoring and preparation for potential MH treatment are recommended, but a contraindication for succinylcholine use is not necessarily warranted."	0.07571911	0.20295243	0.1387208	tensor(-0.1132)	tensor(0.3033)	tensor(0.0628)	0.6553738839616167	0.5703258173271718	0.41499618662823456	0.68885136	0.5142383	0.3966019	0.65348643	0.46866935	0.35111976	0.5533986	0.4809823	0.35840815	0.71017283	0.5777849	0.36818558	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking sulfadiazine, a sulfonamide antibiotic, due to the increased risk of hemolytic anemia. This is because sulfadiazine can trigger hemolysis in G6PD-deficient individuals, leading to severe anemia. As a result, alternative antibiotic options should be considered for these patients.	-0.08047721	0.13967066	0.022150494	tensor(-0.0616)	tensor(0.3689)	tensor(0.1205)	0.621493834394322	0.5539878985424883	0.39551575770825975	0.6002542	0.6469516	0.39778945	0.5555353	0.62818366	0.30606142	0.5844596	0.582103	0.35790816	0.5528211	0.62160903	0.3958778	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency. Therefore, sulfadiazine, a drug that can cause hemolysis in G6PD-deficient individuals, should be used with caution and close monitoring for signs of hemolysis. It is recommended to consider alternative medications or perform further G6PD testing to confirm the individual's G6PD status before initiating sulfadiazine therapy.	0.13078848	0.31025377	0.21692619	tensor(-0.0487)	tensor(0.4363)	tensor(0.1523)	0.6833145520581811	0.5683950409698073	0.35603036417371176	0.60569763	0.5760462	0.28779253	0.61337566	0.6665829	0.2740071	0.6093286	0.514089	0.25587213	0.5828897	0.5759394	0.43425107	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with Class I or II variants (such as CNSHA), are at increased risk of hemolytic anemia when taking sulfadiazine. Therefore, sulfadiazine is contraindicated in these individuals, and alternative antibiotic therapy should be considered. If sulfadiazine is deemed necessary, close monitoring for signs of hemolysis and anemia is recommended.	-0.030486956	0.27296618	0.105673574	tensor(-0.0742)	tensor(0.3600)	tensor(0.1089)	0.4422427966406918	0.5782697008978867	0.43248797621109836	0.4759911	0.5043549	0.51388335	0.46714815	0.6445018	0.43169662	0.46290994	0.5702636	0.38863704	0.50634515	0.6098588	0.4661053	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (wild-type or hemizygous for the G6PD gene) are not at increased risk of hemolysis when taking sulfadiazine. Therefore, no specific precautions or dose adjustments are necessary for these individuals. However, it is essential to monitor for signs of hemolysis, such as anemia, jaundice, or dark urine, as a precautionary measure.	-0.12334105	0.21284646	0.023851868	tensor(-0.1200)	tensor(0.3498)	tensor(0.0737)	0.6644795036646924	0.6020688944033192	0.3573398668916481	0.4868458	0.67035466	0.26242563	0.36074585	0.69699645	0.17112501	0.3793801	0.5905641	0.14959475	0.5285141	0.6088796	0.34481508	1
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	According to clinical guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking sulfadimidine, a sulfonamide antibiotic, due to the increased risk of hemolytic anemia. This is because sulfadimidine can trigger oxidative stress, which can exacerbate the existing enzyme deficiency and lead to severe hemolysis. Instead, alternative antibiotics should be considered, and patients with G6PD deficiency should be closely monitored for signs of hemolysis if sulfadimidine is deemed necessary.	-0.0950902	0.1573017	0.020434974	tensor(-0.0199)	tensor(0.3997)	tensor(0.1594)	0.596548510925709	0.587618150362515	0.4389137835297793	0.6197504	0.6387012	0.43658063	0.60032123	0.6341755	0.3546952	0.59294766	0.5701624	0.39285535	0.5550268	0.582465	0.45433488	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for G6PD deficiency should be treated as if they have G6PD deficiency, and sulfadimidine should be used with caution or avoided due to the risk of hemolytic anemia. If sulfadimidine is necessary, close monitoring of hematological parameters is recommended, and the patient should be counseled on the signs and symptoms of hemolysis. In general, alternative medications without G6PD-related risks should be considered.	0.102851816	0.3199465	0.20504561	tensor(-0.0542)	tensor(0.4135)	tensor(0.1409)	0.65331697378955	0.6526336928541564	0.4034986346711903	0.56086636	0.6341613	0.34958792	0.66082907	0.6760673	0.36899891	0.65287876	0.5421681	0.28533536	0.58178467	0.5909022	0.4350698	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class I or II deficiency (severe or moderate deficiency) should avoid taking sulfadimidine, a sulfonamide antibiotic, due to the increased risk of hemolytic anemia. This is because sulfadimidine can trigger hemolysis in G6PD-deficient individuals, leading to severe anemia and other complications. Therefore, alternative antibiotics should be considered for these patients.	-0.09667742	0.06685858	-0.017832834	tensor(-0.0557)	tensor(0.4289)	tensor(0.1450)	0.4263727732297113	0.6188811519164027	0.45019212841246503	0.4432131	0.62294596	0.53825164	0.42283726	0.6208875	0.48609704	0.4626149	0.5559159	0.41334704	0.4825651	0.6159351	0.46237466	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	According to clinical guidelines, individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity can take sulfadimidine, a sulfonamide antibiotic, without increased risk of hemolytic anemia. This is because sulfadimidine is not expected to cause significant hemolysis in individuals with normal G6PD activity. Therefore, no specific dosage adjustment or precautions are necessary for these individuals.	-0.06386235	0.20870642	0.059917778	tensor(-0.0065)	tensor(0.3727)	tensor(0.1476)	0.6374682870492546	0.6790140276957317	0.38956918905184573	0.5420542	0.6540699	0.28883308	0.47585553	0.6952207	0.20710929	0.4591424	0.5845359	0.17418419	0.51709425	0.6234592	0.40380615	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	According to clinical guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can safely take sulfamethoxazole/trimethoprim (SMX/TMP) without increased risk of hemolytic anemia. SMX/TMP is not contraindicated in G6PD normal individuals, and no dose adjustment is necessary. However, it is still important to monitor for signs of hemolytic anemia, especially in individuals with a history of G6PD deficiency or unknown G6PD status.	-0.05887691	0.24861442	0.07849732	tensor(-0.0399)	tensor(0.5467)	tensor(0.1898)	0.6335343508663356	0.6061771320664031	0.35275595537252347	0.51622987	0.71076494	0.2995159	0.4571046	0.70813966	0.21361533	0.36783046	0.58761144	0.111592695	0.50965714	0.6511451	0.33470994	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	"According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are classified as ""Variable"" for G6PD deficiency should be cautious when taking sulfamethoxazole/trimethoprim, as they may be at increased risk of hemolytic anemia. It is recommended to monitor for signs of hemolysis, such as dark urine, fatigue, and jaundice, and to consider alternative antibiotics if possible. If sulfamethoxazole/trimethoprim is necessary, the patient should be closely monitored for adverse effects and consider genetic testing for G6PD deficiency if the diagnosis is unclear."	-0.16213645	0.1604768	-0.020591835	tensor(-0.0345)	tensor(0.4829)	tensor(0.1777)	0.6308182602470208	0.6122902022586284	0.38739367519917484	0.620559	0.5794397	0.43105203	0.6343486	0.6243433	0.33348823	0.65240514	0.5164112	0.31410483	0.5694057	0.58560115	0.36578175	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	According to clinical guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid taking sulfamethoxazole/trimethoprim (SMX-TMP) due to the increased risk of hemolytic anemia. G6PD deficiency impairs the body's ability to protect red blood cells from oxidative stress, and SMX-TMP can exacerbate this effect, leading to severe hemolysis. Alternative antibiotics should be considered in patients with G6PD deficiency to minimize the risk of adverse reactions.	-0.0841052	0.14779212	0.02328381	tensor(-0.0541)	tensor(0.5524)	tensor(0.1855)	0.6266017238369443	0.5262454460135209	0.38739367519917484	0.63769644	0.65664124	0.43105203	0.6011188	0.64615065	0.33348823	0.5508353	0.53578913	0.31410483	0.524936	0.62039715	0.36578175	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and sulfamethoxazole/trimethoprim should be used with caution or alternative antibiotics considered. This is because sulfamethoxazole/trimethoprim can cause hemolytic anemia in individuals with G6PD deficiency, and the indeterminate result may indicate a reduced enzyme activity. Close monitoring for signs of hemolysis is recommended if sulfamethoxazole/trimethoprim is prescribed in this scenario.	-0.0034535525	0.32153422	0.14130013	tensor(0.0356)	tensor(0.4347)	tensor(0.2086)	0.6777848702542191	0.5667794800729542	0.3546178866243577	0.5726543	0.65530455	0.27878785	0.6740131	0.6456299	0.26774657	0.616416	0.57041544	0.22133353	0.5228334	0.6216567	0.37450424	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For an individual with normal G6PD activity, sulfanilamide can be prescribed without concerns related to G6PD deficiency. However, it is essential to monitor for signs of hemolysis, such as anemia, jaundice, or dark urine, as a precautionary measure, although the risk is low. Additionally, clinicians should be aware of the patient's medical history and concomitant medications that may increase the risk of hemolysis.	-0.08565408	0.2232374	0.051910155	tensor(-0.0371)	tensor(0.3467)	tensor(0.1290)	0.6495097288600677	0.6341490951945171	0.3311607099815618	0.571466	0.61753684	0.2889193	0.478262	0.6373532	0.1765176	0.42009118	0.57617587	0.15292028	0.5458208	0.5595467	0.40059227	1
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency, and therefore, sulfanilamide, a drug known to cause hemolysis in G6PD-deficient individuals, should be used with caution or avoided if possible. Alternative medications should be considered, and if sulfanilamide is necessary, close monitoring for hemolysis is recommended. Additionally, a G6PD enzyme activity assay may be performed to determine the individual's actual G6PD status.	0.1296456	0.3652919	0.23972884	tensor(-0.0775)	tensor(0.3944)	tensor(0.1183)	0.6764264444062145	0.5912978794937812	0.34803956659171237	0.57589275	0.5683523	0.28498	0.7226576	0.57212055	0.25633132	0.68160653	0.4494643	0.26355118	0.62112796	0.5830432	0.47073972	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Based on current pharmacogenomics knowledge, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with the Class I variant CNSHA (Class I variants are the most severe), are at increased risk of hemolytic anemia when exposed to sulfanilamide, a sulfonamide antibiotic. Clinical guidance recommends avoiding sulfanilamide in G6PD-deficient individuals, especially those with CNSHA, due to the high risk of severe hemolysis. Instead, alternative antibiotics should be considered to minimize the risk of adverse effects.	-0.09885954	0.10599335	-0.002623675	tensor(-0.1027)	tensor(0.3773)	tensor(0.0950)	0.41873237510956757	0.5386454456892734	0.4343543597420783	0.46306226	0.41075933	0.5355994	0.40050328	0.5394875	0.46083927	0.44486526	0.4825923	0.37163988	0.5229555	0.57949066	0.48423153	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	According to clinical guidelines, individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking sulfanilamide, a sulfonamide antibiotic, due to the increased risk of hemolytic anemia. Sulfanilamide can trigger acute hemolysis in G6PD-deficient individuals, which can lead to severe anemia, jaundice, and even kidney failure. Therefore, alternative antibiotic options should be considered, and sulfanilamide should be contraindicated in patients with G6PD deficiency.	-0.06258541	0.14697914	0.035779204	tensor(-0.0213)	tensor(0.3631)	tensor(0.1453)	0.5969805450696967	0.5544730622334143	0.38402638888099166	0.6263467	0.655502	0.43161026	0.60090816	0.63102114	0.31422496	0.56664866	0.5346516	0.37327197	0.5896238	0.606654	0.44883904	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid or use with caution sulfasalazine, a sulfonamide antibiotic, due to the risk of hemolytic anemia. This is because sulfonamides can trigger hemolysis in G6PD-deficient individuals, which can lead to severe anemia. Alternative medications should be considered, and if sulfasalazine is necessary, close monitoring of hematologic parameters is recommended.	-0.09064508	0.14480361	0.018133938	tensor(-0.0686)	tensor(0.3605)	tensor(0.1129)	0.6370670851890073	0.5050917741899765	0.3464944966745701	0.62389743	0.6046086	0.37481079	0.57037014	0.5829572	0.25026733	0.5856523	0.572176	0.33196893	0.5591004	0.565901	0.38825053	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and sulfasalazine should be used with caution or alternative medications considered due to the risk of hemolytic anemia. Close monitoring of hemoglobin levels and signs of hemolysis is recommended. If sulfasalazine is deemed necessary, a gradual dose escalation and close monitoring for adverse effects is advised.	0.09098649	0.307863	0.1930468	tensor(-0.0382)	tensor(0.3740)	tensor(0.1358)	0.6471545865857843	0.5466807291504665	0.3065256305567895	0.6262037	0.5420067	0.29117048	0.6067936	0.6327488	0.23816778	0.5848669	0.60099113	0.22397509	0.58585376	0.58022964	0.4090981	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	"According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II deficiency (classified as CNSHA, or ""Class I/II deficient"") should avoid taking sulfasalazine due to the increased risk of hemolytic anemia. This is because sulfasalazine can trigger hemolysis in G6PD-deficient individuals, leading to severe anemia. Alternative medications should be considered, and if sulfasalazine is deemed necessary, close monitoring of hemoglobin levels and signs of hemolysis is recommended."	-0.049602263	0.25009647	0.08489022	tensor(-0.1099)	tensor(0.3910)	tensor(0.0944)	0.4369221627749088	0.5432275830477046	0.42501847418307526	0.4185862	0.609936	0.5063134	0.48384625	0.60703886	0.38050833	0.51924515	0.5360155	0.3941772	0.5390261	0.5934256	0.47548047	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with normal G6PD activity (G6PD normal) can take sulfasalazine without dose adjustment or specific monitoring, as they are not at increased risk of hemolytic anemia. However, it is essential to monitor for signs and symptoms of hemolytic anemia, such as dark urine, fatigue, or jaundice, as a precautionary measure. Additionally, patients should be advised to report any unusual symptoms to their healthcare provider promptly.	-0.13268049	0.20057152	0.013274725	tensor(-0.1046)	tensor(0.3761)	tensor(0.0818)	0.6315991619426591	0.6348746894657356	0.3014259709146181	0.48093718	0.6638358	0.24732888	0.3920518	0.6702396	0.13892257	0.39215106	0.5986049	0.10622728	0.5001898	0.6519139	0.33701587	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with a G6PD deficiency should avoid taking sulfisoxazole, a sulfonamide antibiotic, due to the increased risk of hemolytic anemia. Sulfisoxazole can trigger hemolysis in G6PD-deficient patients, leading to severe and potentially life-threatening complications. Therefore, alternative antibiotics should be considered in patients with G6PD deficiency to minimize the risk of adverse reactions.	-0.070909135	0.15263471	0.033164322	tensor(-0.0153)	tensor(0.4400)	tensor(0.1766)	0.6144232802159347	0.5589289157499081	0.36630344239041895	0.6471491	0.6309034	0.39183953	0.62403744	0.610133	0.28044406	0.6537189	0.49683902	0.31623027	0.59182894	0.57257825	0.37570143	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as if they have G6PD deficiency. Therefore, sulfisoxazole, a sulfonamide antibiotic that can cause hemolysis in G6PD-deficient individuals, should be used with caution and close monitoring for hemolytic anemia. If possible, an alternative antibiotic should be considered to minimize the risk of adverse effects.	0.09410087	0.3087942	0.19525136	tensor(-0.0265)	tensor(0.5128)	tensor(0.1931)	0.623590806925802	0.5713319486181624	0.3206689271164492	0.59344983	0.5259404	0.24950807	0.5841793	0.6026923	0.2140449	0.5620058	0.48990044	0.22769253	0.5359391	0.5323054	0.42085794	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	"According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a Class I or II deficiency (classified as CNSHA, or ""classic severe"" or ""severe"" deficiency, respectively) should avoid taking sulfisoxazole due to the increased risk of hemolytic anemia. This is because sulfisoxazole, a sulfonamide antibiotic, can trigger hemolysis in G6PD-deficient individuals. Instead, alternative antibiotics should be considered to minimize the risk of adverse reactions."	-0.13338004	0.0572272	-0.04321775	tensor(-0.0871)	tensor(0.4235)	tensor(0.1211)	0.422372569142546	0.5802422979422066	0.43373666705249886	0.4531826	0.62296563	0.50519395	0.43870148	0.6381203	0.4033355	0.49636766	0.50278217	0.4151573	0.5034256	0.61371124	0.46724465	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal for G6PD (glucose-6-phosphate dehydrogenase) enzyme activity are not at increased risk for hemolytic anemia when taking sulfisoxazole, a sulfonamide antibiotic. Therefore, no dose adjustment or special monitoring is required for these individuals, and sulfisoxazole can be used as recommended for the treatment of bacterial infections. However, it is essential to monitor for signs and symptoms of hemolytic anemia, as rare cases can still occur even in individuals with normal G6PD activity.	-0.13407207	0.22480148	0.021168813	tensor(-0.0716)	tensor(0.3683)	tensor(0.1061)	0.6088550098209616	0.6306774695377887	0.3147373579552814	0.46899137	0.6123638	0.25704083	0.31499824	0.58883995	0.1578763	0.370836	0.54974645	0.10206577	0.5247977	0.61111915	0.34618077	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a Possible Intermediate Metabolizer for CYP3A5 is likely to have reduced tacrolimus metabolism, which may lead to increased drug exposure and toxicity. Therefore, clinicians should consider initiating therapy with a lower starting dose of tacrolimus, closely monitoring trough concentrations, and adjusting the dose as needed to achieve target concentrations. Additionally, more frequent monitoring of tacrolimus levels and patient response may be necessary to minimize the risk of adverse effects.	-0.015039771	0.08384127	0.035171643	tensor(-0.0468)	tensor(0.3158)	tensor(0.1114)	0.5342059501069875	0.71539087088389	0.4594571134521476	0.5637875	0.5872927	0.47959802	0.4460861	0.52825946	0.5223667	0.49352285	0.5714842	0.47763655	0.5113198	0.7395169	0.32045323	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	No recommendation	['Avoid tacrolimus. Take an alternate therapy.', 'Take tacrolimus with a reduced dose.', 'Take tacrolimus with an increased dose.']	Proceed taking tacrolimus as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an indeterminate CYP3A5 genotype is treated as an intermediate metabolizer, and no specific dosing recommendations are provided for tacrolimus. However, clinicians should consider that the patient may have reduced tacrolimus clearance and monitor tacrolimus concentrations and adjust the dose accordingly to maintain therapeutic levels. Additionally, clinicians may consider genotyping for other genes that influence tacrolimus pharmacokinetics, such as CYP3A4 and ABCB1, to inform personalized dosing.	-0.2604199	0.014914905	-0.13796459	tensor(-0.0604)	tensor(0.2896)	tensor(0.0888)	0.25337892516080796	0.6486432246448803	0.244899304250772	0.23330854	0.6144139	0.26119426	0.09776921	0.61154264	0.15467755	-0.009417785	0.53847456	0.11868071	0.27362213	0.59309494	0.48454058	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are intermediate metabolizers for CYP3A5 (CYP3A5*1/*3 or *3/*3) may require a moderate dose reduction of tacrolimus, as they may have higher tacrolimus concentrations compared to normal metabolizers (CYP3A5*1/*1). The suggested dose reduction is 25-50% of the standard dose, with close monitoring of tacrolimus trough concentrations and adjustment as needed to achieve therapeutic levels. However, the optimal dosing strategy may vary depending on individual patient factors and clinical response.	-0.06649686	0.13880885	0.0300823	tensor(-0.1448)	tensor(0.2687)	tensor(0.0285)	0.5210302764324235	0.7269468118119343	0.4594571134521476	0.5210434	0.5709595	0.47959802	0.521581	0.5513944	0.5223667	0.56767595	0.57517546	0.47763655	0.51452684	0.6776296	0.32045323	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are normal metabolizers for CYP3A5 (CYP3A5*1 carriers) may require higher doses of tacrolimus to achieve therapeutic concentrations, as they are more likely to metabolize the drug efficiently. However, the optimal dosing strategy for these individuals has not been established, and therapeutic drug monitoring is recommended to ensure adequate immunosuppression. Close monitoring of tacrolimus levels and potential dose adjustments may be necessary to prevent graft rejection or toxicity.	-0.030987147	0.07727354	0.0235119	tensor(-0.0832)	tensor(0.2653)	tensor(0.0612)	0.4886787132944635	0.6959423412454373	0.4594571134521476	0.46615374	0.5240029	0.47959802	0.39111936	0.4757593	0.5223667	0.48449484	0.5348815	0.47763655	0.48621702	0.67273176	0.32045323	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	According to the FDA label and clinical guidelines, tafenoquine is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia. G6PD-deficient individuals who take tafenoquine may experience a severe and potentially life-threatening hemolytic reaction. As a result, G6PD testing is recommended prior to initiating tafenoquine therapy, and alternative treatments should be considered for patients with G6PD deficiency.	-0.2980992	0.025655517	-0.15881892	tensor(-0.0600)	tensor(0.3088)	tensor(0.0829)	0.1968551021948357	0.6453678080245537	0.277098275527093	0.2706035	0.6297273	0.3075372	0.14853626	0.6239823	0.18099946	0.10183951	0.57707375	0.21839902	0.34899265	0.613683	0.4829587	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	According to the FDA label and clinical guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient due to the risk of hemolytic anemia with tafenoquine administration. Therefore, tafenoquine is not recommended for individuals with an indeterminate G6PD status, and alternative antimalarial agents should be considered. A confirmatory G6PD activity test may be necessary to determine the individual's G6PD status before initiating tafenoquine therapy.	0.16276707	0.31421077	0.23659062	tensor(-0.0015)	tensor(0.4189)	tensor(0.1785)	0.6396140000617552	0.6129242665057284	0.33900643872575464	0.43905503	0.62212247	0.26299226	0.5116299	0.5867351	0.17630386	0.614987	0.560574	0.15469654	0.5812016	0.53300196	0.43314928	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with a class I or II deficiency (CNSHA, Class I being the most severe) should not take tafenoquine due to the risk of hemolytic anemia. This is because tafenoquine can exacerbate G6PD deficiency, leading to life-threatening hemolysis. Alternative antimalarial medications should be considered for these individuals.	-0.3089357	0.038911875	-0.16157995	tensor(-0.1110)	tensor(0.3780)	tensor(0.0746)	0.1994984539671632	0.6468763379859086	0.277098275527093	0.28252935	0.61079496	0.3075372	0.14726232	0.54499435	0.18099946	0.12654647	0.55315274	0.21839902	0.37773797	0.6093088	0.4829587	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	According to the FDA label and clinical guidelines, individuals who are normal for glucose-6-phosphate dehydrogenase (G6PD) can take tafenoquine without restrictions, as they are not at increased risk of hemolytic anemia. Tafenoquine can be used in these individuals for the prevention of malaria, and no specific dose adjustments or monitoring are required. However, it is still important to monitor for signs of hemolysis, such as dark urine or jaundice, as a precautionary measure.	-0.11814845	0.18666616	0.01743323	tensor(-0.0702)	tensor(0.3904)	tensor(0.1132)	0.5413269253774886	0.6859036932229187	0.33555578408226916	0.41634557	0.5910269	0.28795093	0.33503383	0.62959516	0.1648321	0.27660653	0.525532	0.08093379	0.46744508	0.60837674	0.38195786	1
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient with a CYP2D6 activity score of 2.0, indicating normal metabolizer status, can be considered for tamoxifen therapy without dose adjustment. However, it is recommended to monitor the patient's response to therapy and consider alternative therapies if the patient experiences inadequate response or significant side effects. Additionally, the patient's CYP2D6 genotype may not be the only factor influencing tamoxifen response, and other genetic and non-genetic factors should also be considered.	0.016714023	0.16628395	0.08965437	tensor(-0.1392)	tensor(0.2219)	tensor(-0.0109)	0.6913502539719992	0.5411777569009941	0.6843934098163132	0.67508006	0.5520308	0.73556274	0.7264811	0.5848889	0.7468502	0.72749484	0.52186996	0.68672013	0.73392516	0.6125656	0.8106873	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score of 2.5, clinical guidance suggests that they may not be optimal candidates for tamoxifen therapy due to reduced efficacy. This is because UM individuals may metabolize tamoxifen too quickly, leading to decreased concentrations of the active metabolite endoxifen, which is responsible for the anti-estrogenic effects. As a result, alternative therapeutic options or closer monitoring of treatment response may be necessary.	-0.042673815	0.12947027	0.039986514	tensor(-0.1426)	tensor(0.2402)	tensor(0.0192)	0.6553978278541837	0.5689962210049347	0.6843934098163132	0.6861412	0.58891445	0.73556274	0.73770964	0.60890836	0.7468502	0.67127204	0.5135678	0.68672013	0.6704862	0.5951582	0.8106873	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥3.25, the clinical guidance is to avoid tamoxifen due to reduced efficacy. This is because CYP2D6 UMs are likely to have increased conversion of tamoxifen to its inactive metabolites, leading to decreased levels of the active metabolite endoxifen. As a result, alternative therapies, such as aromatase inhibitors, may be considered for breast cancer treatment.	-0.00580525	0.122262746	0.057595845	tensor(-0.1474)	tensor(0.2483)	tensor(0.0206)	0.6692232249186594	0.5846146864477365	0.6843934098163132	0.72315073	0.62138444	0.73556274	0.6991004	0.5802795	0.7468502	0.64403844	0.49779212	0.68672013	0.72485197	0.6688867	0.8106873	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	Based on the pharmacogenomic profile, as a Normal Metabolizer with a CYP2D6 activity score of 1.75, the clinical guidance for tamoxifen use is to initiate therapy at the standard dose and monitor for efficacy and toxicity. This is because the CYP2D6 activity score suggests normal enzyme function, which is associated with adequate conversion of tamoxifen to its active metabolite, endoxifen. However, close monitoring is still recommended due to the possibility of interindividual variability in tamoxifen metabolism.	0.04241247	0.20363249	0.12048491	tensor(-0.1200)	tensor(0.2750)	tensor(0.0343)	0.6922645058577088	0.5400653204618732	0.6843934098163132	0.6577458	0.45429954	0.73556274	0.7054354	0.58710617	0.7468502	0.65052515	0.5057613	0.68672013	0.73180294	0.6034027	0.8106873	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate CYP2C9 genotype should be treated as if they have a reduced function allele, as the genotype may not accurately predict the phenotype. For tenoxicam, a CYP2C9 substrate, this may lead to increased exposure and risk of adverse effects, such as gastrointestinal toxicity. Therefore, clinicians should consider alternative medications or closely monitor the patient for adverse effects and adjust the dose as needed.	-0.28241584	-0.004639764	-0.15939985	tensor(-0.1165)	tensor(0.4230)	tensor(0.0936)	0.2539425395871088	0.5724674107135721	0.284899373405129	0.12117893	0.46957022	0.17570083	0.090420075	0.53872806	0.08032832	-0.026371503	0.5362112	0.14119314	0.283676	0.58840406	0.5102693	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	Based on the pharmacogenomics data, as a Normal Metabolizer with a CYP2C9 activity score of 2.0, the clinical guidance for taking tenoxicam is as follows: No dosage adjustment is required, and standard dosing of tenoxicam can be used. This is because CYP2C9 is not a significant metabolizing enzyme for tenoxicam, and the normal metabolizer status suggests that the patient's CYP2C9 enzyme activity is within the normal range, which is unlikely to affect tenoxicam pharmacokinetics. Therefore, the patient can be treated with tenoxicam according to the usual dosing recommendations.	-0.08052992	0.19357936	0.043690495	tensor(-0.1023)	tensor(0.2994)	tensor(0.0584)	0.37976112757618896	0.7097466392877189	0.4615705637729402	0.41069746	0.6361462	0.45628294	0.3996768	0.6143286	0.34956938	0.46723327	0.61865723	0.4663936	0.41475353	0.64584637	0.49904817	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking tenoxicam as normal. There is no recommendation.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Avoid tenoxicam. Take an alternate therapy.	Based on the pharmacogenomics data, individuals who are Poor Metabolizers (PMs) of CYP2C9 with an activity score of 0.0 may experience decreased clearance and increased plasma concentrations of tenoxicam, a CYP2C9 substrate. As a result, clinical guidance would recommend exercising caution when prescribing tenoxicam to these individuals, and consider alternative medications or close monitoring for adverse effects, such as gastrointestinal bleeding or nephrotoxicity. Additionally, dose reduction or avoidance of concomitant medications that inhibit CYP2C9 activity may be necessary to minimize the risk of adverse events.	0.052826293	0.14584678	0.10025038	tensor(-0.1318)	tensor(0.3497)	tensor(0.0527)	0.5961129328285645	0.6275408526012279	0.5000033940344748	0.6443664	0.546552	0.5755338	0.70622146	0.57818913	0.46082008	0.60183567	0.5201602	0.35075966	0.6560273	0.65345365	0.5362518	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 1.5 for CYP2C9 is likely to have decreased enzyme activity. As tenoxicam is a CYP2C9 substrate, the clinical guidance would suggest to reduce the initial dose and titrate to response, as well as monitor for adverse effects, due to the potential for increased exposure to the drug. Additionally, alternative medications not metabolized by CYP2C9 may be considered to minimize the risk of adverse reactions.	-0.09021709	0.1622845	0.02539307	tensor(-0.1354)	tensor(0.4144)	tensor(0.0714)	0.45956294600125847	0.588530970535521	0.4615705637729402	0.35271594	0.4680504	0.45628294	0.309552	0.513423	0.34956938	0.34915927	0.5552152	0.4663936	0.4592213	0.59733266	0.49904817	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient who is a Normal Metabolizer for TPMT and a Poor Metabolizer for NUDT15 may require a dose reduction of thioguanine to minimize the risk of toxicity. This is because NUDT15 poor metabolizers are at increased risk of thioguanine-induced myelosuppression, and a normal TPMT metabolizer status does not mitigate this risk. The recommended dose reduction is 30-50% of the standard dose, with close monitoring of hematologic parameters.	0.090090126	0.17388308	0.13316788	tensor(-0.0839)	tensor(0.3051)	tensor(0.0773)	0.6969085858593725	0.62831038477057	0.6748396394216792	0.5667117	0.49664286	0.57125676	0.6352414	0.45539957	0.651729	0.612599	0.5214871	0.5752764	0.65815336	0.6411793	0.5880439	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	Based on the pharmacogenomic profile, the clinical guidance for an individual who is a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15 would be to initiate thioguanine therapy with caution and close monitoring of thioguanine toxicity. A reduced initial dose (e.g., 30-50% of the standard dose) may be considered, with subsequent dose adjustments based on response and toxicity. Regular monitoring of complete blood counts and liver function tests is essential to detect early signs of toxicity.	0.18678461	0.16209011	0.17675528	tensor(-0.0608)	tensor(0.3562)	tensor(0.1166)	0.7319817828131101	0.659348243846955	0.6743967072002456	0.56805223	0.50799716	0.54171747	0.5705863	0.47126547	0.6569239	0.546962	0.53803873	0.5957523	0.6384013	0.6713711	0.5681839	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	Based on the pharmacogenomic profile, a Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15, the clinical guidance for taking thioguanine would be to initiate therapy with a standard dose, but closely monitor for signs of myelosuppression and adjust the dose as needed. This is because the Normal Metabolizer status for TPMT suggests a normal risk of thioguanine toxicity, while the Intermediate Metabolizer status for NUDT15 may affect the activation of thioguanine and increase the risk of myelosuppression. Regular blood count monitoring and dose titration may be necessary to optimize therapy and minimize adverse effects.	0.14157903	0.047097635	0.09521443	tensor(-0.0635)	tensor(0.3546)	tensor(0.1143)	0.7512280795667302	0.6567047512977666	0.6743967072002456	0.70190257	0.53709495	0.54171747	0.71740377	0.52479494	0.6569239	0.6049726	0.50284946	0.5957523	0.6671188	0.62194633	0.5681839	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For an individual who is an Intermediate Metabolizer (IM) for TPMT and a Possible Intermediate Metabolizer (PIM) for NUDT15, clinical guidance suggests exercising caution when considering thioguanine therapy. This genotype combination may increase the risk of myelosuppression and hematological toxicity, and a reduced initial dose with close monitoring of blood counts is recommended to minimize adverse effects. Additionally, frequent monitoring of thioguanine levels and adjustment of dosage as needed may also be necessary to ensure optimal therapy while mitigating toxicity risks.	0.10273271	0.012020468	0.05845112	tensor(-0.0484)	tensor(0.3502)	tensor(0.1228)	0.7158244088423525	0.6624999458689922	0.6743967072002456	0.5096378	0.4685079	0.54171747	0.66762143	0.48880255	0.6569239	0.5500758	0.52762693	0.5957523	0.62232137	0.6801377	0.5681839	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking tobramycin as normal. There is no recommendation.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Avoid tobramycin. Take an alternate therapy.	According to clinical guidelines, individuals with the m.1555A>G or m.1494C>T variants in the MT-RNR1 gene are at increased risk of aminoglycoside-induced hearing loss, including tobramycin. As a result, it is recommended to avoid or use with caution tobramycin in these individuals, and alternative antibiotics should be considered whenever possible. If tobramycin is deemed necessary, close monitoring of hearing function and renal function is recommended to minimize the risk of ototoxicity.	0.009626599	0.20474659	0.102222785	tensor(-0.0597)	tensor(0.2740)	tensor(0.0742)	0.6436615689749945	0.5517552189247691	0.4406070572868627	0.6611696	0.54667693	0.57146436	0.7054729	0.63368195	0.5188651	0.6825126	0.55975014	0.43215543	0.6104657	0.5944739	0.54854894	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss based on MT-RNR1 genotype, the clinical guidance is to use tobramycin with standard precautions and monitoring. No specific dose adjustments or restrictions are recommended, and the drug can be used according to the approved labeling and established clinical guidelines. However, it is still important to closely monitor patients for signs of ototoxicity, as aminoglycosides can cause hearing loss in individuals with or without the high-risk genotype.	0.064476535	0.28573763	0.16827644	tensor(-0.0591)	tensor(0.4473)	tensor(0.1457)	0.6853999646766413	0.6188264377411771	0.47831372971775743	0.67953324	0.62847227	0.5425314	0.6973838	0.65576524	0.5556758	0.72326946	0.52451617	0.501952	0.67869425	0.54063857	0.5707856	0
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	Based on current evidence, individuals with an uncertain risk of aminoglycoside-induced hearing loss due to variants in the MT-RNR1 gene should exercise caution when considering treatment with tobramycin. The Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends that these individuals be monitored closely for ototoxicity and that alternative antibiotics be considered when possible. Additionally, audiometric monitoring and informed consent discussions should be conducted prior to initiating tobramycin therapy.	0.008293944	0.17205276	0.08742941	tensor(-0.0397)	tensor(0.3977)	tensor(0.1454)	0.6131703364501618	0.5872125487433607	0.47831372971775743	0.5213071	0.49624532	0.5425314	0.635751	0.5456318	0.5556758	0.681203	0.48886213	0.501952	0.6854579	0.589091	0.5707856	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	For an individual who is normal for G6PD (glucose-6-phosphate dehydrogenase), there are no specific clinical guidance or contraindications regarding the use of tolbutamide, a sulfonylurea medication used to treat type 2 diabetes. Tolbutamide is not known to cause hemolytic anemia, a concern for individuals with G6PD deficiency, so it can be used as per standard prescribing information. No dose adjustment or special monitoring is required in G6PD-normal individuals taking tolbutamide.	-0.0618557	0.19691792	0.056488268	tensor(-0.0563)	tensor(0.3045)	tensor(0.1011)	0.6246596652892957	0.5985269408033902	0.31856845239916926	0.50906104	0.67673755	0.2771091	0.40759873	0.69311434	0.16549876	0.3528715	0.51372254	0.14322998	0.53322256	0.51710594	0.40040603	1
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are variable for glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at increased risk of hemolytic anemia when taking tolbutamide, a sulfonylurea medication. As a result, it is recommended to use caution and monitor for signs of hemolysis, such as anemia, fatigue, and jaundice, when prescribing tolbutamide to these individuals. Alternative therapies may be considered, especially in individuals with a history of hemolytic anemia or those who are homozygous for G6PD deficiency.	-0.13128784	0.14917038	-0.0051587895	tensor(-0.1287)	tensor(0.3729)	tensor(0.0751)	0.5797288424090379	0.5702205114849097	0.37499509713514806	0.56502634	0.5126964	0.45799047	0.5632007	0.57593536	0.3868779	0.5456695	0.52255636	0.35277054	0.5277281	0.50008494	0.45461333	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient for glucose-6-phosphate dehydrogenase (G6PD) may be at increased risk of hemolytic anemia when taking tolbutamide, a sulfonylurea medication. As a result, it is recommended to avoid or use with caution tolbutamide in G6PD-deficient individuals, especially at high doses or in combination with other medications that may exacerbate hemolysis. Alternative therapies or careful monitoring for signs of hemolysis should be considered in these patients.	-0.09095639	0.19972277	0.03958003	tensor(-0.0992)	tensor(0.3857)	tensor(0.1002)	0.5822993832351139	0.5570661866546459	0.37499509713514806	0.57797307	0.54533523	0.45799047	0.56929064	0.5635063	0.3868779	0.5446761	0.5095965	0.35277054	0.5534765	0.5255378	0.45461333	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be treated as G6PD deficient, and caution should be exercised when prescribing tolbutamide, a sulfonylurea that can cause hemolytic anemia in G6PD-deficient individuals. It is recommended to monitor for signs of hemolysis and consider alternative therapies when possible. If tolbutamide is deemed necessary, close monitoring of hemoglobin and bilirubin levels is advised.	0.08490763	0.2945494	0.1838926	tensor(-0.0610)	tensor(0.4412)	tensor(0.1453)	0.6424571966736641	0.5332901079895638	0.3174458421091449	0.5999478	0.5462172	0.35155743	0.6137308	0.59626716	0.3334111	0.5773886	0.49929047	0.2514467	0.58614814	0.51242083	0.4384012	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	According to clinical guidelines, individuals with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) should avoid using toluidine blue, a topical antiseptic and diagnostic agent, due to the risk of hemolytic anemia. Toluidine blue can trigger oxidative stress, which can exacerbate the G6PD deficiency and lead to hemolysis. Therefore, alternative antiseptics or diagnostic agents should be considered in patients with G6PD deficiency to minimize the risk of adverse reactions.	-0.2792994	0.080564566	-0.12704945	tensor(-0.1037)	tensor(0.2490)	tensor(0.0339)	0.2389653662067673	0.6197260511796134	0.29479974255289393	0.31962043	0.68451273	0.32778567	0.13665685	0.6428242	0.19395544	0.17172901	0.6468722	0.20510112	0.44204208	0.6427976	0.56906027	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with indeterminate G6PD status should be treated as G6PD deficient for clinical decision-making. As such, they should be cautioned against using toluidine blue, which can cause hemolysis in G6PD-deficient individuals. Alternative agents should be considered, and if toluidine blue is necessary, close monitoring for hemolysis is recommended.	0.11742807	0.30742157	0.2081033	tensor(-0.0803)	tensor(0.3973)	tensor(0.1173)	0.6823237700890776	0.5810208802275462	0.3390661986934037	0.502263	0.64967227	0.30528864	0.62278914	0.6393103	0.27142188	0.5717434	0.60619706	0.17657043	0.5761296	0.5833422	0.43268606	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have a Class I variant (severe deficiency) should avoid toluidine blue, a methemoglobin-inducing agent, due to the increased risk of hemolytic anemia. This is because G6PD deficiency impairs the ability of red blood cells to cope with oxidative stress, and toluidine blue can exacerbate this effect. As a result, alternative agents should be considered in G6PD-deficient individuals, and careful monitoring for signs of hemolysis is recommended if toluidine blue is unavoidable.	-0.33005804	0.025453966	-0.18069603	tensor(-0.1560)	tensor(0.2329)	tensor(-0.0116)	0.2387787335599877	0.5847184516175435	0.29479974255289393	0.3174231	0.61465806	0.32778567	0.12428213	0.56207424	0.19395544	0.12544653	0.5401221	0.20510112	0.42881635	0.6643702	0.56906027	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	For an individual who is normal for G6PD (glucose-6-phosphate dehydrogenase), there are no specific precautions or contraindications for taking toluidine blue, as G6PD deficiency is not a concern. Toluidine blue is typically used as a diagnostic agent in medical procedures, such as endoscopy or biopsy, and is not expected to cause hemolytic anemia or other adverse effects in individuals with normal G6PD activity. Therefore, no specific clinical guidance or monitoring is required for G6PD-normal individuals taking toluidine blue.	-0.08028551	0.17467842	0.036387786	tensor(-0.0988)	tensor(0.2938)	tensor(0.0692)	0.5953139109850235	0.6556347792175226	0.3023337294699622	0.5040112	0.6750139	0.23798521	0.4169543	0.7108175	0.1437623	0.3497974	0.6510171	0.10496214	0.53810704	0.6049195	0.34969726	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	Based on the pharmacogenomics data, a patient who is a Normal Metabolizer with a CYP2D6 activity score of 2.25 is expected to have normal enzyme function. For tramadol, which is a substrate of CYP2D6, this suggests that the patient is likely to metabolize the drug normally, and standard dosing is recommended. However, it is essential to monitor the patient's response to tramadol and adjust the dose as needed to manage pain and minimize adverse effects.	-0.06125864	0.1466512	0.03642601	tensor(-0.0659)	tensor(0.3569)	tensor(0.0998)	0.48793196798205724	0.5280874586501936	0.6356358969327758	0.37573758	0.39124957	0.63132113	0.5114247	0.55154437	0.7354743	0.55762243	0.5631322	0.6559709	0.55510134	0.63258404	0.68886834	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	['Proceed taking tramadol as normal. There is no recommendation.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Avoid tramadol. Take an alternate therapy.	Based on the clinical guidance, an individual with an ultrarapid metabolizer (UM) phenotype and a CYP2D6 activity score of 2.75 may require a reduced dose of tramadol due to increased conversion to its active metabolite, O-desmethyltramadol. This is because UM individuals have increased CYP2D6 enzyme activity, which can lead to higher levels of the active metabolite, potentially resulting in increased risk of adverse effects, such as serotonin syndrome or seizures. As a result, close monitoring and dose adjustment may be necessary to minimize the risk of adverse events.	0.0029601331	0.24829605	0.11637585	tensor(-0.1177)	tensor(0.4446)	tensor(0.1024)	0.5535414798280991	0.5535793856351997	0.6282994679798819	0.5726194	0.5146488	0.7733855	0.64332664	0.628685	0.81913	0.56630784	0.6012041	0.69879055	0.5583628	0.58038646	0.71164864	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	No recommendation	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate CYP2D6 genotype may have reduced tramadol efficacy due to impaired CYP2D6-mediated O-demethylation to the active metabolite O-desmethyltramadol. As a result, clinicians may consider alternative analgesics or monitor the patient closely for inadequate pain response. Additionally, a lower tramadol starting dose may be considered to minimize adverse effects, as indeterminate individuals may still have some CYP2D6 activity.	-0.31589904	0.002472419	-0.17891558	tensor(-0.0677)	tensor(0.3836)	tensor(0.1125)	0.22353628106337084	0.5419507970500995	0.24036293548720675	0.11298584	0.4569771	0.16657624	0.03683717	0.5840853	0.07525307	0.020711422	0.55368614	0.11020953	0.292141	0.57609206	0.4865854	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer (IM) with a CYP2D6 activity score of 0.5, clinical guidance suggests that they may have reduced tramadol efficacy due to impaired O-demethylation to its active metabolite, O-desmethyltramadol. This may result in decreased analgesic response or require higher doses to achieve adequate pain relief. Close monitoring of treatment response and potential dose adjustments may be necessary to optimize pain management.	0.012048456	0.14616258	0.078145884	tensor(-0.0505)	tensor(0.3790)	tensor(0.1176)	0.5821062369496156	0.5295086719791079	0.5946809184168795	0.5223102	0.4995638	0.7258896	0.59616023	0.6123858	0.7467311	0.55233514	0.57735014	0.5716707	0.47080258	0.5403934	0.54229766	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, this individual is expected to have reduced CYP2D6 activity, which may lead to higher trimipramine concentrations and increased risk of adverse effects. As CYP2C19 is a minor metabolizer of trimipramine, the rapid metabolizer status is unlikely to have a significant impact. Therefore, the clinical guidance would be to consider a lower starting dose of trimipramine and closer monitoring for adverse effects, particularly during the initial treatment phase.	0.13003525	0.2068076	0.16974807	tensor(-0.0428)	tensor(0.3937)	tensor(0.1249)	0.7847969199102424	0.6133063305907379	0.7076062893313851	0.70281076	0.51784885	0.6455309	0.8074137	0.62572336	0.6698103	0.7910519	0.6070847	0.59470844	0.717357	0.6454077	0.6642536	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	Based on the pharmacogenomic profile, the individual is likely to have reduced metabolism of trimipramine, a tricyclic antidepressant primarily metabolized by CYP2D6 and CYP2C19. As an Intermediate Metabolizer for CYP2D6 and a Poor Metabolizer for CYP2C19, they may experience increased plasma concentrations of trimipramine, which can lead to adverse effects such as drowsiness, dizziness, and anticholinergic effects. Clinical guidance would suggest a reduced starting dose and close monitoring of adverse effects, with consideration of alternative medications or therapeutic drug monitoring to optimize treatment outcomes.	-0.032556992	0.33048147	0.1260456	tensor(-0.1299)	tensor(0.4059)	tensor(0.0797)	0.7365198213403362	0.6446326102166096	0.7900439243714548	0.493952	0.47520864	0.6883971	0.63369024	0.634306	0.75131655	0.51856685	0.65194947	0.6084875	0.5819079	0.72482216	0.62567705	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	"Based on the pharmacogenomics results, a patient with ""No Result"" and activity score = ""No Result"" for CYP2D6 and ""Rapid Metabolizer"" for CYP2C19 may require closer monitoring when taking trimipramine. This is because trimipramine is primarily metabolized by CYP2D6 and CYP2C19, and the lack of information on CYP2D6 activity may increase the risk of adverse effects or reduced efficacy. Additionally, the rapid metabolizer phenotype for CYP2C19 may lead to increased metabolism of trimipramine, potentially requiring dose adjustments to achieve optimal therapeutic response."	0.17515686	0.26382086	0.22034703	tensor(-0.1339)	tensor(0.3150)	tensor(0.0260)	0.6153741069408226	0.6044305673319567	0.5414896841123947	0.6241432	0.49753872	0.5663371	0.57080346	0.60214376	0.51251733	0.5972519	0.5462068	0.5110645	0.61998844	0.5960046	0.55282295	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid trimipramine. Take an alternate therapy.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Proceed taking trimipramine as normal. There is no recommendation.	Based on the pharmacogenomic data, a patient who is a Normal Metabolizer with an activity score of 1.5 for CYP2D6 and No Result for CYP2C19 may not require dose adjustments for trimipramine, a tricyclic antidepressant primarily metabolized by CYP2D6 and CYP2C19. The normal CYP2D6 activity suggests that the patient will metabolize trimipramine at a typical rate, but the lack of data on CYP2C19 activity introduces some uncertainty. Close therapeutic monitoring is recommended to ensure optimal response and minimize potential adverse effects.	-0.22891064	0.18253252	-0.05784343	tensor(-0.1343)	tensor(0.3239)	tensor(0.0500)	0.38721366751599157	0.6537355965223609	0.505262055758224	0.2337004	0.58791757	0.4359396	0.33054867	0.5770282	0.41930565	0.3556791	0.5378219	0.4955695	0.42831427	0.6542382	0.6431537	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer of CYP2D6 (activity score ≥6.0), the clinical guidance for taking tropisetron, a 5-HT3 receptor antagonist, is to use caution and consider a reduced dose or alternative therapy. This is because tropisetron is metabolized primarily by CYP2D6, and ultrarapid metabolizers may experience reduced efficacy or shorter duration of action due to rapid metabolism. Close monitoring of efficacy and potential adverse effects is recommended.	0.049671143	0.3173575	0.17245369	tensor(-0.0976)	tensor(0.4763)	tensor(0.1301)	0.5434560320493886	0.6881329450256424	0.48669862447196693	0.59185433	0.61151886	0.531464	0.75096875	0.5887688	0.4445886	0.687958	0.6351419	0.52936906	0.628856	0.67137635	0.59235305	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid tropisetron. Take an alternate therapy.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Proceed taking tropisetron as normal. There is no recommendation.	Based on the pharmacogenomic data, a patient with a Normal Metabolizer status and an activity score of 1.75 for CYP2D6 is expected to have normal CYP2D6 enzyme function. Tropisetron, a 5-HT3 receptor antagonist, is primarily metabolized by CYP2D6, and normal metabolizers are expected to metabolize the drug normally. Therefore, no dosage adjustment is recommended for tropisetron in this patient, and standard dosing guidelines can be followed.	-0.18935075	0.19708726	-0.025644353	tensor(-0.1075)	tensor(0.3461)	tensor(0.0765)	0.37368255026172653	0.6228137413036672	0.5294213486116714	0.32607734	0.4576437	0.5267077	0.39192563	0.5766798	0.50307465	0.39614335	0.5815789	0.54421604	0.44038633	0.6378755	0.6049727	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	According to clinical guidelines, an individual with an ultrarapid metabolizer (UM) phenotype and a CYP2D6 activity score of 2.75 may metabolize tropisetron, a CYP2D6 substrate, at an accelerated rate. This may lead to reduced efficacy and potentially shorter duration of action. As a result, the patient may require more frequent dosing or higher doses of tropisetron to achieve therapeutic effects, with close monitoring for efficacy and potential adverse effects.	-0.0023854356	0.20703943	0.096189864	tensor(-0.0777)	tensor(0.4001)	tensor(0.1186)	0.5119888782044816	0.5894201339029997	0.48669862447196693	0.5338479	0.5373108	0.531464	0.7147665	0.56123704	0.4445886	0.6671928	0.53537476	0.52936906	0.58797854	0.5979023	0.59235305	0
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥5.0, the clinical guidance for taking tropisetron, a 5-HT3 receptor antagonist, is to exercise caution and consider alternative medications. This is because tropisetron is primarily metabolized by CYP2D6, and UM individuals may experience rapid metabolism, leading to reduced efficacy or shorter duration of action. Close monitoring of response and potential dose adjustments may be necessary to ensure therapeutic efficacy.	0.033206195	0.30951607	0.15932244	tensor(-0.1177)	tensor(0.3796)	tensor(0.0851)	0.5487685318719618	0.6667633542064296	0.48669862447196693	0.58559895	0.6000204	0.531464	0.75571	0.55839235	0.4445886	0.6755411	0.5910134	0.52936906	0.6317157	0.6601738	0.59235305	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers of CYP2D6 (activity score ≥3.5) may require higher doses of venlafaxine to achieve therapeutic levels, as they may metabolize the drug too quickly. However, caution is advised, as higher doses may also increase the risk of adverse effects. Close monitoring of efficacy and toxicity is recommended, and consideration of alternative medications may be necessary.	0.008662379	0.34230906	0.15687142	tensor(-0.0747)	tensor(0.4756)	tensor(0.1466)	0.605123232533583	0.572805830419618	0.5987681240762495	0.40147743	0.5147966	0.5072145	0.73571664	0.59336	0.6390099	0.59998924	0.5641742	0.6055029	0.5747229	0.62696636	0.6036315	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	Based on the clinical guidance, a patient who is a Normal Metabolizer with a CYP2D6 activity score of 1.75 is expected to metabolize venlafaxine normally. This means they are likely to have a normal response to standard dosages of venlafaxine, and no dosage adjustments are recommended. However, it's essential to monitor the patient's response to therapy and adjust the dosage as needed based on clinical response and tolerability.	-0.13429673	0.24091023	0.026769767	tensor(-0.0376)	tensor(0.3890)	tensor(0.1409)	0.37573687771333675	0.6317435559422804	0.5213563458094601	0.3537097	0.6012116	0.45920977	0.40003505	0.61704165	0.42590126	0.4191198	0.57662845	0.51318043	0.37534496	0.622192	0.6266304	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score of 2.75, the clinical guidance for taking venlafaxine is to consider a lower initial dose and more frequent monitoring due to the increased risk of reduced efficacy. This is because UMs of CYP2D6 may metabolize venlafaxine too quickly, leading to subtherapeutic levels of the active metabolite O-desmethylvenlafaxine. Close monitoring of therapeutic response and potential dose adjustments may be necessary to achieve optimal treatment outcomes.	0.011444749	0.27639624	0.13284434	tensor(-0.0398)	tensor(0.4489)	tensor(0.1596)	0.6112250996204336	0.591235477271054	0.5987681240762495	0.3831654	0.55161345	0.5072145	0.61026275	0.5763073	0.6390099	0.5037586	0.5114078	0.6055029	0.53217417	0.5868495	0.6036315	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is an ultrarapid metabolizer (UM) of CYP2D6 with an activity score ≥4.0, clinical guidance suggests that they may require a reduced dose of venlafaxine due to increased metabolism of the drug. This is because UMs of CYP2D6 may experience reduced efficacy or shorter duration of action of venlafaxine due to rapid metabolism. Therefore, a lower dose or more frequent dosing may be necessary to achieve therapeutic levels, and close monitoring of response and tolerability is recommended.	0.016028143	0.27274713	0.13414624	tensor(-0.0585)	tensor(0.4592)	tensor(0.1530)	0.6101397857751254	0.5722243228752166	0.5987681240762495	0.40230557	0.48979306	0.5072145	0.6185999	0.57093227	0.6390099	0.4666641	0.47518235	0.6055029	0.50128627	0.55830985	0.6036315	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, high doses of vitamin C (>1 gram/day) may exacerbate hemolysis, a condition where red blood cells are destroyed prematurely. Clinical guidance recommends caution when taking high doses of vitamin C, and it is advised to start with a low dose (100-200 mg/day) and monitor for signs of hemolysis. Additionally, it is recommended to consult with a healthcare provider before taking vitamin C supplements, especially in individuals with severe G6PD deficiency.	-0.075905696	0.1572672	0.03205547	tensor(-0.0746)	tensor(0.4258)	tensor(0.1272)	0.5790719249429849	0.5322070295870922	0.3300580317164365	0.45382985	0.58932364	0.33852997	0.49628794	0.6506837	0.24183282	0.5091689	0.63869196	0.33727965	0.5034099	0.5518406	0.4060947	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with an indeterminate G6PD status should be considered as potentially G6PD deficient, and caution should be exercised when administering high doses of vitamin C (>1 gram per day). High doses of vitamin C may exacerbate hemolysis in G6PD-deficient individuals, and patients with an indeterminate status should be counselled on the potential risks and benefits of vitamin C supplementation. In general, it is recommended to start with a low dose of vitamin C and monitor for signs of hemolysis.	0.041355986	0.29353052	0.15779819	tensor(-0.0853)	tensor(0.4199)	tensor(0.1207)	0.6480402043717834	0.5330659524041101	0.2590924940244756	0.5126618	0.60217875	0.2161723	0.5283363	0.6582	0.18598738	0.5204537	0.5875216	0.16557878	0.49967805	0.5802374	0.39210156	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with Class I or II variants, including those with Class I variant CNSHA, should avoid high doses of vitamin C (>1 gram/day) due to the risk of hemolysis. However, moderate doses of vitamin C (up to 500 mg/day) are unlikely to cause significant harm. It is essential to weigh the benefits and risks of vitamin C supplementation in these individuals and consider alternative treatments when possible.	-0.118336186	0.06946059	-0.029282454	tensor(-0.1255)	tensor(0.3849)	tensor(0.0812)	0.4418794036570432	0.5579946547038157	0.4118483328687831	0.36066028	0.61215776	0.5076278	0.34466997	0.62654567	0.41366756	0.3996544	0.61114275	0.26224408	0.44281864	0.56952125	0.45122454	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, there are no specific clinical guidelines or restrictions on taking vitamin C. Vitamin C is not expected to exacerbate G6PD deficiency, and high doses of vitamin C are not known to cause hemolysis or other adverse effects in individuals with normal G6PD activity. Therefore, individuals with normal G6PD can take vitamin C supplements as directed without concerns related to G6PD deficiency.	8.000014e-05	0.18157741	0.08684861	tensor(-0.0738)	tensor(0.3211)	tensor(0.0884)	0.6454040893944676	0.5761996992330619	0.2418515422786996	0.4533861	0.6576183	0.21498178	0.44548807	0.65044993	0.12752005	0.45289946	0.55231625	0.117898	0.50801533	0.57708985	0.35104334	1
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at increased risk of hemolytic anemia when taking vitamin K antagonists, such as warfarin. As a result, alternative anticoagulation therapies should be considered, and vitamin K antagonists should be avoided or used with caution in G6PD-deficient individuals. Additionally, G6PD-deficient individuals should be monitored closely for signs of hemolysis when taking vitamin K.	-0.07341713	0.13460861	0.02425746	tensor(-0.1150)	tensor(0.2981)	tensor(0.0598)	0.5985588937208232	0.49874084983545686	0.33983262156600874	0.50700283	0.4561765	0.37794882	0.50897163	0.47907335	0.28925985	0.51315755	0.5177949	0.36321986	0.57121456	0.54176396	0.44014847	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, clinical guidance suggests caution when taking vitamin K, particularly phytomenadione (vitamin K1), as it may exacerbate hemolysis in G6PD-deficient individuals. However, the risk is considered low, and vitamin K is not contraindicated in indeterminate G6PD individuals. Close monitoring for signs of hemolysis is recommended, especially in patients with a history of G6PD-related adverse reactions.	0.0758611	0.23049706	0.15107156	tensor(-0.1034)	tensor(0.2730)	tensor(0.0587)	0.6133430454290033	0.5755320205127044	0.2694000507374588	0.49031833	0.63353354	0.2659907	0.61454296	0.6172621	0.25155193	0.53283405	0.59055483	0.2070198	0.4509901	0.5694886	0.3951822	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with Class I or II variants (CNSHA, Class I being the most severe), vitamin K administration may exacerbate hemolysis due to increased oxidative stress. Clinical guidance recommends caution when administering vitamin K to G6PD-deficient individuals, especially in high doses or in conjunction with other oxidative stressors. It is advised to monitor for signs of hemolysis and consider alternative therapies or reduced dosing regimens.	-0.037660643	0.16928178	0.059728935	tensor(-0.0958)	tensor(0.3697)	tensor(0.0973)	0.47758887926111987	0.5415865700109455	0.4321874172354593	0.5157773	0.57151955	0.49448597	0.4845327	0.61545855	0.38754544	0.476627	0.54396516	0.29333764	0.5092257	0.5425495	0.48585257	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, there are no specific clinical guidance or contraindications regarding vitamin K supplementation or intake. Vitamin K is not metabolized by the G6PD enzyme, and G6PD deficiency primarily affects the metabolism of certain medications and substances that can cause hemolytic anemia. Therefore, individuals with normal G6PD activity can safely take vitamin K supplements or consume vitamin K-rich foods without concerns related to G6PD deficiency.	-0.011706603	0.191343	0.08416033	tensor(-0.0786)	tensor(0.2827)	tensor(0.0786)	0.6353902565921463	0.5970841714742028	0.2867845446291543	0.46074736	0.6377881	0.22765648	0.45930952	0.61670065	0.13543293	0.46104816	0.5567794	0.11219056	0.4847306	0.5736752	0.36901343	1
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	No recommendation	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are indeterminate for CYP2C19 (i.e., have an unknown or unclassified genotype) should be treated as if they have a CYP2C19 intermediate metabolizer phenotype when taking voriconazole. This means that they may require voriconazole dose adjustments and/or monitoring of voriconazole plasma concentrations to ensure therapeutic efficacy and minimize the risk of adverse effects. Additionally, clinicians should consider alternative antifungal agents that are not CYP2C19 substrates, if possible.	-0.32771182	-0.0035764126	-0.1889978	tensor(-0.0886)	tensor(0.3734)	tensor(0.1035)	0.21164391954288753	0.5996351374938519	0.2587279427414255	0.13004653	0.5350195	0.21783486	0.08386225	0.64351857	0.11914129	-0.058419622	0.5282968	0.08720999	0.25968856	0.6122959	0.44794685	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are ultrarapid metabolizers (UM) of CYP2C19 may require higher doses of voriconazole to achieve therapeutic concentrations. The CPIC recommends increasing the voriconazole dose by 50% to 100% in CYP2C19 UMs, with close monitoring of trough concentrations and potential adjustment based on response. However, the optimal dosing strategy for voriconazole in CYP2C19 UMs has not been established and may require individualized titration.	0.044915993	0.18043418	0.1116396	tensor(-0.0828)	tensor(0.3747)	tensor(0.0984)	0.6187456823147313	0.5880927615696472	0.5852280948895408	0.5259755	0.52214044	0.60155034	0.7369611	0.5782112	0.71498805	0.60550326	0.49362645	0.55807173	0.6740799	0.5170826	0.59202236	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Initiate therapy with recommended standard of care dosing	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are intermediate metabolizers (IMs) for CYP2C19 may require closer monitoring and potential dose adjustments when taking voriconazole, as they may have higher voriconazole plasma concentrations compared to normal metabolizers. The CPIC recommends that IMs of CYP2C19 receive a standard starting dose of voriconazole, but with increased monitoring for adverse effects, particularly neurotoxicity and hepatotoxicity. Additionally, consideration should be given to reducing the dose or increasing the dosing interval in IMs who experience adverse effects or have elevated voriconazole plasma concentrations.	-0.20492011	0.057326254	-0.08666646	tensor(-0.0939)	tensor(0.3910)	tensor(0.1057)	0.4430178141426459	0.5928515476782376	0.48443074311508266	0.45436457	0.5337186	0.51388985	0.45773497	0.636282	0.4568128	0.44137552	0.54993206	0.3514512	0.50482535	0.54043657	0.558936	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, individuals who are poor metabolizers (PMs) of CYP2C19 should receive a reduced dose of voriconazole, as they may experience increased exposure to the drug and increased risk of adverse effects. The recommended starting dose for CYP2C19 PMs is 50% of the standard dose, with close monitoring of therapeutic drug levels and adverse effects. Additionally, alternative antifungal agents that are not dependent on CYP2C19 metabolism may be considered in these individuals.	0.23449908	0.28299797	0.26051193	tensor(-0.0932)	tensor(0.4884)	tensor(0.1371)	0.7797839041304772	0.593988755092441	0.6459419390537879	0.60604995	0.5562571	0.6230238	0.83286136	0.5988123	0.7010368	0.780161	0.5466484	0.5556482	0.7211288	0.6245169	0.5768393	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For an individual with an Intermediate Metabolizer phenotype and an activity score of 0.75 for CYP2D6, clinical guidance suggests that they may require a moderate dose adjustment of vortioxetine, a substrate of CYP2D6. The patient may experience reduced efficacy or increased risk of adverse effects due to decreased metabolism of vortioxetine. Therefore, a reduced starting dose and close monitoring of therapeutic response and adverse events are recommended to achieve optimal treatment outcomes.	-0.12442546	0.31464955	0.05897751	tensor(-0.0094)	tensor(0.4721)	tensor(0.1916)	0.4998844056000666	0.6075468986722546	0.5435766630839954	0.45060924	0.5291669	0.45811072	0.41067827	0.6386218	0.4498584	0.50237393	0.5559363	0.54845434	0.5299371	0.59498894	0.64799625	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	['Proceed taking vortioxetine as normal. There is no recommendation.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Avoid vortioxetine. Take an alternate therapy.	Based on the pharmacogenomics data, as an Ultrarapid Metabolizer with a CYP2D6 activity score ≥3.0, the clinical guidance for taking vortioxetine is to consider a reduced dose or alternative medication. This is because Ultrarapid Metabolizers may metabolize vortioxetine too quickly, leading to reduced efficacy or increased risk of adverse effects. A reduced dose or alternative medication can help mitigate these risks and optimize treatment outcomes.	0.1574298	0.22198004	0.19131012	tensor(-0.0356)	tensor(0.4597)	tensor(0.1693)	0.7914485005158615	0.6399736628092095	0.7083544587340355	0.7567923	0.62646365	0.6092807	0.77589417	0.6674792	0.6855015	0.7776111	0.6161363	0.647011	0.74777085	0.7059769	0.6044272	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an intermediate metabolizer (IM) phenotype and a CYP2D6 activity score of 1.0 may require a moderate dose reduction of vortioxetine, which is a CYP2D6 substrate. This is because IMs may have reduced clearance of vortioxetine, potentially leading to increased drug exposure and adverse effects. Therefore, clinicians should consider initiating therapy with a lower dose and monitoring the patient closely for efficacy and toxicity.	-0.17644542	0.35952845	0.036241245	tensor(-0.0464)	tensor(0.5415)	tensor(0.1879)	0.4789061642615302	0.5616389553726737	0.5435766630839954	0.39194465	0.50721246	0.45811072	0.3820702	0.6341496	0.4498584	0.46118435	0.57587665	0.54845434	0.48310038	0.6098657	0.64799625	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, an individual with an intermediate metabolizer phenotype and an activity score of 0.5 for CYP2D6 may require a moderate dose reduction of vortioxetine, which is a CYP2D6 substrate. This is because intermediate metabolizers may have reduced enzyme activity, leading to higher vortioxetine concentrations and potentially increased risk of adverse effects. A dose reduction of 25-50% may be considered to minimize the risk of adverse events.	-0.20811072	0.13915214	-0.05854146	tensor(-0.0712)	tensor(0.4177)	tensor(0.1304)	0.44041746637369683	0.5717761562024622	0.5435766630839954	0.38804343	0.50599253	0.45811072	0.38683942	0.6025035	0.4498584	0.4228722	0.5829837	0.54845434	0.42821777	0.5587544	0.64799625	0
